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ABSTRACT 
The acquisition of an invasive phenotype by neoplastic cells is often associated with 
increased activity of tyrosine kinases, such as Src or epidermal growth factor receptor 
(EGFR). Additionally, cell-cell adhesion, mediated via cadherin-based adherens junctions 
(AJs), profoundly influences whether and how invasion might occur. p120-catenin, which 
undergoes prominent phosphorylation on tyrosine in response to growth factor signalling 
or activation of Src, has emerged as a key player in promoting E-cadherin stability and AJ 
integrity. In this work we address the role of p120, and specifically its tyrosine 
phosphorylation, in determining the adhesive and invasive phenotype of neoplastic cells. 
As an initial step we generated polyclonal site-specific phosphorylation state-specific 
antibodies to recently identified Src phosphorylation sites in p120. Antibodies to two of 
eight sites, phospho-tyrosine-228 and phospho-tyrosine-296 were successfully produced 
and validated and, together with newly available commercial monoclonal p120 phospho- 
specific antibodies, were used to characterise p120 phosphorylation events occurring in 
response to activation of Src or EGFR. 
Over-expression of constitutively active Src in a colon cancer cell line (KM12C) caused 
phosphorylation of p120 at tyrosine residues 228,280,291 and 296 and this was dependent 
on Src kinase activity and the presence of an intact Src SH2 domain. Simultaneous 
phosphorylation of the same sites occurred in a squamous cell carcinoma cell line (A43 1) 
stimulated with EGF, most probably via activation of Src kinase. In both models tyrosine 
phosphorylation of p120 correlated with disruption of AJs. However, studies utilising 
phosphorylation-defective p120 mutants suggested that tyrosine phosphorylation of p120 
was not required for Src-induced inhibition of AJ formation in KM12C cells but, along 
with other events occurring at the p120 N-terminal region, was required for growth factor 
induced scattering of A431 cells. 
RNAi-mediated knockdown of p120 in A431 cells impaired EGF-induced invasion into 3- 
dimensional matrix gels or in organotypic culture, while re-expression of RNAi-resistant 
p 120, or phosphorylation defective p120, restored the collective mode of invasion 
employed by A431 cells in vitro. The requirement for p120 was not due to its effects on 
stabilizing E-cadherin, since RNAi-mediated E-cadherin knockdown did not cause a 
similar reduction in A431 invasion. Thus, we describe a novel requirement for p120 in 
mediating the collective invasion of squamous cancer cells via mechanisms which are 
independent of p120's ability to be phosphorylated or to stabilise E-cadherin. 
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Introduction: p120-catenin, the adherens 
junction and invasion. 
2 
Invasion, the ability of neoplastic cells to breach tissue barriers, is a hallmark of 
malignancy (1). Whether by infiltration and compromise of adjacent tissues, or as an initial 
step in the process of metastasis, invasion is directly responsible for much of the morbidity 
and mortality of cancer. Over the past two decades an understanding of the molecular 
processes fundamental to invasion and metastasis has begun to emerge. It is clear that 
invasion requires co-ordinated changes in cell-cell and cell-matrix adhesion, remodelling 
of the extracellular matrix, reorganisation of the actin cytoskeleton and increased motility. 
Furthermore, current evidence suggests cancer cells are able to utilise differing strategies 
of invasion which are characterised by the relative contribution of each of these factors. 
Although complex these processes are ultimately coordinated and are regulated, to a large 
extent, by tyrosine kinases and their numerous substrates. In this piece of work we have 
attempted to identify the contribution of one such tyrosine kinase substrate, the adherens 
junction (AJ) protein p120-catenin (hereafter referred to as p120), which would seem well 
placed to co-ordinately regulate altered cell-cell adhesion, motility and invasion. Work to 
understand the biology of invasion and metastasis is timely, not least because of the 
recognition that this particular hallmark of malignancy may be susceptible to molecularly 
targeted therapies. To use such agents appropriately will require translation from bench to 
bedside and back again and will demand a sound understanding of the fundamental biology 
of invasion. 
1.1 Structure and function of the adherens junction. 
Epithelial cell-cell adhesion is determined by three types of specialised structure located at 
the basolateral membrane: AJs, tight junctions and desmosomes (Figure 1-1). Of these the 
AJ is the key determinant of cell-cell adhesion, epithelial differentiation and tissue 
morphogenesis (2) and, at least in vitro, formation of AJs is a prerequisite for the formation 
of tight junctions and desmosomes (3). However, far from simply providing inert physical 
adhesion it is increasingly clear that AJs are dynamically regulated sites of bi-directional 
signalling which regulate and are regulated by tyrosine kinases and the actin cytoskeleton 
(2,4). The core components of the AJ are cadherins and their cytoplasmic binding partners 
known as catenins (Figure 1-2). However, it should be borne in mind that diverse 
molecules are physically and functionally associated with the AJ including tyrosine and 
lipid kinases, phosphatases, integrins, nectins and actin regulatory proteins. 
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Tight junction 
Adherens junction 
Desmosome 
0 
Basal membrane 
Figure 1-1 Adhesive structures in epithelia. 
F-actin 
Intermediate 
filaments 
The tight junction (blue) is composed of transmembrane proteins such as claudin and 
occludin. It forms a virtually impenetrable barrier preventing the passage of most dissolved 
molecules from one side of the epithelial sheet to the other. The AJ (green) is formed by 
classical cadherins and catenins. Both AJs and tight junctions are linked to the actin 
cytoskeleton (red circles). The desmosome (grey) is composed of desmosomal cadherins 
and plakophilins and links sites of cell-cell adhesion to intermediate filaments. 
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1.1.1 Cadherins 
Cadherins form a diverse superfamily of transmembrane glycoproteins characterised by the 
presence of one or more extracellular cadherin (EC) repeats. These 110 amino acid long 
conserved sequences contain specific calcium-binding motifs and the binding of calcium 
ions is essential for the proper folding, rigidity and hence function of the cadherin repeat 
(5). Cadherins can be divided into 4 sub-families (6): 1) classical cadherins, including E-, 
N-, and P-cadherin which participate in AJs and to which this discussion is limited; 2) 
desmosomal cadherins which participate in desmosomes; 3) protocadherins which are 
mainly involved in neural development; and 4) cadherin-related proteins like the Flamingo 
and FAT family. 
Classical cadherins are single pass transmembrane glycoproteins with an extracellular 
domain containing 5 EC repeats. This extracellular domain can undergo calcium- 
dependant cis -dimerisation with a cadherin molecule of the same cell or trans- 
dimerisation with a cadherin molecule of an adjacent cell. Mutational studies together with 
the solving of the crystal structure ofXenopus C-cadherin indicate that it is the most 
membrane-distal cadherin repeat which primarily mediates this interaction (7). 
Specifically, a conserved tryptophan side chain in the membrane-distal EC repeat of one 
molecule inserts into a hydrophobic pocket in a separate region of the membrane-distal 
repeat of the second cadherin molecule. 
The cadherin cytoplasmic domain contains two distinct and non-overlapping binding 
domains via which it interacts with members of the Armadillo family of proteins known as 
catenins. The highly-conserved membrane-proximaljuxtamembrane domain (JMD) 
interacts with p120-catenin via residues 75 8-773 (8-10) and other regulatory proteins such 
as Hakai (11) and presenilin (12) whilst residues 815-839 of the membrane distal catenin- 
binding domain (CBD) interact with ß-catenin (13) (numbering refers to E-cadherin). 
E-cadherin, the prototypic classical cadherin, is ubiquitously expressed by epithelial tissues 
while other classical cadherins such as N-, P- and VE cadherin have a more restricted 
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Figure 1-2 p120 and the adherens junction (AJ) 
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#e0 
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nucleus 
Transcription 
Cadherins are single pass transmembrane proteins which form calcium-dependent 
homophilic interactions with cadherin molecules of an adjacent cell via the first 
extracellular cadherin repeat. ß-catenin interacts with the cadherin catenin-binding domain. 
a-catenin is recruited to the AJ via ß-catenin and regulates interaction of the AJ with the 
actin cytoskeleton. p120 binds the cadherin juxtamembrane domain and this physical 
interaction is essential for the stable retention of cadherin at the plasma membrane. p 120 
can also directly modulate the activity of the Rho-family GTPases RhoA, Rae and Cdc42. 
In addition, p 120 may enter the nucleus where it binds to and inhibits the transcriptional 
repressor activity of Kaiso. p 120 is phosphorylated on tyrosine in response to the activation 
of receptor and non-receptor tyrosine kinases but the consequences of this for p120 
function are enigmatic. 
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distribution and display important functional differences. In addition to physically 
mediating intercellular adhesion, cadherin molecules form a hub of signalling activity (14), 
mediate cell sorting during morphogenesis (2), and maintain epithelial polarity and 
homeostasis (15). With such fundamental roles in cell biology it is not surprising that 
cadherin function is often perturbed in human cancer. For example, germline mutations in 
the E-cadherin gene are associated with familial gastric cancer whilst somatic mutations 
have been found in up to 50% of diffuse type gastric cancer and lobular breast cancer. In 
other tumour types mutation of the E-cadherin gene is rare but downregulation of E- 
cadherin is a common occurrence and is often mediated by promoter hypermethylation or 
by the activity of specific transcriptional repressors (16). 
1.1.2 a-catenin 
a-catenin has no sequence homology with the other catenins and does not contain 
Armadillo repeats. Its closest relative is the actin binding protein vinculin with which it 
shares three vinculin homology domains (17). a-catenin is recruited to the AJ via its N- 
terminal domain which interacts with cadherin-bound ß-catenin or plakoglobin (18). The 
N-terminal region is also involved in homodimerisation of unbound cytoplasmic a-catenin 
(19). The central and C-terminal regions of a-catenin bind several actin-binding or 
regulatory proteins such as a-actinin (20), vinculin (21), ZO-1 (22) and formin (23) as 
well as actin itself (24). Until recently the prevailing view was that a-catenin 
simultaneously associated with actin and ß-catenin to physically link E-cadherin to the 
actin cytoskeleton. However, recent work demonstrating that the a-catenin-ß-catenin and 
a-catenin-actin interactions are mutually exclusive has challenged this dogma (25). 
Current data suggests that the true role of a-catenin is to act as a molecular switch 
controlling the pattern of local actin polymerisation which is essential for AJ formation 
(26,27). Loss of function mutations in the a-catenin gene are associated with impaired 
cell-cell adhesion and have been found in tumour cell lines derived from lung, prostate, 
ovarian and colon cancers (28). 
1.1.3 P-catenin 
ß-catenin contains a central Armadillo domain flanked by an amino-terminal domain of 
approximately 130 amino acids and a carboxyl-terminal domain of 110 amino acids. The 
Armadillo domain consists of 12 Armadillo repeats, each of approximately 42 residues, 
which are packed together to form a long positively charged central groove via which ß- 
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catenin interacts with cadherins, APC or TCF transcription factors in a mutually exclusive 
manner (29). The amino-terminus mediates the interaction with a-catenin and also 
contains several serine and threonine residues whose phosphorylation is important in 
regulating ß-catenin stability. The carboxyl terminus has transcriptional activator 
properties (30). 
Taken together current evidence indicates dual roles for ß-catenin in cell adhesion and 
transcription (31). Firstly, ß-catenin serves as an adaptor protein simultaneously binding 
E-cadherin and a-catenin, and hence is necessary for the recruitment of a-catenin to the AJ 
(32). Secondly, a tightly regulated nuclear pool of ß-catenin can act as a transcriptional 
coactivator in the well described Wnt / ß-catenin / TCF pathway (Figure 1-3) (33). In the 
absence of Wnt signalling, cytoplasmic ß-catenin is bound by the APC / axin / glycogen 
synthase kinase-3D (GSK3-ß) complex and undergoes N-terminal serine / threonine 
phosphorylation. This targets ß-catenin for ubiquitination and destruction (34-38). Wnt, an 
extracellular matrix-associated growth factor signals via its receptor, Frizzled, to inhibit 
GSK3-ß causing stabilisation of cytoplasmic ß-catenin. This pool of cytoplasmic ß-catenin 
can then translocate to the nucleus where it cooperates with TCF transcription factors to 
induce expression of target genes including myc (39), cyclin D1 (40,41) and MMP7 (42, 
43). Importantly, the interactions of ß-catenin with cadherin, APC and TCFs are mutually 
exclusive. Thus, by sequestering ß-catenin in Als, E-cadherin may act as an inhibitor of 
this pathway (44-46). Indeed, the ability to coordinate cell-cell adhesion with diverse 
cellular pathways via mutually exclusive competitive molecular interactions is a recurring 
theme in catenin biology. 
The Wnt signalling pathway, with nuclear ß-catenin as its main effector, has a critical role 
in morphogenesis and organogenesis via the regulation of migration, proliferation and 
differentiation (31). Deregulated activity of the Wnt pathway is a common event in 
oncogenesis (47). Although upregulation of Wnt-1 expression is an important event in 
mouse mammary tumour virus-induced carcinogenesis (48), increased production of Wnts 
does not appear to be a common event in human cancer. Rather, mutations in APC or ß- 
catenin are the dominant mechanism by which the Wnt / ß-catenin / TCF pathway is 
upregulated. For example, a loss of function mutation in APC can be detected in 
approximately 80% of spontaneous colorectal cancers (49). Furthermore, germline 
mutations of APC cause the cancer syndrome familial adenomatous polyposis coli (49). In- 
keeping with a critical role of the Wnt / l-catenin / TCF pathway in colorectal 
carcinogenesis, those tumours which retain functional APC often contain mutated ß- 
8 
catenin which is resistant to GSK3-ß-dependent phosphorylation and, consequently, 
degradation (50). Stabilising mutations in the ß-catenin gene and, less commonly loss of 
function mutations in APC, have also been reported with varying incidence in many other 
human tumour types including breast, endometrial, gastric, hepatocellular, ovarian and 
pancreatic cancer (28). 
1.1.4 Plakoglobin 
Plakoglobin, also called y-catenin, can substitute for ß-catenin but preferentially binds to 
desmosomal cadherins (51). Plakoglobin shares overall 70% amino acid identity with 
catenin and as much as 80% within the Armadillo domain (29). Plakoglobin binds E- 
cadherin, a-catenin, APC, and TCF transcription factors, and is involved in cell adhesion 
as well as Wnt signalling. However, differences exist in both the N-terminal regulatory 
events and in the pattern of TCF target gene expression (29). The potential role of 
plakoglobin in cancer has been less extensively studied. 
1.1.5 p 120-ca Lenin 
p120 was initially identified as a Src substrate whose tyrosine phosphorylation correlated 
with transformation (52) and was subsequently recognised to be a catenin (8,53,54) and 
the prototypic member of a new subfamily of Armadillo proteins (55). Whilst p120 is 
ubiquitously expressed other family members, namely ARVCF (Armadillo Repeat gene 
deleted in Velo-Cardio-Facial syndrome), S-catenin, p0071 and the plakophilins tend to 
have a tissue specific distribution and have been less extensively studied (55). Although 
over-expression of p120 can rescue depletion of ARVCF and vice versa (56) there is 
currently no strong evidence for functional redundancy in vivo. 
In common with ß-catenin, p120 exists in membrane, cytoplasmic and nuclear fractions 
and cadherins are both necessary and sufficient for recruitment of p120 to the cell 
membrane (9,10). It is increasingly clear that p120 is a fundamental regulator of epithelial 
biology with functions which place it at a critical intersection in the regulation of cell-cell 
adhesion and, potentially, invasion. For clarity these regulatory roles will be considered in 
turn but, by virtue of crosstalk occurring at multiple levels, any such distinction is 
somewhat arbitrary. 
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Figure 1-3 Catenins regulate gene expression. 
In the absence of Writ signalling cytoplasmic ß-catenin is bound by the APC / axin / GSK- 
3ß complex and phosphorylated by GSK-3ß. Phosphoryation targets 3-catenin for 
degradation by the ubiquitin-proteosome pathway. Writ signalling via its receptor Frizzled 
activates Dishevelled (Dsh) which inhibits GSK-3ß thus causing accumulation of 13- 
catenin. Loss of function mutations in APC or stabilising mutations in ß-catenin have a 
similar effect. Cytoplasmic ß-catenin can then translocate to the nucleus where it interacts 
with the TCF family of transcription factors to promote transcription of target genes. 
Unlike ß-catenin, p120 has no specific degradative pathway and its level in the cytoplasm 
is determined primarily by cadherin levels. In the nucleus p120 competitively inhibits the 
interaction of the transcriptional repressor Kaiso with DNA hence increasing transcription. 
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1.1.5.1 p120 isoforms and nomenclature. 
Due to alternative splicing of a single gene there may be as many as thirty-two isoforms of 
p120 (57). These isoforms are expressed in a cell and tissue specific manner (58) which 
may be altered in malignancy (59,60) and which have distinct effects when over-expressed 
(61). The four major p120 isoforms in the human are generated by alternative N-terminal 
splicing events leading to the use of one of four different start codons (57) and are labelled 
isoform 1-4 in order of reducing size (Figure 1-4). Alternative splicing at the C-terminal 
end leads to inclusion of exons A or B. A third exon, labelled C, is rarely translated and 
encodes a looped out region within the central Armadillo region. A specific isoform is 
therefore designated 1-4 depending on the start codon used and attributed the letters of any 
additional coded exons (55). In this way isoform IABC is the longest and 4N (N = none) is 
the shortest. Isoform 1 and 3 are the most commonly expressed whilst 4 is rarely detected. 
In the mouse two major isoforms have been identified which correspond with human 
isoforms 1 and 3 (59). There is a high degree of conservation between human and murine 
p120 with 97.2% homology at the protein level for isoform 1A although there does not 
appear to be a murine equivalent of exon C. 
As alluded to above, the pattern of expression of isoforms varies between different tissues 
but is constant between tissues of fetal and adult origin (60). Motile cell lines such as 
fibroblasts and macrophages preferentially express isoform 1 while epithelial cell lines 
express predominantly isoform 3. Immunohistochemical studies of mouse tissues have 
shown that isoform 3 is expressed primarily at the cell-cell junctions of keratinocytes, 
squamous epithelium of oesophagus and also in villi of small intestine (58). These tissues 
stained weakly or not at all for isoform 1 which was present at cell-cell junctions of 
vascular endothelial cells, serosal epithelium, retina and intercalated discs of 
cardiomyocytes. 
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Figure 1-4 p120 structure and isoforms. 
Four major p120 isoforms exist due to alternative N-terminal splicing events resulting in 
the use of different start codons. Furthermore, alternative splicing also determines the 
inclusion of exons A, B or C (purple boxes). The longest isoform, p120-1ABC, is 
illustrated along with two shorter isoforms for comparison. Arrows indicate the start sites 
for each major isoform. p120 isoform 1, but not isoforms 2-4, contains an N terminal 
coiled-coil domain (blue box). The regulatory domain (red box) contains all identified sites 
of tyrosine phosphorylation (96,112,228,257,280,291,296,302; red diamonds) and six 
of the eight identified sites of serine / threonine phosphorylation (122,252,268,288,310, 
312; but not 873 and 910; green circles). Tyrosine-96 is present in isoforms I and 2 but not 
3. Isoform 4 lacks the entire regulatory domain. All isoforms contain a central Armadillo 
domain which consists of 10 Armadillo repeats. Exons A and B encode additional 
sequences in the carboxy terminal region whilst exon C encodes a short sequence within 
the Armadillo domain (adapted from (62)). 
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1.1.5.2 Structure of p120. 
p120 contains a central Armadillo domain consisting of 10 Armadillo repeats (Figure 1-4) 
(55). By comparison with the known crystal structure of ß-catenin each repeat consists of 
three helices and all 10 repeats would be predicted to pack together forming a long 
positively charged groove (63). Armadillo repeats four, six and nine contain additional 
short looped out structures between the second and third helices. The additional looped 
sequence within Armadillo repeat six constitutes a highly basic, nuclear localisation 
sequence (64). The Armadillo domain mediates protein-protein interactions and is 
necessary for the interaction of p120 with cadherins (65), Kaiso (66) and tubulin (67). 
At the N-terminus of full length p120, but not isoforms 2-4, is a coiled-coil region, a motif 
usually associated with protein-protein interactions. However, no binding partners for this 
region in p120 have yet been reported. Between this region and the Armadillo domain lies 
the regulatory domain, so called because most sites of tyrosine and serine / threonine 
phosphorylation are contained within. Using a 2-dimensional tryptic mapping approach 
Mariner et al identified eight sites of tyrosine phosphorylation in p120 isolated from 
fibroblasts expressing constitutively-active Src. These residues, tyrosines 96,112,228, 
257,280,291,296 and 302 are all contained within the regulatory region (68). Of these 
only tyrosine-291 is not conserved in human, mouse and chicken. Subsequently, serine 
residues 122,252,268 288,312, and 873 and threonine residues 310 and 910 were also 
identified as sites of phosphorylation (69). Again, with the exception of C-terminal serine- 
873 and threonine-910, all of these sites are contained within the regulatory region. 
Exon A encodes a twenty-one amino acid sequence in the carboxyl terminal region 
adjacent to serine-873. When present this sequence reveals a protein kinase C 
phosphorylation consensus sequence for serine-873 (69). Exon B encodes a highly 
negatively charged stretch of twenty-nine amino acids at the carboxyl terminus which 
contains a bona fide nuclear export signal (70). Exon C codes for six amino acids which, 
when expressed, may disrupt the nuclear localisation signal within Armadillo repeat six. 
1.1.5.3 p120 regulates the surface retention of cadherin. 
To date the main function identified for p120 at the AJ is to stabilise membrane-bound 
cadherin via the regulation of cadherin trafficking. 
13 
1.1.5.3.1 Cadherin Trafficking is a continuous process. 
Ms are not static but rather must be amenable to rapid remodelling during, for example, 
embryogenesis or wound healing. Even in a confluent epithelial monolayer there is a 
continual endocytosis and recycling of cadherin molecules, albeit to a lesser extent than in 
subconfluent cells (71). A variety of proteins have been implicated in the exocytic and 
endocytic trafficking of cadherins although the mechanisms of cadherin trafficking are not 
yet fully elucidated (72). Exocytosis of cadherin requires sorting of cadherin and delivery 
in a polarised manner to the basolateral membrane. This requires a conserved dileucine 
motif in the cadherin JMD which is recognised by a specific adaptor complex at the trans 
golgi network which directs cadherin molecules into clathrin coated vesicles for polarised 
exocytosis (73). Several routes of cadherin endocytosis have been identified including 
clathrin-dependent (71,74-76) and independent mechanisms (77) and caveolae (78,79). 
Thus, multiple pathways of cadherin endocytosis and exocytosis may exist, the relative 
contribution of which may be determined by cellular context or specific regulatory events. 
1.1.5.3.2 p120 regulates cadherin trafficking. 
Recent evidence has identified p120 as a key determinant of cadherin trafficking and 
suggests that regulating the membrane retention of cadherin is the core function of p120 at 
the AJ (80). The first clue linking p120 to cadherin stability was the finding that the SW48 
colon cancer cell line lacked p120 due to mutations in both alleles, had reduced levels of 
E-cadherin, and displayed impaired intercellular adhesion (81). Reconstitution of SW48 
cells with exogenous p120 caused a 10-fold increase in E-cadherin levels and a rescue of 
epithelial morphology. Levels of E-cadherin RNA transcripts were unaltered but the half- 
life of E-cadherin was more than doubled indicating a post-transcriptional effect of p120. 
Deletional studies of the p120 Armadillo repeats showed this effect to be dependent on 
direct interaction of p120 with E-cadherin (81). Subsequently Xiao and Davis 
independently utilised siRNA to demonstrate a dose-dependent reduction in E- , P- , N- 
and VE-cadherin levels in response to p 120 silencing in a variety of cell lines (82,83). In 
the absence of p120 there was no difference in the rate of synthesis of cadherin molecules 
or in the rate of their delivery to the plasma membrane. However, on arrival at the plasma 
membrane cadherin molecules were rapidly endocytosed and degraded by a proteosomal I 
lysosomal pathway (82,83). The level of p120 and the levels of cadherins were strictly 
related indicating that p 120 functions as a "rheostat" to control the steady state level of 
cadherins (80). Furthermore, ß-catenin and a-catenin are degraded in the absence of E- 
cadherin and thus the p120-cadherin interaction determines the stability of the entire 
complex. In this respect p120 has been called the "master-regulator" of the AJ (62). 
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This appreciation of p 120's role has also provided a prism through which to re-evaluate 
earlier literature on cadherin biology. For example, the observation that expression of 
dominant negative cadherins (which have intact cytoplasmic but non-functional 
extracellular domains) causes downregulation of endogenous cadherin (84-86) is now 
explained by competition of exogenous and endogenous cadherin molecules for a limiting 
pool of p120 (82,87). Importantly, work utilising DN-cadherins has also provided further 
evidence for the key role of p120, rather than ß-catenin, as master regulator of the AJ (82). 
Firstly, forced expression of p120 but not ß-catenin prevents downregulation of 
endogenous cadherin by DN-cadherins. Secondly, DN-cadherins require an intact JMD but 
not CBD if they are to cause downregulation of endogenous cadherin. 
1.1.5.3.3 Mechanisms by which p120 may regulate cadherin trafficking. 
Several non-exclusive models with varying levels of evidence have been proposed by 
which p120 could inhibit the internalisation and destruction of cadherin (80,88). 
1. p120 acts as a "cap" to inhibit endocytosis. 
Fusion of the VE-cadherin cytoplasmic domain to the interleukin 2 receptor (IL-2R) 
extracellular domain dramatically enhanced IL-2R endocytosis suggesting that the 
cadherin cytoplasmic region encodes a signal for constitutive internalisation (75). 
Internalisation of the chimeric protein occurred via a clathrin mediated pathway and 
was inhibited by the over-expression of p120 and enhanced by a mutation in the 
cadherin JMD which prevented p120 binding. This inhibition of endocytosis was 
specific for VE-cadherin as overexpression of p120 did not interfere with the 
internalisation of other proteins known to undergo clathrin mediated endocytosis 
such as the transferrin receptor. p120 could not be detected with internalised 
cadherin. Taken together this suggested a model where p120 might function to "cap" 
the cytoplasmic domain, preventing the access of adaptor proteins which would 
recruit VE-cadherin to clathrin mediated endocytosis (75). It is not known whether 
the cytoplasmic domains of other cadherins contain similar signals for constitutive 
endocytosis. However, the JMD of E-cadherin interacts with Hakai, an E3 ubiquitin 
ligase, in a mutually exclusive manner with p120 (11). On binding E-cadherin Hakai 
induces ubiquitination and endocytosis of the cadherin complex. The effect of Hakai 
is specific for E-cadherin and whether similar molecules regulate other cadherins is 
unknown. As will be discussed below, both the interaction of p 120 with VE-cadherin 
and Hakai with E-cadherin are regulated by tyrosine phosphorylation (11,89). 
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2. p120 stabilises cadherin via the promotion of stable adhesions. 
The constitutive turnover of cadherin is diminished as cells become confluent 
suggesting that the engagement of cadherin molecules in AJs might directly inhibit 
their endocytosis (71). Several lines of evidence implicate p120 in the conversion of 
initial cell-cell contacts into mature Ms. For example, cadherin molecules with a 
p120 uncoupling mutation in the JMD can mediate some cell-cell adhesion but cells 
typically display defects in cadherin clustering (90), cadherin mediated signalling 
(91), local organisation of the actin cytoskeleton and formation of stable cell-cell 
junctions (10). Thus by promoting the formation of stable Ms p120 may reduce the 
pool of free cadherin available for endocytosis. 
3. p120 promotes recycling from the endocytic pathway to the plasma membrane. 
Experimental evidence so far has not been of sufficient temporal or spatial resolution 
to definitively demonstrate whether p120 acts to inhibit internalisation or whether 
p120 is involved in trafficking already endocytosed cadherin away from destructive 
pathways back to the plasma membrane. This possibility is suggested by the finding 
that p 120 promotes the trafficking of newly synthesised N-cadherin to intercellular 
junctions (92). Specifically, N-cadherin associates with p120 (via the p120 
Armadillo domain) in the perinuclear golgi region immediately after it is synthesised 
(93). The N-terminal domain of p120 then interacts with kinesin heavy chain thus 
facilitating transport of the N-cadherin-catenin complex along the microtubule 
network to the cell membrane (67,92). However, whether p 120 may similarly 
regulate the trafficking of endocytosed cadherin is not known. 
1.1.5.3.4 p120 similarly stabilises cadherins in vivo. 
Recently the in vitro role of p120 as master regulator of the AJ has been confirmed in vivo. 
The depletion of p120 with morpholino oligonucleotides (stable oligonucleotides 
complementary to the translation start site which effectively block translation of the target 
gene) in Xenopus embryos caused a loss of AJ proteins which was associated with gross 
defects in early embryogenesis (56). Similarly, knockout of p120 was lethal at an early 
stage of murine embryogenesis (62). However, the creation of transgenic mice with 
targeted deletion of p120 in the skin or salivary gland was possible and resulted in loss of 
E-cadherin, a- and ß-catenin in these tissues (94,95). In the salivary gland this was 
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associated with severe defects in epithelial polarisation and glandular morphogenesis. 
Depletion of p120 in the skin also caused loss of AJ components although, surprisingly, no 
overt defect in morphology. Ultrastructural analysis showed desmosomes to be intact and 
functional studies identified no defect in barrier function. However, in-keeping with the 
phenotype of p120 deficient cell lines, primary keratinocytes derived from p120 null skins 
were unable to form effective junctions when cultured in vitro. The requirement for AJs to 
exist for the formation of tight junctions and desmosomes in vitro but not in vivo is 
intriguing and may reflect the fundamentally different environmental contexts. 
Specifically, keratinocytes in vivo are packed together and adopt a cuboid morphology 
whereas cultured cells in vitro are less densely packed and are flat rather than columnar so 
that the surface area for adhesive interaction is reduced. In vitro there may also be cell- 
substratum signalling or actin dynamics which do not favour AJ formation. 
Despite this evidence confirming p120 as a master-regulator of the AJ in vertebrates, the 
depletion of p 120 did not alter levels of AJ proteins in Drosophila or C. elegans. 
Furthermore, p120 was not required for their development even though the genomes of 
these organisms lack potentially redundant p120 family members (96,97). However, in 
both organisms loss of p120 potentiated the effect of mutations in cadherin or other 
catenins suggesting a positive but non-critical role for p 120 at the AJ. The critical 
requirement for p120 in vertebrate, but not invertebrate, development is likely to reflect the 
increased complexity and regulation of the AJ in evolutionary higher organisms. 
1.1.5.4 p120 regulates Rho GTPases. 
Multiple lines of evidence link p120 to the Rho family of small GTPases which includes 
RhoA, Rac and Cdc42. Rho GTPases control a wide variety of signal transduction 
pathways impacting on cell polarity, microtubule function, membrane trafficking and 
survival (98). However, it is their key regulatory role in control of the actin cytoskeleton, 
adhesion and motility which is most relevant in understanding the potential role of Rho 
GTPases in neoplastic invasion (99,100). 
1.1.5.4.1 The activity of Rho GTPases is tightly regulated. 
Rho family GTPases cycle between an inactive GDP-bound state and an active GTP-bound 
form (Figure 1-5). These processes are controlled by specific regulatory proteins. Rho 
GTPase activating proteins (GAPs) catalyse the hydrolysis of GTP to GDP and therefore 
cause inactivation. Conversely, Rho guanine nucleotide exchange factors (GNEFs) 
promote exchange of GDP for GTP and hence increase activity. Rho GTPases are often 
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bound to a third class of regulatory protein, guanine dissociation inhibitors (GDIs), which 
stabilise the Rho-GDP interaction maintaining the inactive state. Binding of the Rho-GDI 
complex to an activated receptor promotes release of the Rho GTPase which is then free to 
be activated by local GNEFs. The activity of Rho GTPases is thus tightly controlled both 
spatially and temporally within the cell to ensure specific and localised effects (98,101). 
1.1.5.4.2 Rho GTPases regulate the actin cytoskeleton. 
The activity of each Rho GTPase is associated with a specific type of remodelling of the 
actin cytoskeleton (102). Increased activity of RhoA results in the formation of contractile 
actin-myosin filaments known as stress fibres and promotes the formation of integrin- 
containing cell-matrix focal contacts. Rac activity promotes the formation of a meshwork 
of actin filaments at the cell periphery which form lamellipodia. Cdc42 activity causes the 
formation of peripheral actin rich protrusions known as filopodia. Integrin dependent cell- 
matrix adhesion, cadherin-based cell-cell adhesion and cellular motility are all processes 
dependent on the integrity and appropriate remodelling of the actin cytoskeleton and Rho 
GTPases are therefore in a pivotal position to regulate these activities. For this reason 
aberrant activity of Rho GTPases might be expected in invasive carcinomas and indeed 
increased levels and activity of Rho GTPases have been reported in breast, colon and lung 
cancer (103). In vitro studies have demonstrated a direct role for Rho and Rac proteins in 
invasion (103). However, the influence of Rho GTPases on adhesion and invasion is 
complex and may vary depending on the particular cell context or be influenced by specific 
integrin-derived signals (104). One such example is the activation of Rac by its GNEF, 
Tiam1, which promotes adhesion in Ras- or Src-transformed MDCK cells (105,106) but 
has the opposite effect in a breast cancer cell line (107). 
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Figure 1-5 Regulation of Rho GTPases 
Rho GTPases exist in either an inactive GDP-bound or active GTP-bound state. Guanine 
nucleotide exchange factors (GNEFs) promote the exchange of GDP for GTP thus 
favouring activation whilst GTPase-activating proteins (GAPs) catalyse the hydrolysis of 
GTP to GDP causing inactivation. GDP-dissociation inhibitors (GDIs) associate with GDP 
bound Rho proteins keeping them in the inactive state. p 120 can activate Rac and Cdc42 
via the recruitment of Vav2, a GNEF. p120 also directly interacts with and inhibits RhoA 
in a GDI-like manner. 
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1.1.5.4.3 Rho GTPases regulate the AJ. 
The activity of Rho GTPases has been associated both positively and negatively with the 
AJ. Several studies have demonstrated a requirement for Rho GTPases in AJ formation 
(108-111). Indeed, Rho GTPase driven actin polymerisation directly determines the 
physical strength of intercellular adhesion (112). This activity of Rho GTPases is required 
at multiple stages of cell-cell adhesion. For example, one of the earliest steps in AJ 
formation is the Rho GTPase-dependent formation of multiple filopodia (113) or 
lamellipodia (114) (the specific structure appears to vary with cell type) which become 
embedded in the plasma membrane of the opposing cell. Further Rho GTPase dependent 
actin reorganisation is also involved in later stages such as the formation of a 
circumferential actin "cable" interconnecting cells throughout the entire epithelial sheet 
(113). In contrast, the forced expression of constitutively active RhoA (115) or Rac (78, 
116) has been associated with disruption of AJs and loss of cell-cell adhesion. 
The molecular mechanisms by which Rho-GTPases regulate the AJ, positively or 
negatively, are poorly defined although actin regulation appears to be a critical event (103, 
117,118). The apparently contradictory data showing both positive and negative effects on 
adhesion presumably reflects a need for tight spatio-temporal regulation if productive 
adhesions are to be formed. One possible molecular explanation was provided by Sahai 
who identified two opposing pathways by which Rho signalling may regulate AJs (115). 
Firstly, Dia-dependent actin polymerisation stabilised AJs. Secondly, ROCK-mediated 
acto-myosin contractility disrupted AJs. Which pathway dominated depended on the level 
of Rho activity and on the expression of particular Rho members. Low levels of RhoA 
activity favoured signalling through Dia whereas higher levels preferentially signalled to 
ROCK. In contrast, even low levels of activity of RhoC, a close relative of RhoA linked to 
metastasis (119), favoured signalling to ROCK. (115). 
A potential mechanism by which Rae and Cdc42 may promote AJ formation is provided 
by IQGAPI which localises to cell-cell junctions and negatively regulates adhesion by 
binding ß-catenin and displacing a-catenin from the AJ (120). Active Rae and Cdc42 bind 
and sequester IQGAP 1 thus preventing its interaction with ß-catenin and positively 
regulating adhesion (121). Rho GTPases may also regulate the endocytic trafficking of AJ 
proteins (122) and expression of dominant negative (DN)-Rac or Ccd42 mutants in MDCK 
cells effectively blocked trafficking of E-cadherin from the trans-Golgi network to the 
basolateral membrane (123). 
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1.1.5.4.4 Rho family GTPases are regulated by cytoplasmic p120. 
The first suggestion that p120 may act in concert with Rho family GTPases to regulate the 
actin cytoskeleton came from the distinct phenotype observed in NIH3T3 fibroblasts 
forced to over-express p120 (124). This caused cells to adopt a so-called dendritic 
morphology characterised by long branching processes suggestive of active actin 
remodelling. Subsequently three groups independently demonstrated that over-expression 
of p120 in fibroblasts resulted in loss of actin stress fibres and focal adhesions, acquisition 
of a dendritic phenotype and increased cell motility (125-127). Critically, this phenotype 
could be suppressed by co-transfection of cells with DN-Rac or DN-Cdc42 and was 
exacerbated by expression of DN-RhoA. Affinity precipitation assays confirmed that Rac 
and Cdc42 activity was increased whereas RhoA activity was diminished. Finally, 
sequestration of p 120 from the cytoplasm to the membrane by over-expression of E- 
cadherin abrogated any effects on GTPase activity. Although these experiments utilised 
supra-physiological amounts of p120 they provide proof-of-principle that p120 regulates 
Rho GTPases and that this effect is mediated by free cytoplasmic rather than cadherin- 
bound p 120. 
Similar effects of cytoplasmic p120 have subsequently been identified in epithelial cells. 
For example, RNAi-mediated depletion of p120 in the SKBR-3 breast cancer cell line 
(which lacks E-cadherin and in which p120 is cytoplasmic) caused an increase in RhoA 
activity but no change in Rac activity (128); re-localisation of p120 from the membrane to 
the cytoplasm increased Rac and Cdc42 activity in a pancreatic cancer cell line (129); and 
TGFO-treated LIM1863 colorectal cancer cells have increased cytoplasmic p120 which is 
associated with inhibition of RhoA activity (130). Despite the evidence that over- 
expression of p120 appears to inhibit RhoA and activate Rac in most cell types there are 
exceptions. For example, in keratinocytes the over-expression of p120 activated RhoA in a 
Ras / PI 3-K dependent manner but had no effect on Rac or Cdc42 (131). In MCF-1OA 
breast epithelial cells RNAi-mediated depletion of p120 increased Rac activity whilst over- 
expression of p120 or the introduction of a p120 uncoupling mutation in the E-cadherin 
JMD, both of which caused cytoplasmic accumulation of p120, inhibited Rac activity 
(132). 
A potential molecular explanation for Rac and Cdc42 activation by p120 was elucidated by 
Noren et al who observed the co-immunoprecipitation and hence potential recruitment of 
Vav2, a GNEF for RacI and Cdc42, by p120 (125). Co-expression of a dominant negative 
Vav2 mutant with p120 was sufficient to abrogate p120's ability to induce a dendritic 
phenotype in fibroblasts. Taken together this strongly suggested that activation occurred 
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via the p120 / Vav2 complex (125). The mechanism by which cytoplasmic p120 might 
inhibit Rac activation in MCF-1OA cells has not been addressed (132). 
p120 appears to inhibit RhoA by direct GDI activity although p120 shares no sequence 
homology with known Rho GDIs. However, using purified proteins, p120 demonstrated in 
vitro RhoGDI activity (127). Similarly, in Drosophila p120 was found to interact directly 
with Rho! the Drosophila homolog of RhoA. Consistent with a GDI role, p 120 interacted 
preferentially with GDP rather than GTP-bound RhoI (133). The inhibition of RhoA 
activity by cytoplasmic p120 in LIM1863 cells was associated with formation of a p120- 
RhoA complex, again consistent with p 120 having direct GDI activity. 
1.1.5.5 p120 and RhoGTPases cooperate in AJ formation and cadherin- 
activated signalling. 
In addition to the studies linking cytoplasmic p120 to the regulation of Rho GTPases there 
is also data suggesting a more spatially restricted and perhaps more physiological role for 
membrane localised p120 in mediating the activation of RhoGTPases following cadherin 
engagement. This might reflect a situation where cytoplasmic p120 binds RhoA causing 
direct inhibition via its RhoGDI activity. On recruitment to cadherin complexes at the 
basolateral membrane p120 could then release RhoA creating a pool available for 
activation by local GNEFs which may then contribute to AJ function (62). A paradigm for 
this type of spatio-temporal control is the binding of Rho-GDI complexes to CD44 which 
is coupled to release and local activation of Rho (101). Alternatively, as discussed below, 
cadherin-bound p120 may be an integral part of the cadherin-activated signal transduction 
machinery as evidenced by the inability of cadherins with a p120 uncoupling mutation to 
activate Rac when ligated (91,134). 
1.1.5.5.1 Cadherin-activated signalling. 
Rac, PI 3-K, SFKs and EGFR are recruited to and activated at nascent Ms (135-138). 
These events can be blocked by an E-cadherin neutralising antibody (DECMA-1). 
However, to clarify whether such events were cadherin-dependent (that is cadherin 
engagement simply functioned to bring cell membranes into apposition facilitating 
juxtacrine signalling events) or whether they were truly cadherin-activated, several groups 
developed model systems where cadherin expressing cells are plated at low density and in 
the absence of serum on to an artificial surface expressing recombinant cadherin 
extracellular domains (14,139-142). This reductionist approach has provided proof that 
cadherin ligation in the absence of other juxtacrine interactions is sufficient to initiate 
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intracellular signalling and that this is important for coordinated changes in the actin 
cytoskeleton required for the formation of stable cell-cell adhesions. The two molecules 
most implicated are the small GTPase, Rac and the lipid kinase, PI-3 kinase. 
E-cadherin expressing cells plated on a substrate coated with E-cadherin extracellular 
domain underwent rapid cell spreading with the development of prominent lamellipodial 
protrusions (143). Both Rac and PI 3-K were activated and were co-localised with AJ 
components at the leading edge of lamellipodia. Rae activation consisted of an early PI 3- 
K independent phase followed by a PI 3-K dependent amplification phase. The conversion 
of initial contacts to broad zones of adhesion required the activity of both Racl and PI 3-K. 
PI 3-K inhibition could be overcome by a DA-Rac mutant consistent with PI 3-K acting as 
an upstream activator of Rac (143). Critically, a minimal p120-uncoupling mutation in the 
E-cadherin JMD prevented recruitment or activation of Rac and the formation of stable 
adhesions although activation of PI 3-K was not altered (91). This was highly suggestive of 
a role for p120 in cadherin-mediated Rac activation. Subsequent work by Gavard et al has 
further implicated p120 as an essential player in this process. N-cadherin expressing 
myogenic C2 or S180 cells plated on a recombinant N-cadherin substrate typically 
underwent two experimentally distinguishable responses (134). Firstly, the induction of 
lamellipodial protrusions associated with new actin assembly which was PI 3-K and Rac- 
dependent. Secondly, the PI 3-K-independent / Rac-dependent reorganisation of N- 
cadherin, catenins and actin filaments into higher order "cadherin adhesions" located at the 
tips of lamellipodia. The formation of "cadherin adhesions" was inhibited by activated 
RhoA. Silencing of p120 by RNAi prevented both lamellipodium extension and cadherin 
adhesion formation from occurring. Lamellipodia extension but not maturation of contacts 
into "cadherin adhesions" could be rescued by expression of DA-Rac. Additionally, high 
level over-expression of p120 had an inhibitory effect, apparently by inhibition of Rac and 
this could be prevented by sequestration of p 120 at the membrane by a cadherin JMD 
construct. This would suggest that membrane-localised p120 is essential for the activation 
of Rac by cadherin engagement and that an excess of cytoplasmic p120 may inhibit this 
activation, perhaps by sequestering GEFs. 
1.1.5.5.2 Regulation of Rho GTPases by p120 in vivo. 
Several lines of evidence suggest that the effects of p120 on Rho GTPases identified in 
vitro may be relevant in vivo. Over-expression of p120 in Drosophila embryos enhances 
the Rho1 null phenotype consistent with it being a negative regulator of Rhol activity 
(133). In Xenopus the carefully titrated expression of DN-RhoA, DA-Rac or C-cadherin 
was sufficient to rescue the defect seen in gastrulation resulting from p120 depletion (56). 
23 
This would be consistent with a role for endogenous p120 in inhibiting RhoA, activating 
Rac and stabilising cadherin. Whether DN-RhoA and DA-Rac acted by enhancing the 
adhesive or signalling function of residual cadherin or by regulating the trafficking of 
cadherin was not addressed. Finally, levels of active RhoA were increased in the epidermis 
of mice with conditional deletion of p120 in the skin (95). Taken together, these in vivo 
finding are in keeping with the in vitro data suggesting that, in many cell types, p120 
inhibits RhoA and activates Rac. 
1.1.5.6 p120 regulates gene transcription via Kaiso. 
Utilising a yeast-two hybrid assay with p120 as bait, Daniel et al. identified a novel 
transcriptional repressor which they named Kaiso (66). Kaiso was an addition to the 
BTB/POZ (Broad complex, Tramtrak, Bric a brac, Pox virus and Zinc finger) family, 
containing an amino-terminal protein-protein interaction POZ domain and a carboxy- 
terminal DNA-binding zinc finger domain. Other members of this family include BCL-6 
and PLZF which have been causally implicated in non-Hodgkin lymphoma and acute 
promyelocytic leukaemia respectively (144). Kaiso is a bi-modal DNA binding protein 
able to recognise both methyl-CpG sequences and the non-methylated sequence CTGCNA 
(145,146). The interaction of p120 with Kaiso is mediated by p120 ARM repeats 1-7 and, 
interestingly, the carboxy-terminal DNA-binding region of Kaiso rather than the N- 
terminal protein-protein interaction domain. Consequently the interaction of p120 with 
Kaiso inhibits Kaiso-DNA binding in vitro either via direct steric hindrance or 
conformational change (146). Similarly, in vivo studies demonstrated that both Kaiso- 
DNA interaction and Kaiso-mediated transcriptional repression are inhibited by over- 
expressed p120 (147-149). Inhibition of Kaiso-mediated transcriptional repression requires 
an intact p120 nuclear localisation sequence suggesting that p120 inhibits Kaiso in the 
nucleus rather than by sequestering Kaiso in the cytoplasm (64,147,149). This action of 
p120 is reminiscent of, but mechanistically different to, that of ß-catenin. Specifically, in 
the absence of (3-catenin TCFs repress transcription either by acting in an endogenous 
dominant negative fashion or by recruiting transcriptional repressors such as Groucho. 
Binding of ß-catenin does not displace TCFs from DNA but rather functions to contribute 
a transactivation domain and to recruit other components of a larger promoter complex 
(47). In contrast, Kaiso appears to repress transcription via recruitment of the histone 
deacetylase-containing N-CoR complex and the role of p120 is to dissociate this entire 
complex from DNA, hence facilitating transcription (148,150). 
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Several Kaiso target genes with potential roles in development and / or cancer have now 
been identified including MMP7 (149), rapsyn (151), MTA2 (150), Wntl1 (147), Siamois, 
c-Fos, Cyclin D1 and c-Myc (148). Crucially, some of these are also targets of the 
canonical Wnt pathway and therefore p120-Kaiso and ß-catenin-TCF may regulate target 
genes in parallel (Figure 1-3) (152). A further level of interaction is provided by the ability 
of Kaiso to interact directly with TCFs thus providing a second mechanism by which it can 
recruit N-CoR to Wnt target genes (148). It is unclear what upstream pathways might 
regulate the p120-Kaiso interaction. Unlike ß-catenin, a dedicated destructive pathway has 
not been identified for p120 and there is no evidence that p120 acts downstream of Wnt 
receptor activation (144). Therefore potential levels of regulation could include: 1) altered 
cadherin-p 120 binding thus leading to an increased pool of cytoplasmic p120; 2) altered 
nucleo-cytoplasmic shuttling of p120; or 3) a p120 isoform switch which can, in itself, 
influence nuclear localisation. An exciting but untested hypothesis is that parallel 
regulation of canonical Wnt target genes by TCFs and Kaiso may allow for differential 
regulation by cadherins, acting via ß-catenin and p120, versus Wnt signalling acting via ß- 
catenin alone (152). 
Recent evidence suggests biologically significant roles for Kaiso both in development and 
cancer. Depletion of Kaiso caused severe defects in gastrulation of Xenopus embryos (147, 
153). In contrast deletion of the mouse Kaiso gene did not result in any obvious phenotype 
perhaps due to redundancy with the protein Kaiso-like 1 which is absent in amphibians. 
Alternatively, as zygotic transcription is detected at the two cell stage in mice but not until 
the 5000 cell mid-blastula stage in frogs, a requirement for Kaiso in ensuring delayed 
activation of genes may have no murine counterpart (51). 
When the Kaiso-null mouse was crossed with the ApcM""+mouse, a model for human 
adenomatous polyposis (154), a significant reduction in intestinal tumorigenesis was 
observed (51). In addition Kaiso was found to be upregulated in invasive tumours 
developing in Muc2-/' mice and was present, although not consistently upregulated, in 
human colorectal tumours (51). Tumorigenesis in the mouse intestine is dependent on 
DNA methylation (155) and it seems likely that Kaiso could promote intestinal 
tumorigenesis via the repression of methylated tumour suppressor genes. The elucidation 
of p 120's role in this process and how it might be regulated will be fascinating. 
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1.1.5.7 p120 is altered in human cancer. 
An alteration in the protein level or localisation of p120 is a common observation in human 
cancers. However, the incidence of other potential tumour related changes such as altered 
p120 isoform expression or elevated tyrosine phosphorylation are less well defined. 
1.1.5.7.1 p120 is commonly reduced or mis-localised in cancer. 
In normal epithelial tissues p120 co-localises with E-cadherin at cell-cell junctions and is 
not detectable in the cytoplasm. To date there are almost 20 reports in the pathology 
literature describing altered levels or localisation of p120 in colorectal, oesophageal, 
gastric, pancreatic, bladder, prostate, endometrial, cutaneous squamous cell, melanoma, 
non-small cell lung and breast tumours (summarised in (156)). The most useful studies 
attempt to correlate p120 staining with that of other AJ components although a significant 
number have studied p120 in isolation. Also differences in the categorisation of 
immunohistochemical staining patterns by different authors hinders cross comparison of 
studies. The largest series is that of Bellovin who, utilising a tissue array containing 557 
colorectal tumours, reported complete loss of p120 in 5.4% of cases, re-localisation of 
p120 from the membrane to the cytoplasm in 52.9% and normal membranous distribution 
in 41.7% (130). All tumours with absent p120 demonstrated absent or cytoplasmic E- 
cadherin. In tumours with cytoplasmic localisation of p120, E-cadherin was absent in 36%, 
cytoplasmic in 62% and membrane-localised in only 2%. Smaller colorectal studies report 
a higher incidence of complete loss of p120 expression in 18-23% of cases (157-159). 
In a study of 193 non-small cell lung cancer specimens Bremnes reported absent or low 
membranous p120 staining in 61% of cases, intermediate staining in 33% and high in 6%. 
Again, p120 and E-cadherin expression were significantly correlated. A second study 
confirmed cytoplasmic redistribution of p120 in 114 of 143 (79.7%) of non-small cell lung 
cancers (160). 
In invasive ductal breast cancers complete loss of p120 occurs in 2.1-10% of cases with 
reduced membranous staining in 40-57% and normal membranous staining in 30.8-50% 
(161,162). Re-localisation of p120 to the cytoplasm appears to be a relatively uncommon 
event, occurring in approximately 10% of cases. In contrast, lobular breast cancers in 
which E-cadherin was undetectable in 78.3% and cytoplasmic in 8.7% demonstrated re- 
localisation of p120 to the cytoplasm in 88% of cases (162). Similar results were obtained 
in lobular carcinoma in situ and even atypical lobular hyperplasia underlining this as an 
early event in the neoplastic process (163). A high incidence of cytoplasmic redistribution 
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(90%) also occurred in diffuse-type gastric cancers, another tumour type characterised by 
loss of E-cadherin expression (164). 
In most studies the reduction or loss of p120 correlated with the grade and stage of the 
tumour (157,158,165-169). Unsurprisingly then, several studies also report altered p120 
to correlate with poor prognosis (130,158,165,166,168). However, in only one study did 
multivariate analysis suggest aberrant p120 expression to be an independent prognostic 
factor (168). 
Viewed in their entirety these descriptive studies are consistent with two key observations 
arising from the mechanistic p120 studies described above. Namely, 1) in the absence of 
p120, E-cadherin cannot be stably retained at the AJ; and 2) E-cadherin is necessary and 
sufficient to recruit p120 to the membrane and in its absence p120, which is relatively 
stable, can accumulate in the cytoplasm. The potential consequences of these observations 
for cancer will be considered more fully below. 
Finally, two important questions arise from these studies. Firstly, the mechanism by which 
p120 is lost in a minority of tumours, whether mutation, promoter methylation, 
transcriptional repression or post-translational modification is not known. Secondly, 
despite the evidence that approximately 5-20% of colon, breast, pancreatic and bladder 
cancers have undetectable p120, to date only one tumour derived cell line has been 
identified in which p120 is absent (81). Possible explanations are that the downregulation 
of p120 is a reversible event and is dependent on the tumour microenvironment. 
Alternatively, p120 null cells may, for as yet unknown reasons, be selected against during 
the establishment of cell lines in vitro. 
1.1.5.7.2 Alternative splicing leads to altered p120 isoform expression in cancer. 
Malignant cell lines often express an altered pattern of p120 isoforms in comparison to 
their tissue of origin (60). One such example is the absence of isoform 4A in cell lines 
derived from melanoma and cutaneous squamous cell carcinomas despite its presence in 
normal keratinocytes and melanocytes (61). Similarly, exon B which is present in p120 
from healthy pancreatic, prostate and colonic epithelia was absent in tumour tissues from 
the corresponding organs (61). In comparison to normal thyroid epithelium, four anaplastic 
thyroid carcinoma cell lines had an upregulation of p120 isoform 1 (170). Similarly, cell 
lines derived from a colorectal primary tumour and metastases from the same patient 
demonstrated upregulation of isoform 1 in the metastatic line (171). Interestingly 
expression of constitutively-active Src in MDCK cells is sufficient to cause an 
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upregulation of isoform 1 and concomitant downregulation of shorter isoforms (59). 
Furthermore, Snail, Slug or E47 induced epithelial-mesenchymal transition (EMT) 
(discussed in 1.3.1.2) in MDCK cells was associated with a switch from p120 isoform 3 to 
isoform 1 (162,172). A similar isoform switch occurred during c-Fos induced EMT in 
mouse mammary epithelial cells (173) although in other models of EMT such as TGFP and 
TNFct induced EMT in LIM1863 colon cancer cells no change in p120 isoform occurred 
(130). 
Unfortunately, despite the existence of antibodies which specifically detect p120 isoform 1 
(174) no large scale immunohistochemical study to identify the prevalence of p120 isoform 
switching in human cancer specimens has been performed. 
1.1.5.7.3 Tyrosine Phosphorylation ofp120. 
A constitutive increase in p120 tyrosine phosphorylation has been detected in a variety of 
tumour derived cell lines (175,176). However, whether and with what frequency elevated 
tyrosine phosphorylation of p120 may occur in cancers has barely been addressed. 
Nishimura et al demonstrated increased tyrosine phosphorylation of 100-130 kDa proteins 
in cell lysates from lung cancer tissue in comparison to adjacent normal mucosa and 
showed that a significant component of this could be attributed to p120 (177). However, 
large scale immunohistochemical studies have been impossible to date due to the lack of 
p120 phosphorylation state specific antibodies. 
1.2 Tyrosine phosphorylation regulates the AJ. 
The AJ is an active hub of tyrosine kinase signalling. Specifically, Src family kinases (178, 
179) and EGFR (137) are activated on cadherin engagement and participate in "outside-in" 
signalling pathways. Conversely, phosphorylation of AJ proteins by SFKs, EGFR or other 
receptor tyrosine kinases (RTKs) can mediate "inside-out" signalling by influencing the 
adhesive state or stability of the AJ (180). 
The major tyrosine kinase substrates within the AJ are p120, ß-catenin, and plakoglobin, 
but not a-catenin (180). For example, p120 is heavily phosphorylated in v-Src transformed 
cells (52) and in response to EGF, PDGF, CSF-1 and VEGF (181-184). Similarly ß-catenin 
and / or plakoglobin are phosphorylated in v-Src transformed cells (185,186) and in 
response to EGF (187-190), HGF (187), TGF-a (191) and IGF-1 (192). In most models 
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cadherins are only weakly phosphorylated (185-187,193). Nevertheless, cadherin 
phosphorylation has recently emerged as a significant regulatory event. 
In this section we consider some of the tyrosine kinases linked to phosphorylation of AJ 
proteins and consider the functional consequences of tyrosine phosphorylation for the AJ. 
Kinases may also regulate the AJ via mechanisms other than direct phosphorylation of AJ 
proteins such as via the regulation of acto-myosin contractility. In addition aberrant kinase 
activity can drive changes in gene transcription leading to the phenomenon of EMT and 
this is considered separately in section 1.3.1.2. 
1.2.1 Src family kinases (SFKs) 
1.2.1.1 Structure function relationships of SFKs. 
There are nine members of the Src family of kinases: Src, Yes, Fyn, Lyn, Lck, Hck, Blk, 
Fgr and Yrk. Most are expressed primarily in haematopoietic cells whilst Src, Yes and Fyn 
have a ubiquitous distribution with particularly high levels in platelets, neurons and 
osteoclasts and are also enriched at epithelial cell-cell junctions (138,194). SFKs are basic 
components of the cell signalling machinery and are involved in diverse signalling 
pathways promoting growth, survival, motility and invasion which originate from receptor 
tyrosine kinases, integrins, cadherins, cytokine receptors and G-protein coupled receptors. 
c-Src (hereafter referred to as Src) consists of an N-terminal unique region containing a 
myristylation site which is essential for membrane localisation, an SH3 domain, an SH2 
domain, a kinase domain and a C-terminal regulatory sequence (195). The SH3 domain 
mediates protein-protein interaction by binding proline rich sequences whilst the SH2 
domain binds regions containing phosphorylated tyrosines. Tyrosine-416 (by convention 
numerical positioning refers to chicken Src, the corresponding tyrosine residue in human 
Src is at position 418) which lies within the activation loop of the kinase domain undergoes 
autophosphorylation and is often used as a surrogate marker of Src kinase activity. 
Tyrosine-527 (tyrosine-530 in human Src) lies in the C-terminal regulatory region and its 
phosphorylation is associated with inactivation of Src (196). 
The activity of Src is regulated by several mechanisms which have in common the ability 
to influence the stability of inhibitory intra-molecular interactions (195). Phosphorylated 
tyrosine-527 forms an intra-molecular interaction with the SH2 domain. A further intra- 
molecular interaction occurs between the SH3 domain and a short stretch of amino acids 
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between the SH2 domain and kinase domain. In this conformation not only is the kinase 
domain inaccessible but access of potential binding partners to the protein-protein 
interacting domains is sterically hindered. v-Src, the oncogene isolated from Rous Sarcoma 
virus, lacks the C-terminal regulatory region and so is constitutively active (197). 
Similarly, targeted mutation of tyrosine-527 to phenylalanine (Src527F) is sufficient to 
render the proto-oncogene c-Src constitutively active. Consequently the activity of Src can 
be regulated in several ways (198). Firstly, the SH2 and SH3 domains may bind ligands 
with greater affinity than their intra-molecular binding sites thus forcing Src to adopt an 
open conformation. Alternatively dephosphorylation of Src tyrosine-527 may occur via 
decreased activity of C-terminal Src kinase (Csk) or increased activity of protein tyrosine 
phosphatases such as PTP-a and SHP-1. 
1.2.1.2 Src expression and activity is increased in cancer. 
Src expression or activity is upregulated in many tumours (199). For example, the activity 
of Src is elevated in colorectal cancer specimens when compared to adjacent normal 
mucosa and the degree of activity increases in parallel with advancing stage of disease 
(200-202). Elevated Src kinase activity has also been reported in pathological specimens 
from human breast cancer (203,204), gastric cancer (205), pancreatic cancer (206) and 
oesophageal cancer (207). However, the molecular mechanisms by which Src activity may 
be elevated in tumours are poorly understood. Although an activating mutation in a subset 
of colorectal cancers has been reported by one group (208) other studies have failed to 
replicate this finding (209-211) suggesting that mutational activation of Src is an 
infrequent event. Increased expression of Src frequently occurs but Src activity is usually 
increased by a relatively greater extent than protein levels indicating additional regulation 
at the post-translational level. In many cancers the activity of RTKs such as EGFR or 
HER2 are increased, commonly by activating mutation or gene amplification (212). Src is 
recruited and activated via displacement of tyrosine-527 as the Src SH2 domain binds to 
phosphotyrosine residues in the receptor with higher affinity (213). Therefore elevated Src 
activity may be secondary to activation of a more upstream receptor to which it is coupled 
(214,215). Alternatively cytoplasmic proteins such as focal adhesion kinase (FAK) are 
often over-expressed in tumours and could similarly activate Src by competition with Src 
tyrosine-527 for the Src SH2 domain (216). Other potential mechanisms include reduced 
phosphorylation of tyrosine-527 either by decreased expression of Csk which has been 
reported in some hepatocellular cancers (217) or increased expression of phosphatases 
such as PTP-1B as has been reported in breast cancer cell lines (218). 
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1.2.2 Receptor tyrosine kinases. 
As alluded to above, signalling from various RTKs is associated with phosphorylation of 
AJ proteins. However, with regard to potential roles in modulating cell-cell adhesion, 
members of the EGFR family and c-Met have been the most intensively studied. EGFR 
directly associates with the AJ via ß-catenin (188) and is the prototypic member of a 
family of RTKs consisting of EGF receptor/HERI, neu/ErbB2/HER2, ErbB3/HER3, and 
ErbB4IHER4. All consist of an extracellular ligand binding domain, a transmembrane 
domain, and a cytoplasmic domain which, with the exception of HER3, has intrinsic 
tyrosine kinase activity. Binding of ligand to the extracellular domain of EGFR causes 
homo- or hetero-dimerisation and intermolecular phosphorylation of tyrosine residues 
within the cytoplasmic tail including positions 992,1068,1086,1148 and 1173. Phospho- 
tyrosine binding adaptor or signalling proteins such as Src, PI 3-K, She and Grb2 are then 
recruited and propagate downstream signals influencing growth, survival and invasion 
(219). EGFR activity is aberrantly increased in many cancers by mechanisms including 
gene amplification (220,221), increased ligand stimulation via autocrine loops (222) and 
activating mutations within the kinase domain (223,224). Like EGFR, HER2 also 
associates with the AJ via ß-catenin (225). HER2 is over-expressed in a subset of breast 
and ovarian cancers due to gene amplification events (226). Activating mutations in the 
HERZ kinase domain have also been reported but this appears to be less frequent than for 
EGFR (227). The potential role of HER3 and HER4 in cancer is less well defined. 
c-Met, the receptor for hepatocyte growth factor consists of an a and ß chain dimer held 
together by disulphide bonds. Ligation elicits intramolecular phosphorylation of two 
critical tyrosines residues (tyrosine-1349 and tyrosine-1356) located at the C-terminal of 
the 3 chain, forming a docking site for multiple SH2-containing signal transducers, 
including Src, PI 3-K, and the adaptor proteins Grb2, Shc and Gabt (228). Signalling via 
c-Met in several models appears to trigger a biological program favouring invasive growth 
(228). Aberrant c-Met signalling in human cancer may occur via gene amplification (229, 
230), activating mutation (231), or an autocrine signalling loop (232). 
1.2.3 EGFR and SFKs cooperate in signal transduction. 
Src is activated on stimulation of the EGFR (233) and this is thought to be primarily due to 
recruitment of Src via its SH2 domain to phosphorylated tyrosine residues in the 
cytoplasmic tail of the receptor. Over-expression of Src potentiates EGF-stimulated DNA 
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synthesis and proliferation (234). Conversely, inhibition of Src activity by dominant 
negative Src mutants or pharmacological inhibition can block EGF-dependent activation of 
the downstream STAT3 pathway and inhibit proliferation (235). Interestingly, most of the 
actin remodelling that occurs downstream of EGFR appears to involve Src substrates such 
as FAK, pl30Cas and cortactin (236). As well as being an EGFR effector, Src may 
contribute to activation of the EGFR itself. Src phosphorylates EGFR at several positions 
including tyrosine-845 although the role of this is controversial with mutation of tyrosine- 
845 to phenylalanine either inhibiting EGF-dependent proliferation (237,238) or having no 
effect (239) in different models. In addition to directly modulating EGFR activity by 
phosphorylation Src may also regulate the EGFR via receptor endocytosis or ubiquitination 
(240). Src also associates with HERZ (241) and c-Met (242) via its SH2 domain in a 
tyrosine phosphorylation dependent manner and similarly participates in their downstream 
signalling. 
1.2.4 Protein tyrosine phosphatases. 
At any time the degree of tyrosine phosphorylation of AJ proteins is determined not just by 
kinase activity but also by the relative activity of protein tyrosine phosphatases (PTPs) 
(243). Several receptor and non-receptor PTPs interact with and dephosphorylate 
components of the AJ (244-249). Of these DEP-1 (249), rPTPp. (247) and SHP-1 (248) are 
recruited specifically by p 120. Phosphatase activity is essential for AJ formation as 
demonstrated by the ability of vanadate, a phosphatase inhibitor, to cause disruption of AJs 
in association with increased phosphorylation of AJ proteins. Consistent with this is the 
upregulation of phosphatase activity in a confluent monolayer as compared to more 
sparsely plated cells. For example, the expression of DEP-1 is increased more than 10-fold 
in various cell lines as they approach confluence (250). 
1.2.5 Regulated tyrosine phosphorylation occurs in nascent Als. 
A transient increase in phosphotyrosine content occurs at nascent AJs (138,251) whilst the 
phosphotyrosine content of mature junctions in a confluent monolayer is diminished (251). 
Activation of both SFKs (178,252) and EGFR (137) can be detected at nascent junctions. 
Cadherin engagement alone is sufficient to activate SFKs as it occurs in cells plated on 
cadherin ectodomain-coated cover slips which effectively excludes any contribution due to 
juxtacrine activation of other cell surface receptors (252). Phosphorylated proteins in 
nascent junctions include cadherins, ß-catenin and p120 (138,176,251). The physiological 
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importance of AJ phosphorylation and the identity of potential kinases was demonstrated 
by the finding that keratinocytes in mice with a disruption of the Src and Fyn genes have 
reduced phosphorylation of p120 and ß-catenin and are defective in Ai formation (138). 
A molecular explanation of the requirement for SFK activity in AJ formation has recently 
been proposed. Initial work showed that pharmacological SFK inhibition or the dominant 
negative expression of a kinase-defective Src mutant prevented the recruitment and 
activation of PI 3-K at nascent cadherin contacts and impaired the development of initial 
cadherin contacts into broad zones of adhesion (179). The effects of Src inhibition could be 
reversed by expression of constitutively active PI-3 kinase. Thus Src appeared to influence 
AJ formation via the recruitment of PI 3-K (179). Subsequently Fukayama et al confirmed 
that inhibition of Src activity prevented the cadherin-dependent activation of Rac and the 
conversion of initial contacts to broad areas of adhesion. In this model Src phosphorylated 
Vav2 (a Rae GNEF), although this phosphorylation was not sufficient for Vav2 activation. 
Src also phosphorylated the Crk adaptor protein which recruited C3G, an exchange factor 
for Rapt (253), resulting in the local activation of Rap1 at nascent sites of cadherin 
engagement. Rapl activation caused activation of PI 3-K and both PI 3-K signalling and 
tyrosine phosphorylation of Vav2 were required for full activation of Vav2 and subsequent 
activation of Rac (252). Thus the regulated activity of SFKs is required for the activation 
of Rac at nascent cadherin contacts via a Src-Rapt-PI 3-K-Vav2 pathway. 
1.2.6 Deregulated tyrosine phosphorylation disrupts the AJ. 
In contrast to the role of SFKs in AJ formation many studies have reported a negative 
effect of kinase activity on AJ function. In general these studies utilise constitutively active 
kinases or cells which over-express growth factor receptors. Deregulated tyrosine 
phosphorylation of AJs by SFKs (185,186,189,193,254-257) or RTKs (187,189,190, 
258,259) causes disruption of cell-cell adhesion, often accompanied by increased 
invasiveness. These effects are reversible with pharmacological inhibition of kinase 
activity (185,186,189,193,254-256). Similarly, the ectopic expression of protein 
tyrosine phosphatases favours cell-cell adhesion (260,261) whilst the expression of 
dominant negative phosphatase-deficient mutants (262) or pharmacological inhibition of 
phosphatase activity (254) causes increased phosphorylation and disruption of AJs. 
Conflicting evidence for the role of tyrosine phosphorylation at the AJ can be reconciled if 
tightly regulated phosphorylation has a physiological role in AJ formation and turnover 
whereas non-physiological sustained or elevated phosphorylation has a deleterious effect. 
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For example, although endogenous Fyn was required for AJ assembly in keratinocytes, 
expression of constitutively active Src impaired AJ formation (138). Such sustained kinase 
signalling is a common pathological event in oncogenesis. 
Multiple signalling pathways with pleotropic effects are activated in Src-transformed cells 
(198) or in response to growth factor signalling (228). It has therefore been a challenge to 
causally link phosphorylation of an individual substrate with regulatory changes at the AJ. 
However, several plausible models can be proposed by which aberrant tyrosine 
phosphorylation might disrupt the AJ (180,263). The simplest model proposes that 
phosphorylation, via changes in charge or conformation may interfere with cadherin - 
catenin binding to cause direct physical disruption of the AJ. Alternatively tyrosine 
phosphorylation could trigger the recruitment of other signalling proteins to the AJ as, for 
example, occurs at focal adhesions. In addition tyrosine phosphorylation might "target" 
proteins for increased turnover or degradation. Finally, tyrosine kinases may exert their 
effects on the AJ by mechanisms which are spatially distinct from the AJ and which may 
be independent of phosphorylation of the AJ itself. Examples of this would include 
unfavourable alterations in acto-myosin contractility or alterations in gene transcription. 
These potential mechanisms are not mutually exclusive and indeed may overlap at multiple 
levels. 
1.2.6.1 Direct effects of cadherin phosphorylation. 
In most models cadherins are only weakly phosphorylated (185-187,193). However 
several lines of evidence now support an important role for the tyrosine phosphorylation of 
cadherins. Interestingly, distinct mechanisms have been identified for different cadherins. 
Whether this indicates genuine differences or simply reflects the experimental models used 
is not yet clear. 
Phosphorylation of VE-cadherin at tyrosine-658 and tyrosine-731 is sufficient to cause 
dissociation of p120 and ß-catenin respectively (89). The JMD of VE-cadherin contains a 
sequence motif for constitutive endolysosomal processing which is "unmasked" on 
detachment of p120 (75). Thus the ability of p120 to retain VE-cadherin at the membrane 
is determined by the phosphorylation state of VE-cadherin tyrosine-658. 
In E-cadherin the phosphorylation of tyrosine residues 755 and 756 promotes interaction 
with the E3 ubiquitin ligase, Hakai, which targets cadherin for endocytosis with a resulting 
decrease in cell-cell adhesion (11). These residues are within the p120-binding cadherin 
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JMD so, reminiscent of the situation for VE-cadherin, it has been suggested that p120 may 
act to limit access of Hakai and hence stabilise E-cadherin. 
Phosphorylation of tyrosine-860 in N-cadherin causes dissociation of ß-catenin and was 
important for the transendothelial migration of melanoma cells, an EMT-like process 
which is driven by the accumulation of nuclear ß-catenin (264). This residue is within the 
core ß-catenin interacting region and is conserved in all classical cadherins (29) although 
its equivalent residue in VE-cadherin, tyrosine-733, did not influence ß-catenin binding 
(89). Taken together these experiments demonstrate an important regulatory role for 
cadherin phosphorylation. 
1.2.6.2 Direct effects of ß-catenin phosphorylation. 
Tyrosine phosphorylation of ß-catenin causes dissociation of the cadherin / ß-catenin / a- 
catenin complex, loss of cell-cell adhesion, and increased ß-catenin-dependent 
transcription (262,265-268). This phenotype is specifically mediated by the 
phosphorylation state of tyrosine-142 in the first Armadillo repeat and tyrosine-654 in the 
last Armadillo repeat (266,268). Phosphorylation of tyrosine-654 prevents binding of 
catenin to E-cadherin but does not inhibit binding of ß-catenin to TCFs and so 
transcriptional activation is promoted (267). Phosphorylation of ß-catenin at tyrosine-142 
inhibits its interaction with a-catenin (268). In addition, the phosphorylation of tyrosine- 
142 is also important for the transcriptional activity of ß-catenin by promoting binding of 
ß-catenin to BCL9-2 (269). BCL9-2 has transcriptional cofactor and nuclear localisation 
activity and is essential for the nuclear localisation and transcriptional activity of ß-catenin 
(269). Consequently, tyrosine phosphorylation of ß-catenin drives a switch from the 
adhesive function of cadherin-bound ß-catenin to the transcriptional function of the ß- 
catenin / TCF / BCL9 complex (270). 
1.2.6.3 Direct effects of p120 phosphorylation. 
Ironically, given its discovery as a prominent kinase substrate, the effects of tyrosine 
phosphorylation of p120 are largely unknown. Despite repeated assertions in the literature 
that tyrosine phosphorylation is likely to regulate the activity of p120 at the AJ (55,271) 
definitive evidence is lacking. Early work reported increased cell-cell adhesion in cell 
lines, including HT29 and Colo205, when cadherin with ap 120-uncoupling JMD mutation 
or p 120 with a deleted N-terminal region were expressed (9,272). Treatment with 
35 
staurosporine, a relatively non-specific kinase inhibitor also promoted adhesion. This was 
interpreted as demonstrating a negative modulatory role for p120 and specifically its N- 
terminal region, perhaps due to phosphorylation mediated by a constitutively active 
staurosporine-sensitive kinase. However this work did not distinguish the contribution of 
tyrosine phosphorylation, serine/threonine phosphorylation, or indeed other events 
requiring the p 120 regulatory region. Subsequently Ozawa et al demonstrated that the 
reduction in E-cadherin dependent cell-cell adhesion in L cells (a cadherin-deficient 
fibroblast cell line) occurring when E-cadherin and active Src were co-expressed compared 
to L-cells expressing E-cadherin alone required an intact cadherin JMD (273). Moreover, 
expression of p120 with a tyrosine to phenylalanine substitution at position 217 was 
sufficient to abrogate the effects of active Src, although this mutation did not diminish the 
tyrosine phosphorylation of p120. In the light of our current knowledge of the p120 
tyrosine phospho-acceptor sites (which do not include tyrosine-217) it appears that this 
substitution altered p120 conformation or function in an as yet undefined, but 
phosphorylation-independent, manner. 
The recent identification of p120 tyrosine phospho-acceptor residues has facilitated more 
targeted investigation of p120 phosphorylation. For example, over-expression of p120 
rendered phosphorylation-defective by mutation of all 8 tyrosine phospho-acceptor 
residues to phenylalanine did not inhibit the Src induced transformation of fibroblasts (68) 
and did not impair the ability of A431 cells to form Ms (176). However, a possible adaptor 
role for phosphorylated p120 is suggested by the finding that the phosphatase SHP-1 could 
be recruited by wild type but not phosphorylation defective p 120 (68). Interestingly, the 
total number of tyrosine residues which were phosphorylated rather than the 
phosphorylation state of any specific residue determined the strength of binding. 
It has been suggested that one consequence of the tyrosine phosphorylation of p 120 may be 
to reduce the affinity of its interaction with cadherin, perhaps exposing signals for 
internalisation on the JMD. However, most evidence suggests that tyrosine 
phosphorylation of p120 either increases its affinity for E-cadherin (138,265,266,268) or 
has no effect (8,176,273-275). Piedra has suggested that increased binding of p 120 to 
cadherin may impair AJ stability if p120 functions as an adaptor to recruit the tyrosine 
kinase Fer, which may be constitutively associated with p 120, to the AJ (276). In this 
model phosphorylation of p120 promotes its association with E-cadherin and hence 
recruits Fer which subsequently negatively regulates the AJ by phosphorylation of ß- 
catenin at tyrosine-142 (268). Directly contradicting this model is work by Xu et al which 
demonstrated that Fer, recruited to the AJ via p120, phosphorylated the tyrosine 
36 
phosphatase PTP1B at tyrosine-152 enabling it to bind the cytoplasmic domain of cadherin 
(277). PTP1B then promoted AJ stability by maintaining tyrosine-654 of ß-catenin in a 
dephosphorylated state. This inconsistency may reflect the different experimental systems 
with Xu et al using chick retinal cells and fibroblasts which predominantly expressed N- 
cadherin whilst Piedra used E-cadherin expressing epithelial cells. Thus whether tyrosine 
phosphorylation of p120 is involved in regulation of the AJ remains enigmatic. 
1.2.6.4 Kinase-driven acto-myosin contractility may disrupt the AJ. 
Several lines of evidence now suggest that increased RhoA activity may influence tensile 
forces within the cell in such a way as to be either unfavourable to AJ formation or, in 
some cases, to literally pull established AJs apart. In this context Sahai has shown that 
constitutively active RhoA disrupts Ms via its effector kinase ROCK in a myosin light 
chain kinase (MLCK) and myosin ATPase dependent manner consistent with a mechanism 
requiring contractile force (115). Src appears able to induce similar effects as expression of 
constitutively active Src in a colorectal cancer cell line disrupted AJ formation and this was 
associated with localised activation of ERK, MLCK and ROCK at integrin-based cell- 
matrix adhesions and accumulation of phospho-myosin at these sites (278). Blockade of 
ERK, ROCK or MLCK activity inhibited accumulation of phosphomyosin and was 
sufficient to allow AJs to form. A strikingly similar mechanism has been elicited for cell 
scattering mediated by RTKs (279). To assay cadherin-mediated adhesion without 
interference from other adhesion receptors De Rooij et al plated MDCK cells on coverslips 
coated with a cadherin extracellular domain fusion protein. Similar to the N-cadherin 
adhesions reported by Gavard et al (134) E-cadherin plaques formed at the termini of F- 
actin bundles and contained vinculin, a-, ß- and p120-catenin. Surprisingly, stimulation 
with HGF increased rather than inhibited cadherin-mediated homotypic adhesion to the 
substrate. Furthermore, live cell imaging of small clusters of cells plated on extracellular 
matrix and treated with HGF showed that GFP-labelled E-cadherin remained localised at 
cell-cell contacts until cells suddenly pulled apart with no alteration in cadherin 
localisation preceding the moment of detachment. Subsequently, as migrating cells 
contacted one another new junctions formed with rapid accumulation of GFP-cadherin, 
again suggesting that HGF did not impair the intrinsic ability of E-cadherin to form 
homotypic adhesions. HGF treated cells formed thick bundles of actin perpendicular to 
areas of cell-cell contact which terminated in focal adhesions rather than in relation to the 
AJ itself and which accumulated phospho-myosin light chain. Taken together this 
suggested that HGF-induced scattering was mediated mainly via increased myosin- 
dependent tension literally pulling cells apart rather than by direct impairment of cadherin 
37 
homotypic adhesion. In keeping with these findings was the observation that AJs were 
rapidly disrupted in a TGFß-treated mouse mammary epithelial cell line in a RhoA and 
ROCK dependent manner (280). 
Unfavourable acto-myosin contractility has also been proposed to explain the adhesive 
defect seen in primary enterocytes derived from the ApcM"n/+ mouse. When cultured in 
vitro they display impaired cadherin-dependent cell-cell adhesion resulting from elevated 
EGFR and Src activity. This was associated with increased MAPK and RhoA activity. 
Pharmacological inhibition of EGFR or of ROCK suppressed the expression of actomyosin 
contractility markers and simultaneously restored E-cadherin adhesion (281). 
Taken together these findings strongly suggest that SFKs or RTKs can cooperate with 
RhoA to promote acto-myosin contractility which physically impairs AJ stability. 
1.3 Tyrosine kinases and the AJ regulate the invasive 
phenotype. 
The ability of neoplastic cells to penetrate into and survive in neighbouring tissues defines 
cancer. Local invasion may cause destruction or compromise of surrounding tissues and is 
a prerequisite for malignant cells to enter the circulation and hence metastasise. Invasion 
requires coordinated changes in several aspects of the cells phenotype. Namely, alterations 
in cell-cell and cell-matrix adhesion, remodelling of the actin cytoskeleton, increased 
motility and the production of substances capable of degrading extracellular matrix. As 
described below it is the particular combination of these factors which determines the 
mode of invasion utilised. The AJ and tyrosine kinases, both RTKs and cytoplasmic 
kinases such as Src, play critical roles in the regulation of invasion. 
1.3.1 The invasive phenotype is modulated by the AJ. 
1.3.1.1 E-cadherin is frequently downregulated in cancer. 
Complete loss of E-cadherin is unusual in human cancer. However reduced levels or mis- 
localisation of E-cadherin occurs in a high proportion of cancers and this may occur by 
several mechanisms (28,282). 
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1. Germline mutation of the E-cadherin gene (CDH 1) 
CDH1 lies on chromosome 16g22.1. Germline mutations have been causally linked 
to hereditary diffuse-type gastric cancer (283), a tumour type characterised by 
scattered growth with loss of cell-cell cohesion. These kindreds also have an 
increased incidence of colorectal, lobular breast and prostate cancer. Mutations are 
dispersed throughout CDH1 and are usually frameshift, nonsense or splice site 
resulting in truncated proteins. A smaller proportion are missense mutations and 
these are clustered in the second and third EC repeats. In cancers the wild type allele 
is usually inactivated by promoter hypermethylation (284). Thus CDHI follows 
Knudson's two-hit model for inactivation of a tumour suppressor gene (285). 
2. Somatic mutation of CDH1 
Although rare in most tumour types somatic mutation of CDHI occurs in 
approximately half of all diffuse-type gastric and lobular breast cancers (286-288). A 
lower frequency of mutations has also been identified in endometrial and ovarian 
cancer (289). In contrast to hereditary diffuse-type gastric cancer the second hit in 
sporadic gastric and breast cancers is usually via loss of heterozygosity of the wild 
type allele (287,288). 
3. Epigenetic silencing / transcriptional repression 
Hypermethylation of the CDH1 promoter region has been reported in a variety of 
tumour types including breast (290), ovarian (291), oesophageal (292), colorectal 
(293), non-small cell lung (294), hepatocellular (295), bladder (296), gastric (297) 
and oral squamous cell carcinoma (298). Treatment of various E-cadherin deficient 
cancer cell lines with the demethylating agent 5-azacytidine is sufficient to restore 
expression (299-302) suggesting that the promoter methylation is a cause rather than 
effect of gene downregulation (303). Silencing of E-cadherin can also occur due to 
the binding of specific transcriptional repressors such as Snail (304,305), SIP1 (306) 
and Twist (307) to E box motifs in the E-cadherin promoter. In general this occurs in 
the context of EMT and is discussed below. 
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4. Post-translational modification 
Cadherin levels or activity are also regulated at the post-translational level. Increased 
degradation may occur via increased endocytosis and targeting to the degradative 
compartment. As discussed above, Src kinase activity may drive this process via the 
action of the E3 ubiquitin ligase Hakai (11), or via ARF6-GTPase dependent 
endocytosis (308). Alternatively proteolytic cleavage of cadherin may occur via the 
action of presenilin-1 (309), calpain (310), ADAM10 (311) or MMPs (312,313). 
The potential role of direct tyrosine phosphorylation of AJ proteins in impairing AJ 
function has been described above. Finally, as already alluded to, the correlation 
between p120 loss and downregulation of E-cadherin in tumour specimens provides 
circumstantial evidence that loss of p120 as a primary event may account for some 
cases of E-cadherin downregulation. 
1.3.1.2 Epithelial-mesenchymal transition is characterised by 
downregulation of E-cadherin. 
EMT describes a phenotypic change occurring naturally during development and which, it 
has been suggested, may be adopted by tumour cells as a means of increasing their 
invasiveness. Whilst mechanisms such as post-translational modification of E-cadherin 
may contribute to the EMT phenotype, full EMT represents a coordinated program of 
genetic changes coordinated by transcription factors such as Snail (304,305), Slug (314), 
SIP! (306) and Twist (307) and by the nuclear translocation of ß-catenin (315). The 
hallmarks of EMT are loss of apico-basal polarity and cell-cell adhesive architecture, often 
associated with a decrease or switch in cadherin expression from E-cadherin to 
mesenchymal cadherins such as N-cadherin. Typically there is a change in intermediate 
filaments from cytokeratins to vimentin (316). 
1.3.1.2.1 EMT occurs in human cancers. 
EMT was first identified as a developmental process occurring, for example, at gastrulation 
when the primitive ectoderm invaginates at the primitive streak and undergoes transition to 
migratory mesenchymal cells which form the mesodermal layer (316). Although EMT type 
transitions have been extensively modelled in vitro both the exact definition of EMT and 
whether it plays any role in human cancer has been the subject of controversy (317,318). 
This is in part, due to the difficulty in relating mechanistic research on model systems to 
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the inherently descriptive studies of human cancer specimens. It has been argued that as 
metastases usually recapitulate the cell-cell adhesion architecture of the primary tumour 
EMT must be an uncommon process (317). However, recent detailed 
immunohistochemical studies of common human tumours have identified coordinated 
patterns of expression of proteins such as cadherins, vimentin, Snail and Twist which bear 
a strong resemblance to the phenotypic changes of EMT induced in model systems (307, 
319,320). In colorectal cancer Brabletz et al have identified a transient EMT driven by 
nuclear ß-catenin which occurs only at the invasive front of the tumour whilst the 
remainder of the tumour and metastases do not show evidence of mesenchymal change 
(315). Thus EMT in cancer, as in development, may be a transient and reversible process. 
The transient nature of EMT may explain the infrequency with which EMT is recorded by 
diagnostic pathologists. In addition carcinoma cells which have undergone EMT may 
easily be mistaken for stromal cells (321). 
1.3.1.2.2 Kinase activity drives EMT. 
Multiple lines of evidence suggest that the sustained aberrant activation of kinases can 
initiate EMT. In most models increased RTK signalling cooperates with signalling via 
TGFß, a receptor serine/threonine kinase, to cause EMT (322,323). The effects of TGFß 
are mediated via Smad transcription factors and via Smad-independent activation of P13-K 
and MAPK (324). Diverse mechanisms contribute to the cooperation between TGFß and 
RTKs including convergence at the level of transcriptional regulation, joint regulation of 
Smad-independent signalling effectors and via autocrine production of TGFß and other 
ligands (322). RTKs implicated include c-Met (228), EGFR (325-327), HERZ (328,329), 
IGFR (330) and FGFR (331,332). Downstream events include activation of Src, Ras and 
P13-K signalling along with increased activity of the Raf / MAPK pathway (316,323,333- 
335). In addition increased activity of the ß-catenin / TCF transcriptional pathway which 
may occur via Wnt signalling, secondary to downregulation of E-cadherin, or via inhibition 
of GSK-3ß by PI 3-K also favours EMT (31). 
1.3.1.3 E-cadherin inhibits invasion. 
Multiple lines of evidence indicate that E-cadherin acts to suppress invasion although the 
mechanisms by which it exerts this effect are poorly understood. For example, many 
cadherin deficient cell lines are invasive and expression of exogenous E-cadherin caused 
reversion to a well differentiated and non-invasive phenotype (336,337). Conversely, 
treatment with E-cadherin blocking antibodies (336,337), expression of DN-E-cadherin 
(338), or depletion of E-cadherin by anti-sense (337) or RNAi techniques (339) increased 
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invasiveness. Although these experiments confirmed a critical role for E-cadherin in the 
suppression of invasion in cultured tumour cells they could not demonstrate whether loss 
of E-cadherin occurring in vivo was required for tumour progression or whether it was a 
consequence of de-differentiation. This question was elegantly addressed by Christofori, 
utilising a transgenic mouse model of pancreatic ß cell carcinogenesis (340). Expression 
of the SV40 large-T antigen under control of the rat insulin promoter (RIP ITAG2) caused 
development of pancreatic ß cell tumours (341). Progression of tumours from the adenoma 
to invasive carcinoma stage was invariably associated with loss of E-cadherin (340). The 
role of E-cadherin loss was then directly tested by crossing RIPITAG2 mice with 
transgenic mice expressing either wild type E-cadherin or DN-E-cadherin, also under the 
rat insulin promoter (340). Maintained expression of wild type E-cadherin arrested tumour 
progression at the adenoma stage whereas DN-cadherin induced early invasion. This 
confirmed a causal role for E-cadherin loss in the development of the invasive phenotype. 
Further support for an invasion suppressor role for E-cadherin comes from studies 
characterising the effect of germline CDH1 mutations on E-cadherin function. Wild type 
E-cadherin when expressed in CHO epithelial cells (which lack endogenous cadherin), 
inhibits their ability to invade a3 dimensional extracellular matrix. In contrast expression 
of a variety of E-cadherin mutants identified in hereditary diffuse-type gastric cancer was 
associated with impaired cell-cell adhesion and an inability to inhibit in vitro invasiveness 
(342-344). 
Despite these findings it should be reiterated that complete loss of E-cadherin is 
uncommon in most human cancers. Although some detailed studies do show a localised 
loss of E-cadherin at the invasive front of tumours, for example, in oesophageal squamous 
cell carcinoma (345), the invasion of coherent groups of cells which retain E-cadherin at 
sites of cell-cell contact is also a frequent finding in human cancer specimens. 
Furthermore, although E-cadherin expression often correlates with low grade and low 
invasiveness this is not always the case. For example, inflammatory breast cancer which is 
extremely invasive is characterised by the retention of E-cadherin containing cell-cell 
contacts both in infiltrative tumour and in tumour emboli detected in the lymphovascular 
space (346,347). Thus the invasion-suppressor activity of E-cadherin is not absolute but 
must reflect the specific cellular context. 
Finally it is perhaps misleading to regard E-cadherin solely as an "invasion-suppressor" 
when the evidence also suggests direct tumour-suppressor activity. Firstly, germline 
mutations in CDH1 are sufficient to cause cancer in a high proportion of carriers. The loss 
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of the wild type allele is required following Knudson's two hit hypothesis for a tumour 
suppressor gene. Secondly, loss of E-cadherin expression occurs at high frequency in 
lobular breast carcinoma in situ and thus precedes invasiveness (348). 
1.3.1.4 Mechanisms by which E-cadherin may inhibit invasion. 
Despite the overwhelming evidence that E-cadherin can inhibit invasion the molecular 
mechanisms by which this effect is exerted remain elusive. Seemingly contradictory data 
exist although perhaps this is not surprising if invasion is viewed simply as the phenotypic 
end result of disparate and mechanistically distinct pathways. Therefore, whilst no 
overarching mechanism can be proposed several potential mechanisms have been 
described. 
1.3.1.4.1 Inhibition via direct cell adhesion. 
The idea that E-cadherin solely acts as a physical "glue" to prevent cells invading is 
probably simplistic (349). Indeed the adhesive and anti-invasive roles of E-cadherin have 
been experimentally separated by Gumbiner (350). In MDA-MB-231 breast cancer and 
TSU-Prl prostate cancer cell lines (both of which lack E-cadherin and are invasive) the 
adhesive activity of E-cadherin was neither necessary nor sufficient to mediate suppression 
of invasion. Specifically, chimeric constructs containing the IL2 receptor extracellular 
domain fused to the E-cadherin cytoplasmic domain were able to inhibit invasion to the 
same extent as wild type E-cadherin without conferring any cell-cell adhesiveness. 
However, these results would appear to be inconsistent with reports that antibodies which 
bind E-cadherin and prevent adhesion can induce invasiveness. This probably reflects 
genuine differences in cell lines as it has been reported in MDCK (351) and some 
carcinoma cells (336) but not in others (350,352). It therefore seems possible that 
inhibition of cell-cell adhesion may be sufficient to cause invasiveness in some, but not all, 
cellular contexts. 
1.3.1.4.2 Inhibition via sequestration of f -catenin. 
In Gumbiner's work only E-cadherin constructs with an intact ß-catenin binding domain 
could inhibit invasion (350). Furthermore, Gumbiner showed that RNAi-mediated 
depletion of ß-catenin was also sufficient to inhibit invasion. Taken together this suggested 
a model where E-cadherin suppressed invasion by sequestering ß-catenin at the AJ. 
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However, other experimental data directly challenge any model where membrane 
delocalisation of ß-catenin is invoked as a mechanism by which loss of E-cadherin 
promotes invasiveness. For example, in the RIPITAG2 transgenic mouse model the DN- 
cadherin which was expressed effectively sequestered ß-catenin at the cell membrane and 
yet promoted invasiveness (340). 
Interestingly, in Gumbiner's work the p 120 binding site was not required to inhibit 
invasion. However, in the light of current knowledge of p120's function this result in no 
way excludes an important anti-invasive role for p 120. Single cell clones expressing wild 
type or JMD mutant cadherin were selected to have equal protein levels of E-cadherin. 
Presumably the selected JMD mutant clones had very high expression levels to maintain an 
identical amount of cadherin at the membrane despite its rapid turnover secondary to loss 
of interaction with p120. In consequence, this approach would be inherently unable to 
identify an anti-invasive role for p 120 if that role were solely mediated via stabilisation of 
anti-invasive E-cadherin. 
Both Wnt / ß-catenin / TCF pathway dependent and independent signalling have been 
proposed as mechanisms by which by ß-catenin might promote invasion: 
1.3.1.4.2.1 Modulation of Wnt Signalling. 
It has been proposed that E-cadherin, by sequestering ß-catenin, may reduce its 
transcriptional activity and thereby inhibit invasion. This hypothesis poses two questions: 
firstly does ß-catenin-TCF transcription influence invasiveness and secondly can E- 
cadherin negatively regulate this pathway by sequestering ß-catenin. In answer to the first 
question, ß-catenin-TCF target genes such as MMP7 (42), c-Met (353), Nr-CAM (354), 
osteopontin (354), laminin (355) and urokinase plasminogen activator (356) have been 
linked to invasion. Furthermore, ß-catenin-TCF signalling is involved in developmental 
EMTs and circumstantial evidence suggests a similar role in malignant invasion (356). 
As alluded to above, activation of the Wnt-ß-catenin-TCF pathway in human cancer 
usually occurs secondary to mutations in APC or ß-catenin. Whether E-cadherin, via 
sequestration of ß-catenin, actually participates in this pathway in human cancer is 
controversial. Proof-of-principle that cadherins can antagonise ß-catenin transcriptional 
activity exists in Drosophila (357) and Xenopus (44,358). An identical pattern of 
competitive inhibition of ß-catenin transcriptional activity via cadherin binding has been 
demonstrated in human malignant and non-malignant cells in vitro (45,338,359,360). 
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Whilst phenotypic changes such as a reduction in proliferation were reported in these 
studies no assessment of invasion or motility was made. In some models of EMT 
downregulation of E-cadherin was associated with nuclear accumulation of ß-catenin (173) 
(79) and increased invasiveness (79). However, in such models multiple pathways would 
have been expected to be induced in addition to downregulation of E-cadherin and the 
increased invasiveness was not proven to be dependent on nuclear ß-catenin. 
Refuting the participation of E-cadherin in the Wnt / ß-catenin / TCF pathway is the 
observation that none of 10 breast cancer cell lines with mutated or absent E-cadherin 
displayed activation of ß-catenin-TCF transcription (361). Similarly gastric and pancreatic 
cancer cell lines with loss of E-cadherin did not display upregulated transcriptional activity 
of TCF targets (362). Rather constitutive transcriptional activity, when it occurred, was 
always associated with APC or ß-catenin mutations. Expression of E-cadherin in cadherin- 
negative MDA-MB-231 breast cancer and TSU-Prl prostate cancer cell lines was not 
associated with any reduction in ß-catenin-TCF transcriptional activity (350). Furthermore 
the expression of DA- or DN-TCFs did not influence invasion in this system. Interestingly, 
the expression in CHO cells of E-cadherin mutants isolated from hereditary diffuse-type 
gastric cancer kindreds promoted invasion in comparison to wild type E-cadherin whilst 
actually reducing ß-catenin-TCF transcription to the same degree as the wild type cadherin 
(342). 
On balance it seems probable that, at least in some cellular contexts, E-cadherin can 
participate in the Wnt-ß-catenin-TCF pathway and that upregulation of this pathway via 
loss of E-cadherin may contribute to the invasive phenotype. However, this does not 
appear to be a universal mechanism. 
1.3.1.4.2.2 Wnt-independent signalling by ß-catenin. 
Gumbiner's work suggested a key role for cytoplasmic ß-catenin that was not related to 
alterations in transcription of TCF target changes (350). The molecular mechanisms 
underlying this are undefined although a variety of cytoplasmic 1-catenin binding partners 
including NF-kB (363) have potential roles in invasion. Alternatively, ß-catenin may 
mediate the interaction of EGF (225) or HER2 (225) with the AJ and Gumbiner's data 
does not exclude a model where ß-catenin was required to mediate this interaction. Indeed, 
disruption of the AJ-HER2 complex by expression of an N-terminally truncated ß-catenin 
which binds HERZ but not cadherin inhibited the recruitment of HERZ to the AJ and 
suppressed invasion (191). 
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1.3.1.5 Cadherin switching promotes invasion. 
Recent studies have demonstrated increased expression of non-epithelial cadherins such as 
N-cadherin or P-cadherin in gastric (320), prostate (364) and breast (365) tumour 
specimens and in various cancer derived cell lines (366-368). Expression of N-cadherin 
induced an invasive phenotype in squamous carcinoma cells (366) and increased motility, 
invasion and metastasis of breast cancer cells (369,370). This is reminiscent of the well 
characterised developmental EMT when epiblast cells switch from E to N-cadherin to 
ingress the primitive streak (2), although upregulation of N-cadherin is not a universal 
event in other developmental EMTs (16). Interestingly a cadherin hierarchy seems to exist 
with N-cadherin trumping E-cadherin as expression of even small amounts of N-cadherin 
promoted motility (371) and increased invasion in E-cadherin expressing cell lines (369, 
370) whereas increased expression of E-cadherin could not inhibit the motile and invasive 
properties of an N-cadherin expressing breast cancer cell line (369). Increased expression 
of cadherin-1 1, a related cadherin, is also associated with increased invasiveness in breast 
cancer cell lines (367,369). 
The role of P-cadherin in invasion is less clear with data supporting both a pro- and anti- 
invasive role. In a breast cancer cell line an increase in P-cadherin was associated with a 
gain of invasiveness (372). In contrast, other studies have reported an anti-invasive role for 
P-cadherin when expressed in lung or melanoma cell lines (354,373,374). 
The molecular mechanisms by which cadherin switching may favour invasion are 
incompletely understood. However, in general terms these may include: 1) downregulation 
of endogenous anti-invasive E-cadherin via competition for p120 by newly expressed 
mesenchymal cadherins; or 2) dominant pro-invasive mechanisms of mesenchymal 
cadherins which occur despite maintained E-cadherin expression. Several such pro- 
invasive mechanisms may exist: 
1. N-cadherin may mediate more dynamic intercellular adhesions allowing single 
cells to dissociate from the tumour and invade (375). 
2. N-cadherin expressed by neoplastic cells may participate in homophilic interactions 
with N-cadherin expressed on stromal cells including myofibroblasts and 
endothelial cells to promote invasion (376). One such example is the intravasation 
of melanoma cells which required the formation of N-cadherin dependent contacts 
with endothelial cells (264,377). A similar phenomenon may occur in breast cancer 
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cell lines in which expression of Twist causes an EMT with an E- to N-cadherin 
switch. The orthotopic injection of breast cancer cells transfected with Twist into 
mouse mammary fat pad was shown to specifically enhance intravasation whilst 
having no effect on survival, growth, or extravasation (307). 
3. N-cadherin may potentiate pro-invasive signalling through the FGF receptor. N- 
cadherin associates with the FGF receptor and inhibits its ligand-induced 
internalisation resulting in sustained MAPK-ERK activation which leads to 
increased MMP9 gene transcription and increased invasiveness (378). This may 
represent the co-opting by malignant cells of a pathway whose physiological role is 
in neunte outgrowth (379). 
4. Cadherin switching may be associated with alterations in Rho GTPase activity and 
it has been suggested this may reflect altered affinity of mesenchymal cadherins for 
p120. For example, the expression of R-cadherin in tumour cells was associated 
with downregulation of endogenous cadherins, decreased association of p120 with 
R-cadherin compared to E-cadherin, and increased motility and sustained activation 
of Rae (380). Similarly, over-expression of P-cadherin in a pancreatic cancer cell 
line was associated with cytoplasmic accumulation of p120, activation of Rae and 
Cdc42, and increased motility (129). 
The processes which regulate the coordinated expression of cadherins and, in particular, 
the often inverse relationship between E-cadherin and mesenchymal cadherins are poorly 
understood. The co-ordinated transcriptional reprogramming of EMT provides one 
explanation. The reciprocal regulation of cadherins may also occur via competition by 
different cadherins for a limiting amount of p120 (82,87). An additional level of regulation 
might be provided by the pattern of p120 isoform expression. This is suggested by the 
observation that p120 isoform 1 preferentially associates with N-cadherin whereas isoform 
3 preferentially associates with E-cadherin (381). Thus a switch in expression from p120 
isoform 3 to 1 could conceivably contribute to an increase in N-cadherin and simultaneous 
downregulation of E-cadherin, although this has not been experimentally investigated. 
1.3.2 Deregulated kinase activity promotes invasion. 
1.3.2.1.1 Src promotes invasion and metastasis. 
Increased activity of SFKs may have multiple effects in cancer including proliferation, 
survival and angiogenesis (198). However, several lines of evidence support there being a 
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critical role for Src in invasion and metastasis. Specifically, the over-expression of Src in a 
rat colon epithelial cell line (382) and in human breast or colon tumour derived cell lines 
(256) increased in vitro invasiveness. Similarly, expression of Src in MDCK cells 
increased invasiveness (186) and was sufficient to render them metastatic to lung when 
injected orthotopically in the murine kidney (383). Conversely, inhibition of Src activity by 
over-expression of Csk (a negative regulator of Src activity) in a mouse colon 
adenocarcinoma cell line did not inhibit the formation of primary tumours in mice but 
prevented the development of lung metastases in vivo and inhibited in vitro invasion (384). 
In-keeping with this, the expression of Csk inhibited the in vitro invasiveness of two 
human colorectal cancer cell lines (385) whilst the expression of Csk or of a kinase- 
deficient dominant-negative Src mutant in a rat carcinoma cell line specifically prevented 
metastasis without preventing the formation of primary tumours (386). Furthermore, 
depletion of Src by RNAi was sufficient to reduce the incidence of metastases in a 
pancreatic cancer orthotopic model (387). 
Recently several relatively specific ATP-based small molecule inhibitors of Src kinase 
activity have been developed (388). Treatment of an MCF-7 derived cell line with 
AZD0530 inhibited in vitro motility and invasion (389). Treatment of pancreatic, head and 
neck squamous cell carcinoma and non-small cell lung cancer derived cell lines with 
dasatinib was associated with inhibition of migration and invasion of all cell lines (390, 
391) and with a reduction in metastases in vivo (387). Invasion of NSCLC cell lines was 
inhibited by M475271 (392). CGP77675 and CGP76030 inhibited in vitro invasion of 
prostate cancer cell lines (393). The in vitro invasion and in vivo metastases of a breast 
cancer cell line was inhibited by PP2 (394). Similarly the development of lymph node or 
liver metastases in an orthotopic pancreatic cancer model was prevented by administration 
of AZM475271 (395). Importantly, the pharmacological inhibition of invasion in SW620 
and HT29 colorectal cancer cell lines was mimicked by RNAi-mediated depletion of Src 
protein (335). 
1.3.2.1.2 The EGFR family promote invasion. 
Like Src, EGFR family members can regulate many of the hallmarks of malignancy (212). 
However, several lines of evidence suggest that the aberrant activity of EGFR can 
specifically induce invasiveness. For example, exposure to EGF increased invasiveness of 
oral (396) and cutaneous (397) squamous cell carcinoma, renal (398), pancreatic (399), 
breast (256,400) and oesophageal cancer cell lines (189). Interestingly, several studies 
suggest that HER2 may be required to heterodimerise with EGFR for efficient induction of 
invasion (401-403). 
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Gefitinib, a small molecule inhibitor of EGFR kinase activity, blocked in vitro 
invasiveness and establishment of bone metastases in an in vivo nude mouse model (404) 
and inhibited invasion of prostate (405), pancreatic (406), head and neck squamous cell 
and breast carcinoma derived cell lines (407). As alluded to above Src and EGFR 
signalling are intimately linked. In this context cooperation of Src and EGFR in mediating 
invasiveness has been reported (214,256) and pharmacological inhibition of Src activity 
can prevent EGF-dependent invasion (408). 
1.3.3 Malignant cells use diverse invasion strategies. 
EMT provides one mechanism by which cancer cells may adopt an invasive phenotype 
which is characterised by detachment of cells from their neighbours and the subsequent 
invasion of single cells. However, in many cases invasion occurs without EMT and 
malignant cells may remain in contact with their neighbours and invade as coherent sheets 
or clusters. Importantly, invasive cells often demonstrate plasticity in response to 
environmental cues or in response to pharmacological inhibition. In vitro studies combined 
with in vivo imaging of labelled tumour cells have defined at least three broad categories 
of malignant migration and invasion (Figure 1-6) (409,410). 
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Figure 1-6 Cancer cells utilise diverse modes of invasion. Cancers may invade via 
mesenchymal (A) or amoeboid (B) single cell invasion or via collective invasion (C). 
Mesenchymal invasion is characterised by integrin and MMP dependence with forward 
motion generated by traction. In contrast, amoeboid invasion is integrin and MMP 
independent and forward motion is created by propulsive cytoplasmic streaming. 
Collective invasion occurs by similar mechanisms to mesenchymal invasion but Ms are 
maintained and traction generated by pathfinder cells is transmitted to the entire epithelial 
sheet (Figure adapted from (410)) 
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1.3.3.1 MesenchymalInvasion. 
Mesenchymal invasion has been the most intensively studied, largely because it can be 
partially recapitulated in 2-dimensions and hence has been more readily accessible. 
Mesenchymal invasion requires cells from an epithelial cancer to have undergone an EMT. 
and is characterised by loss of the AJ and cell-cell cohesion with migration of individual 
elongated and polarised cells moving at relatively slow speeds. This pattern of migration 
has been divided into a continuous cycle of five phases (409,410): 
1. Protrusion of the leading edge. 
Chemokine or growth factor receptor signalling activates PI 3-K and PI 4,5-K whose 
products recruit the Arp2/3-WASP actin-nucleating complex and GNEFs which 
activate Rho-family GTPases. This results in forward propulsion of a pseudopod 
driven by actin polymerisation. 
2. Formation of focal contacts. 
As the pseudopod forms ß1 and ß3 integrins, along with other adhesion receptors 
such as CD44, are engaged by their extracellular matrix ligands and become 
clustered in the cell membrane. Various adaptor, signalling and actin regulatory 
proteins such as a-actinin, talin, vinculin, FAK, paxillin, PI 3-K, protein kinase C 
and Rho-family GTPases are recruited. This guides the local polymerisation of actin 
and cross-linking of actin into filaments. Cytoplasmic bundles of actin, termed stress 
fibres, extend back from the focal contact along the longitudinal axis. Stress fibre 
formation is predominantly controlled by Rho and its downstream effecter ROCK. 
3. Focalized proteolysis. 
Whilst actin polymerisation is occurring proteases are recruited to focal contacts. 
Soluble proteases such as separase, MMP1 and MMP2 bind directly to integrins and, 
together with membrane bound proteases such as MT-MMP1 (411), cause localised 
degradation of the extracellular matrix creating a defect which is occupied by the 
advancing cell body (412). 
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4. Acto-myosin contraction. 
Myosin II binds actin filaments and generates contraction thus generating force to 
pull the cell body and trailing edge forward. Myosin II is activated by 
phosphorylation of the myosin light chain by myosin light-chain kinase and 
deactivated by myosin light-chain phosphatase (MLCPtase). This is regulated by Rho 
via its effecter ROCK which inhibits MLCPtase (413). 
5. Detachment of the trailing edge. 
Focal contacts at the trailing edge are disassembled by a variety of mechanisms 
including the activity of actin severing proteins such as cofilin (414) and cleavage of 
focal contact components by the protease calpain (415). 
Mesenchymal invasion is thus characterised by its dependence on cell-matrix interactions, 
the generation of traction forces via actin stress fibres and extensive extracellular matrix 
remodelling. A requirement for Src kinase activity has been demonstrated perhaps acting 
via its effector calpain to promote the turnover of focal adhesions (416). 
1.3.3.2 Amoeboid Invasion 
A second mode of invasion utilised by single cells is amoeboid migration. This differs in 
several important respects from mesenchymal migration. It has been most extensively 
characterised in the single cell amoeba Dictyostelium, but has also been observed in 
leukocytes and tumour cells, both in vitro and in vivo (409,410). Amoeboid movement is 
characterised by weak diffuse cell matrix interaction and cannot by inhibited by integrin 
blocking antibodies. Mature focal contacts and stress fibres are lacking. The initial step in 
amoeboid migration occurs via the activation of chemokine or growth factor receptors 
which triggers formation of a pseudopod. A wave of cortical actin polymerisation then 
occurs around the cell cortex and the cell undergoes contraction to generate propulsive 
force with streaming forward of the cytoplasm. Rather than degrading matrix, cells squeeze 
through gaps between fibres and achieve far higher speeds than in mesenchymal invasion 
(417). Mesenchymal cells treated with protease inhibitors, integrin blocking antibodies or 
inhibitors of Src kinase activity (416,418,419) have been shown to switch to an amoeboid 
invasive phenotype. This may have relevance for therapeutic anti-invasion strategies. 
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1.3.3.3 Collective Invasion 
On histopathological examination many human tumours clearly retain cell-cell junctions 
and invade either as clusters of cells which have detached from the primary tumour or as 
strands or sheets remaining in contact with the primary tumour (410,420). It is likely that 
this process recapitulates developmental processes such as migration of cell sheets in the 
blastoderm or ectoderm following closure of the neural tube. This form of invasion shares 
certain traits with mesenchymal invasion. A subset of cells at the invasive front, termed 
pathfinder cells, generate pseudopods which adhere to extracellular matrix via clustered ß1 
and 03 integrins. Focal contacts form and traction is generated by actomyosin contractility 
whilst localised extracellular matrix degradation occurs in a similar manner to 
mesenchymal invasion (421,422). AJs are maintained and actin organised at a 
supracellular level so that traction force is transmitted across the entire cohort (422). Cells 
in the centre and trailing edge of the cohort are largely non-motile, maintain identical 
positions relative to each other and are pulled along passively (423). Perhaps the greatest 
advantage of this mode of invasion is the maintenance of a favourable microenvironment 
for tumour cells via high local concentrations of growth and survival signals. For example, 
E-cadherin mediated intercellular adhesion is able to promote anchorage independent 
growth and prevent apoptosis of carcinoma cells in vitro (424) perhaps via ligand 
independent activation of EGFR which causes upregulation of the anti-apoptotic protein 
Bcl-2 (425). The in vivo relevance of this is demonstrated by the observation that clusters 
of 6-7 tumour cells injected into the tail vein of mice generate significantly more metastatic 
foci than injection of an identical number of single tumour cells (426,427). Such 
circulating tumour cell clusters are relatively common in the peripheral blood of patients 
with common solid tumours such as colorectal (428) or prostate cancer (429). 
The mechanisms regulating collective invasion are poorly understood. Recent work 
suggests a pivotal role for the mucin-like transmembrane glycoprotein, podoplanin, in 
inducing collective invasion (430). Expression of podoplanin in the previously discussed 
RIPITAG2 transgenic mouse model of pancreatic carcinogenesis (341) caused a 
significant increase in the number of invasive tumours forming. Crucially, these tumours 
retained AJs and invaded in a collective manner. This was in complete contrast to tumours 
forming in the absence of podoplanin which undergo EMT with loss of E-cadherin and in 
which loss of E-cadherin is a rate-limiting step for the development of invasive tumours 
(340,430). Thus, expression of a single protein, podoplanin, was sufficient to override the 
requirement for EMT and to promote collective invasion. 
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Immuno-histochemical analysis of 189 human squamous cell carcinoma specimens 
(oesophageal, cutaneous, cervical and lung) demonstrated that in 80% of cases invasion 
adopted a collective morphology (430). Whilst E-cadherin was retained at cell-cell 
junctions in all layers podoplanin was found exclusively in the outermost cell layer of the 
invasive front. Thus the expression of podoplanin by an individual cell is affected by the 
tumour microenvironment, perhaps by growth factors produced by stromal cells. EGF, for 
example, increased expression of podoplanin in cultured cells in vitro. As would be 
predicted the collective invasion induced by podoplanin was sensitive to matrix 
metalloproteinase inhibition. The mechanism by which podoplanin promotes invasion 
awaits definition but may be related to alterations in Rho family GTPase activity (430). 
Integrins also appear to play an important role in collective invasion, not just in attachment 
of the leading edge to the matrix but also to promote cell-cell cohesion. For example, when 
primary melanoma explants were treated with aß1-integrin blocking antibody collective 
invasion was inhibited and individual cells dispersed by amoeboid migration (422). Indeed 
several lines of evidence suggest that integrins are important in maintaining cell-cell 
adhesion in collective migration (431,432). Potential mechanisms include integrin 
signalling pathways which modulate Rho GTPase activity (431) or incorporation of a3ß1 
integrin into the AJ where it interacts with the tetraspanin CD151 and recruits PTPµ to 
stabilise Ms. Alternatively a5ß 1 integrin may remodel fibronectin into an extracellular 
scaffold which functionally links individual cells to each other (432). 
1.3.4 Potential roles for p120 in invasion. 
Based on current knowledge of p120's central role in cadherin and epithelial biology two 
major scenarios by which p120 might influence invasion have been proposed (156). 
1.3.4.1.1 p120 as an invasion suppressor. 
As described above there is overwhelming evidence that, in many situations, E-cadherin 
acts to inhibit invasion. Consequently, p120 via its core function in maintaining E-cadherin 
levels may logically be expected to similarly inhibit invasion. Indeed, the finding that E- 
cadherin is almost always absent or redistributed to the cytoplasm in tumours lacking p120 
provides circumstantial evidence that loss of p 120 may be an important mechanism for the 
downregulation of E-cadherin in human tumours. 
No invasive behaviour was detected in the skin or salivary gland of mice with targeted 
knockout of p120 in these tissues (94,95) although the effect of knockdown of p120 in 
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combination with manipulations of known tumour suppressor or oncogenes has not been 
directly addressed. However, as alluded to above, an intriguing hypothesis is that, by 
effectively sequestering p120, the transgenic expression of DN-cadherin may phenocopy 
p120 knockout. In this regard it is tempting to speculate that the ability of DN-E-cadherin 
to promote invasion in the RIPITAG2 mouse model may predict the effects of knocking 
out p120 in this model (271). 
1.3.4.1.2 p120 as an invasion promoter. 
A second situation may occur, as described for example in lobular breast and diffuse-type 
gastric cancers where E-cadherin is downregulated by mutation or transcriptional 
repression. In these tumours, as in vitro (10), p120 appears relatively stable and a 
redistribution of p120 to the cytoplasm occurs. In vitro, cytoplasmic re-localisation of p120 
is often associated with alterations in Rho GTPase activity and an increase in 2- 
dimensional planar migration (433). Whilst it is tempting to speculate that this may 
translate into increased invasion, no test of this hypothesis has yet been reported. 
A second mechanism by which re-localisation of p120 from the membrane to the 
cytoplasm or nucleus could influence cellular phenotype is via its interaction with Kaiso. 
Loss of E-cadherin causes increased entry of p120 into the nucleus (434) whilst loss of the 
nuclear export signal encoded by p120 exon B, as reported in colon and prostate cancer 
(61), may also favour nuclear accumulation. An increase in nuclear p120 would be 
predicted to release Kaiso-mediated transcriptional repression of its target genes. Although 
these include target genes with known roles in invasion, recent in vivo data has shown that 
Kaiso, rather than inhibiting oncogenesis, was required for intestinal tumorigenesis in the 
ApcM"J+mouse (51). Whether Kaiso has similar or divergent roles in other tissues and how 
this might be regulated by p120 remains unexplored. 
Finally, the potentially pro-invasive role of the switch from p120 isoform 3 to 1 which has 
been detected in some tumour cell lines and which may occur during EMT is intriguing. 
p120 isoform 1 is found naturally in more motile cell types and it associates preferentially 
with the pro-invasive N-cadherin. Whether a p120 isoform switch may causally contribute 
to the invasive phenotype is unknown. 
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1.4 Aims. 
p120 as "master-regulator" of the AJ, prominent tyrosine kinase substrate, and regulator of 
Rho GTPase activity would appear well placed to integrate and disseminate signals leading 
to altered cell-cell adhesion and invasion. However, the biological consequences of p120 
phosphorylation and the role, if any, of p120 in invasion are unknown. We therefore set out 
to: - 
1. Develop new tools to facilitate the study of p120 tyrosine phosphorylation. 
2. Identify the role of p120 tyrosine phosphorylation in Src or EGFR induced 
disruption of the AJ. 
3. Investigate role of p120 and its tyrosine phosphorylation in growth factor 
dependent invasion. 
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2 Materials 
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Materials used in the experiments described in this thesis are listed below. 
2.1 Plasmids and oligonucleotides 
Supplier: Dr J Collard, The Netherlands Cancer Institute, The Netherlands 
pGEX2TK-GST-PAK-CD 
pGEX2TK-GST-C21 
Supplier: Prof A. Reynolds, Vanderbilt University Medical School, Nashville, USA 
pLZRS-IRES-murine (m) p120-3A / HA-GFP 
pLZRS-IRES-(m) p 120-3A / 7F / HA-GFP 
pLZRS-IRES- (m) p 1204A / HA-GFP 
Supplier: Dr J. van Hengel, Flanders Interuniversity Institute for Biotechnology, Belgium 
pEFBOS-human p120-lA 
Supplier: BD Biosciences, Oxford, UK 
pECFP 
Supplier: Dharmacon, Colorado, USA 
siCONTROL Non-targeting siRNA duplexes 
Supplier: Invitrogen, Paisley, UK 
pCR-Blunt II-TOPO 
Supplier: Oligoengine, Seattle, USA 
pRetroSuper 
2.2 Cell lines 
Supplier: American Type Culture Collection, LGCPromochem, Middlesex, UK 
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A431 cutaneous squamous cell carcinoma cell line 
Supplier: Dr V. Brunton and Dr E. Avizientye, Beatson Institute 
KM12C cell lines expressing Src constructs (listed in Table 5) 
Supplier: Prof1. Fidler, M. D. Anderson Center, Texas, USA 
KM12C colon cancer cell line 
Supplier: Dr G Nolan, Stanford University, California, USA 
Phoenix Ampho packaging cell line 
2.3 Antibody generation 
Supplier: Affiniti Research Products Ltd., Exeter, UK 
Free phosphorylated peptides 
Free non-phosphorylated peptides 
KLH-conjugated phosphorylated peptides 
Agarose-bound non-phosphorylated peptides 
Supplier: Amersham International, Little Chalfont, UK 
HiTrapTm Protein G Column 
Supplier: Bio-Rad Laboratories, California, USA 
Coomassie Brilliant Blue R-250 Staining Solution 
Supplier: Harlan UKLtd, Oxfordshire, UK 
Rabbits, New Zealand White 
Supplier: Sigma Chemical Co, Poole, UK 
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Freund's Adjuvant, complete 
Freund's Adjuvant, incomplete 
2.4 Cell culture reagents 
Supplier: Amaxa GmbH, Cologne, Germany 
Amaxa Nucleofector System 
Supplier: Beatson Institute Central Services 
Sterile PBS 
Sterile PBS/1mM EDTA 
Supplier: Clonetics Corporation, distributed by TCS Biologicals, Botolph Claydon, UK 
Keratinocyte Growth Medium 
Calcium chloride solution 
Bovine pituitary extract 
Human EGF 
Hydrocortisone 
Insulin 
Amphotericin-B 
Gentamicin 
Supplier: Gibco Europe Life Technologies Ltd, Paisley, UK 
Dulbecco's Modified Eagle Medium 
Eagles' Minimal Essential Medium 
Hanks' buffered saline solution 
L-glutamine 
Non-essential amino acids 
Trypsin solution 
Supplier: Invitrogen 
Oligofectamine Transfection Reagent 
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Supplier: Roche Diagnostics Ltd, Sussex, UK 
DOTAP Liposomal Transfection Reagent 
Supplier : Sigma Chemical Co. 
Foetal bovine serum (FBS) 
HEPES-buffered saline (HBS) 
MEM vitamin solution 
Puromycin 
Polybrene 
Sodium pyruvate 
2.5 Cell culture plasticware 
Supplier: BD Biosciences, Oxford, UK 
Falcon tissue culture dishes (60mm, 90mm and 120mm) 
Supplier: TCS biologicals 
Eight well chamber slides 
Nunc tissue culture flasks 
Nunc cryotubes 
2.6 Growth factors and drugs 
Supplier: Ariad pharmaceuticals, Massachusetts, USA 
AP23464 
Supplier: CNBiosciences Ltd, Nottingham, UK 
AG1478 
Supplier: R&D Systems, Abingdon, UK 
62 
Recombinant human EGF 
2.7 Primary antibodies 
Supplier: Abcam Ltd, Cambridge, UK 
Rabbit anti-a-catenin 
Rabbit anti-p 120-catenin 
Supplier: BD Biosciences 
Mouse anti-ß-catenin 
Mouse anti-y-catenin 
Mouse anti-Cdc42 
Mouse anti-E-cadherin 
Mouse anti-EGFR 
Mouse anti-phospho-EGFR 
Mouse anti-FAK 
Mouse anti-N-cadherin 
Mouse anti-P-cadherin 
Mouse anti-p 120 
Mouse anti-pl20-phospho-Y96 
Mouse anti-pl20-phospho-Y228 
Mouse anti-pl20-phospho-Y280 
Mouse anti-p 120-phospho-Y291 
Mouse anti-paxillin 
Mouse anti-phosphotyrosine (clone PY20) 
Mouse anti-p1300' 
Mouse anti-Racl 
Supplier: B. Serrels, Beatson Institute 
Anti-Src kinase domain antibody (435) 
Supplier: New England Biolabs (UK) Ltd, Hertfordshire, UK 
Mouse anti-phospho-Ser/Thr 44/42 MAP Kinase 
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Mouse anti-Myc Tag (clone 9B11) 
Mouse anti-STAT3 
Rabbit anti-STAT3-phospho-Y705 
Rabbit anti-Src-phospho-Y416 
Supplier: Roche Diagnostics Ltd 
Mouse anti-HA tag 
Supplier: Santa Cruz Biotechnology, Santa Cruz, USA 
Mouse anti-RhoA 
Supplier: Sigma Chemical Co. 
Mouse anti-Actin 
Rabbit anti-MAP kinase 
2.8 Immunofluorescence 
Supplier: Fisher Scientific UK Ltd, Loughborough, UK 
Formaldehyde 
Supplier: Jackson ImmunoResearch, Luton, UK 
FITC labelled sheep anti-mouse IgG 
FITC labelled goat anti-rabbit IgG 
TRITC labelled sheep anti-mouse IgG 
TRITC labelled goat anti-rabbit IgG 
Supplier: Sigma Chemical Co. 
Phalloidin-FITC 
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Supplier: Vector Laboratories Ltd, Peterborough, UK 
Vectashield mounting medium 
2.9 Protein immunoprecipitation, electrophoresis and 
Western blotting 
Supplier: Amersham International 
Sheep anti-mouse/horseradish peroxidase conjugate 
Donkey anti-rabbit/horseradish peroxidase conjugate 
ECL reagent 
High molecular weight rainbow markers 
Supplier: Chemicon International, Harrow, UK 
Re-blot kit 
Supplier: CNBiosciences, Nottingham, UK 
Anti-v-Src conjugated agarose 
Recombinant LAR protein tyrosine phosphatase 
Supplier: PERBIO, Glasgow, UK 
Micro BCA protein assay kit 
Supplier: Premier Foods, St Albans, UK 
Marvel milk powder 
Supplier: Schleicher and Schuell, London, UK 
Nitrocellulose membrane 
Supplier: Severn Biotech Ltd, Kidderminster, UK 
Design-a-gel 30% acrylamide 
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Supplier: Sigma Chemical Co. 
Ammonium persulphate (APS) 
Anti-mouse IgG agarose 
Aprotinin 
Bovine serum albumin (BSA) 
IgG conjugated agarose beads 
Phenylmethylsulphonyl fluoride 
N, N, N', N'-Tetramethylethylenediamine (TEMED) 
Supplier: Whatman, Maidstone, UK 
3MM filter paper 
2.10 Manipulation of DNA 
Supplier: Bioline Ltd., London, UK 
Hyperladder I Quantitative Markers 
Supplier: Gibco Life Technologies 
DH5a competent cells 
Phosphatase and buffer 
Restriction endonucleases and buffers 
Supplier: Invitrogen, Paisley, UK 
Zero Blunt Topo PCR cloning kit 
Supplier: Melford Laboratories Ltd, Suffolk, UK 
Electrophoresis grade agarose 
Supplier: Promega, Madison, USA 
Wizard® PureFection Plasmid DNA Purification System 
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Supplier: Qiagen, Crawley, UK 
QlAquick gel extraction kit 
QlAprep miniprep kit 
Supplier: Roche Diagnostics Ltd 
Rapid DNA ligation kit 
Supplier: Sigma Chemical Co. 
Ampicillin 
Kanamycin 
Supplier: Stratagene, La Jolla, USA 
PFU Turbo DNA polymerase 
Quickchange Site Directed Mutagenesis Kit 
XL10-Gold Ultracompetent cells 
2.11 Invasion assays 
Supplier: BD Biosciences, Oxford, UK 
BD Matrigel Basement Membrane Matrigel 
Supplier: Corning Life Sciences, Acton, MA, USA 
Transwell (8.0 µm Pore) 
Supplier: Gibco Europe Life Technologies Ltd 
HEPES-buffered Dulbecco's Modified Eagle Medium 
Supplier: Invitrogen 
Calcein AM 
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2.12 Proliferation assay 
Supplier : Promega UK Ltd, Southampton, UK 
CellTiter 96® Non-Radioactive Cell Proliferation Assay kit 
2.13 Rho GTPase activity assay 
Supplier: Amersham International 
Glutathione Sepharose 4B 
2.14 Chemotactic migration assay 
Supplier: CNBiosciences Ltd 
InnocyteTM Cell Migration Assay kit, 96 well 
Supplier: Corning Life Sciences, Koolhovenlaan, Netherlands 
Clear bottom black 96 well plate 
2.15 Stock solutions and buffers 
2.15.1 Cell culture solutions 
2.15.1.1 A431 / Phoenix Ampho growth medium 
DMEM (lx) supplemented with: 
Foetal bovine serum 10% 
L-glutamine 2 mM 
2.15.1.2 KM12C growth medium 
Eagles' minimal essential medium supplemented with: 
Foetal bovine serum 10% 
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MEM vitamin solution 
Non-essential amino acids 
L-glutamine 
Sodium pyruvate 
2x (final concentration) 
lx 
2mM 
1 mM 
2.15.1.3 Low calcium growth medium 
KGM supplemented with: 
Bovine pituitary extract 30 pg/ml 
Human EGF 10 ng/ml 
Hydrocortisone 0.5 µg/m1 
Insulin 5 µg/ml 
Amphotericin-B 50 ng/ml 
Gentamicin 50 pg/ml 
Calcium 0.03 mM 
2.15.1.4 Trypsinization solution 
PBS supplemented with: 
Trypsin 0.25% (w/v) 
EDTA 1 mm 
2.15.2 Immunoprecipitation, electrophoresis and Western 
blotting solutions. 
2.15.2.1 RIPA lysis buffer 
Tris/HCI, pH 7.4 50 mM 
NaCl 150 mM 
Triton X-100 1% 
Sodium deoxycholate 0.5% (w/v) 
Sodium dodecyl sulphate (SDS) 0.1% (w/v) 
EDTA 2 mM 
Sodium orthovanadate 100 µM 
PMSF 2 mM 
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Aprotinin 10 µg/ml 
2.15.2.2 Co-immunoprecipitation lysis buffer 
Tris-HC1, pH 7.6 50 mM 
NaC1 200 mM 
MgC12 5 mM 
NP40 0.1% 
DTT 1 mM 
NaF 25 mM 
PMSF 1 mM 
Aprotinin 10 µg/ml 
Sodium orthovanadate 100 µM 
2.15.2.3 LAR phosphatase buffer 
Imidazole, pH 7.0 25 mM 
NaC1 50 mM 
EDTA 2.5 mM 
DTT 5 mm 
BSA 100 µg/ml 
2.15.2.4 Resolving gel buffer 
Tris-HCI, pH 8.9 1.5 M 
SDS 0.4% (w/v) 
2.15.2.5 Acrylamide gel -10% 
Resolving gel buffer 12 ml 
Acrylamide (30% w/v) 10.7 ml 
H2O 20 ml 
APS (10% w/v) 400 µl 
TEMED 30 µl 
2.15.2.6 Acrylamide gel - 7% 
Resolving gel buffer 12 ml 
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Acrylamide (30% w/v) 11.2 ml 
H2O 24.8 ml 
APS (10% w/v) 400 µl 
TEMED 30 µl 
2.15.2.7 Stacking Gel Buffer 
Tris-HCI, pH 6.7 0.5 M 
SDS 0.4%(w/v) 
2.15.2.8 Stacking gel 
Stacking gel buffer 4.5 ml 
Acrylamide (30% w/v) 2.4 ml 
H2O 11.1 ml 
APS (10% w/v) 200 µl 
TEMED 15 µ1 
2.15.2.9 Laemmli Sample buffer - 4x 
Tris-HCI, pH 6.8 150 mM 
SDS 6% (w/v) 
Glycerol 30% 
2-mercaptoethanol 15% 
Bromophenol blue to colour 
2.15.2.10 Tank buffer - 5x 
Tris-HC1 0.26 M 
Glycine 0.26 M 
SDS 0.5% (w/v) 
2.15.2.11 Transfer Buffer -I Ox 
Tris-HC1 0.48 M 
Glycine 0.39 M 
SDS 0.37% (w/v) 
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Diluted to lx with H2O containing 20% methanol 
2.15.2.12 Tris buffered saline (TBS) 10x 
Tris-HCI, pH 7.6 20 mM 
NaCl 150 mM 
2.15.2.13 Wash Buffer 
TBS 
Tween 20 0.2% 
2.15.3 Molecular biology solutions 
2.15.3.1 TAE Buffer 
Tris-acetate 40 mM 
Sodium acetate 5 mM 
EDTA 1 mm 
pH to 7.8 with glacial acetic acid 
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3 Methods 
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3.1 Production of sequence-specific phosphorylation- 
state specific antibodies. 
Peptides corresponding to the amino acid sequences encompassing human p120 tyrosine 
residues 96,112,228,257,280,291,296 and 302 were synthesised with the addition of an 
amino-terminal cysteine residue to facilitate coupling to the carrier protein keyhole limpet 
haemocyanin (KLH) (Table 1). Murine p120 is fully homologous over these sequences. 
Peptides were estimated to be greater than 90% pure by high performance liquid 
chromatography, and composition was confirmed by amino acid analysis (synthesis and 
analysis of peptides was carried out by Affiniti Research Products Ltd). KLH-conjugated 
peptide was emulsified in Freund's adjuvant, either complete for the primary immunization 
or incomplete for subsequent immunizations. Two rabbits were then immunised with 200 
µg of peptide by subcutaneous inoculation on four occasions over a three to four month 
period and sacrificed 14 days after the final immunisation. All animal handling including 
immunisation was performed by trained staff of the Beatson Institute animal facility and 
was in accordance with a Home Office license for this project (Home Office license no: 
PPL603576). 
After collection, blood was allowed to clot for 60 minutes at room temperature. The clot 
was separated from the sides of the glass collection vessel using a Pasteur pipette and the 
vessel incubated at 4°C overnight to allow the clot to contract. Serum was then aspirated 
and centrifuged at 10 000g for 10 minutes to remove any remaining particulate material. 
To isolate the IgG fraction 1 ml of serum was diluted in 14 ml of binding buffer (20 mM 
sodium phosphate, pH 7.0), any insoluble material removed with a 0.45 µm filter and ran 
through a Protein G Sepharose column. After washing with 10 column volumes of binding 
buffer the IgG was eluted with 0.1 M glycine-HCI, pH 2.7 into 1 ml aliquots pre-filled with 
60 pl 1M Tris-HCI, pH 9.0. The IgG-containing fraction was dialysed against phosphate- 
buffered saline (PBS) at 4°C for 16 hours. Non-phospho-specific antibodies were then 
removed by absorption against a Sepharose column containing the immunizing peptide in 
its non-phosphorylated form and the remaining fraction was again absorbed against a 
protein G column, eluted and dialysed against PBS. Purified IgG was aliquoted and stored 
at -70°C. Approximate quantification was obtained by comparison of the density of bands 
produced by purified IgG and BSA standards on electrophoresis and subsequent 
Coomassie Brilliant Blue staining of the gel. 
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Tyrosine Sequence Residues 
96 QDHSHLLpYSTIPRM 89-102 
112 QIVETpYTEEDPEG 107-119 
228 CGGSDNpYGSLSRV 222-234 
257 CSRQDVpYGPQPQVR 251-264 
280 HRFHPEPpYGLEDDQR 273-287 
291 DDQRSMGpYDDLDY 284-296 
296 GYDDLDpYGMMSD 290-301 
302 GMMSDpYGTARRTG 297-309 
Table I Peptide sequences used for immunisation. 
In each case the phosphorylated tyrosine residue is highlighted. 
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3.2 Generation of plasmids 
Full length human p120 isoform IA with a C-terminal myc tag was generated by PCR 
using pEFBOS-p120-1A as a template and the 5' primer TTACCCTGCCCT- 
GCGGCGGCTCCGC and the 3'primer 
CGGTCGACTTACAGATCCTCTTCTGAGATGAGTTTFTGTTCAATCTTCTGCATC 
AAGGG which includes a myc tag and stop codon. The PCR product was cloned directly 
into pCR-Blunt II-TOPO and sequenced to ensure no mutations had occurred during 
amplification. The insert was then subcloned into the retroviral vector pLZRS-IRES-GFP 
using EcoRI sites to generate pLZRS-p120-1A / myc-IRES-GFP. 
For the generation of pRetroSuper constructs oligonucleotides were synthesised which 
contained a 19 nucleotide human p120-specific RNAi sequence 
(GCCAGAGGTGGTTCGGATA) or scrambled control sequence 
(GATAAGGTGCTGCGTGGAC) in sense and antisense orientations separated by a9 
nucleotide spacer sequence. Oligonucleotides were inserted into pRetroSuper using the 
Hind III and Bgl II sites. 
To digest plasmids 1.0 µg of DNA was incubated for 90 minutes at 37°C with 5-10 units of 
the appropriate restriction endonuclease and buffer in a final volume of 20 µl. Where 
vector was being linearised 1 µl of shrimp alkaline phosphatase and 2 µl l OX buffer were 
then added and the reaction incubated for a further 30 minutes at 37°C. Fragments were 
separated by electrophoresis on a 0.8 - 1.5% agarose gel run in 1X TAE at 90V for 30-90 
minutes and were visualised by UV transillumination. Gels were prepared by dissolving 
electrophoresis grade agarose in 1X TAE buffer by microwaving. After cooling to 50°C 5 
pg/ml ethidium bromide was added and the molten gel poured into an appropriate gel 
former. The band of interest was excised with a scalpel and extracted using the QlAquick 
Gel Extraction kit according to the manufacturer's instructions and resuspended in 20pl TE 
(10 mM Tris-HCI pH7.4,1 mM EDTA pH 8.0). Purified DNA was quantified by agarose 
gel electrophoresis and comparison with a quantitative DNA ladder. Subsequent DNA 
ligation was performed with the Rapid DNA Ligation kit using 20-100 ng of linearised 
vector and a molar ratio of vector to insert of 1: 3. 
76 
3.3 Site-directed mutagenesis 
Site-directed mutagenesis of tyrosine residues 96,112,228,257,280,291,296 and 302, 
either singly or in combination, was performed in myc-tagged p120 in pCR-Blunt II-TOPO 
prior to subcloning into pLZRS-IRES-GFP and the sequence verified by sequencing. 
Mutagenesis was performed using the QuickChange Site-directed mutagenesis kit and the 
following primers incorporating the desired point mutation (synthesised by TAGN Ltd): - 
CCAGGATCACAGTCACCTTCTATTTAGCACCATCCCCAGG 
GGCAGATTGTGGAGACCTTTACGGAGGAGGATCCTGAGGG 
CCAGGTGGCAGTGATAACTTTGGCAGTCTGTCCCGGG 
CCTAGTAGACAGGATGTGTTTGGGCCCCAACCCCAGG 
GCTTTCATCCAGAGCCTTTTGGGCTAGAGGATGACCAGCG 
CTAGAGGATGACCAGCGTAGTATGGGCTTTGATGACCTGG 
TGATGACCTGGATTTTGGTATGATGTCTGATTATGGCACTGCC 
TGGTATGATGTCTGATTTTGGCACTGCCCGTCGGACTGGG 
(Y96F) 
(Y1 12F) 
(Y228F) 
(Y257F) 
(Y280F) 
(Y291 F) 
(Y296F) 
(Y302F) 
100 ng of primer was combined with 100 ng of ds-DNA template, 1 µl of dNTP mix, 1 µl 
QuickChange multi enzyme blend and buffer in a final volume of 25 µl. 30 thermal cycles 
were performed using an extension time of 14 minutes. The reaction mixture was then 
incubated with Dpn I at 37°C for 1 hour. 1.5 µl of the Dpn I treated DNA was subsequently 
used to transform XL10-Gold competent cells. 
3.4 Preparation of DNA 
E. coli (DH5a or XL10-Gold) competent cells, stored at -70°C, were thawed on ice and 20 
µl aliquoted into pre-chilled Eppendorf tubes. Various amounts of DNA, ranging from 0.1 
to 1 µg, were added to the competent cells and the solution was gently mixed with a pipette 
tip. The mixture was incubated on ice for 30 minutes, after which the cells were heat- 
shocked for 30 seconds in a 42°C water bath. After an additional 2 minutes on ice 250 µl 
of pre-heated L-broth was added and cells were incubated for one hour at 37°C in a 
shaking incubator (at 225 rpm). The mixture was then spread on agar plates containing 
100 µg/ml of ampicillin or 50 µg/ml of kanamycin (depending on the resistence cassette in 
the plasmid) and incubated overnight at 37°C. Single colonies were picked and grown 
overnight in L-broth containing 100 µg/ml of ampicillin or 50 , tu/ml of kanamycin. DNA 
77 
extraction was carried out by Wizard PureFection plasmid DNA Purification System 
according to the manufacturer's instructions. 
3.5 Retroviral infection 
pLZRS-IRES-GFP and pRetroSuper based constructs were introduced into KM12C- 
Src527F or A431 cells by retroviral infection. 5-7.5 pg of DNA was incubated with 30 µ1 
of DOTAP Liposomal Transfection Reagent in a final volume of 150 µl HBS for 15 
minutes at room temperature. The transfection mixture was then added to Phoenix Ampho 
packaging cells which had been plated at 5x 105 cells per 60 mm tissue culture dish 6 
hours earlier. The transfection medium was removed 16 hours later and replaced with fresh 
DMEM and 10% FBS. After 24 hours the viral supernatant was collected, filtered through 
a 0.45 µm membrane and added to sparsely plated cells in the presence of 4 µg/ml 
polybrene. Fresh medium was added to the Phoenix Ampho cells and a second infection 
carried out 24 hours later. Cells with stable retroviral integration were selected on the 
basis of GFP expression (KM12C-Src527F / pLZRS-IRES-p120-GFP constructs) or with 2 
pg/ml puromycin (A43 1 -pRetroSuper). 
3.6 Nucleofection 
Nucleofection of A431-p120- cells with pLZRS-murine (m)p120-3A-IRES-GFP, pLZRS- 
mpl20-3A/7F-IRES-GFP and pLZRS-mpl20-4A-IRES-GFP was performed with the 
Amaxa Nucleofector System in accordance with the manufacturer's instructions. Briefly, 2 
x 106 cells were suspended in 100 µl Nucleofector solution V in a cuvette and 5 µg DNA 
added. The chemical composition of Solution V was proprietary information and not 
available from Amaxa. Nucleofection was performed using program P-20 and cells 
immediately transferred to a culture dish at 37°C. Pooled populations with uniform levels 
of expression were selected according to GFP expression using a BD FACSVantage SE 
flow cytometer. 
3.7 Routine cell culture 
A431 and Phoenix Ampho cell lines were routinely grown in DMEM supplemented with 
10% FBS and L-glutamine. KM12C-derived cell lines were cultured in MEM 
supplemented with 10% FBS, L-glutamine, MEM vitamin solution, non-essential amino 
acids and sodium pyruvate. All cell lines were maintained in a humidified 37°C / 5% CO2 
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incubator. To sub-culture adherent cells the medium was removed by aspiration and the 
monolayer rinsed with PBS followed by 10% trypsin/PE solution. Upon detachment the 
cells were resuspended in complete medium, counted, and then transferred into tissue 
culture flasks, plates or chamber slides. 
3.8 Growth factors and drugs 
Recombinant human EGF was dissolved in 10 mM acetic acid / 0.1% BSA to a stock 
concentration of 100 µg/ml and diluted in serum-free medium to a final concentration of 
10 or 100 ng/ml immediately prior to use. AP23464 was dissolved in DMSO to a stock 
concentration of 10 mM. Immediately prior to use it was diluted in medium to achieve a 
final concentration of 1 µM. AG1478 was dissolved in DMSO to a stock concentration of 
10 mM and was further diluted in medium to a final concentration of 300 nM immediately 
prior to use. 
3.9 Immunofluorescence 
Cells plated on 8-well glass (A431) or plastic (KM12C) chamber slides were washed in 
PBS then fixed in 3.7% formaldehyde for 10 minutes. They were then washed twice in 
PBS and permeabilised with PBS/0.5% Triton X-100/1% BSA for 15 minutes. After 
blocking with PBS/10% FCS for 1 hour, cells were incubated with primary antibodies 
(Table 2) in blocking buffer overnight at 4°C. Detection of p120-phospho-Y228 mAb was 
by reaction with anti-mouse biotin (diluted 1 in 750 in blocking buffer) for 60 minutes 
followed by Alexa-488 Streptavidin (diluted 1 in 200 in blocking buffer) for 40 minutes. 
For all other primary antibodies detection was with FITC- or TRITC-conjugated secondary 
antibodies (diluted 1 in 100 in blocking buffer) for 45 minutes. Cells were visualised using 
a Leica DM IRBE confocal microscope (Leica UK Ltd., Milton Keynes, UK). 
Antibody Dilution 
Anti-E-cadherin 1: 100 
Anti-HA tag 1: 200 
Anti-myc tag 1: 2000 
Anti-p120 1: 1000 
Anti-p l20-phospho-Y228 
monoclonal 
1: 200 
Table 2 Primary antibodies used for Immunofluorescence 
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3.10 Preparation of protein extracts 
Dishes were transferred directly from the incubator onto ice. Cells were then washed twice 
with PBS and then lysed in ice-cold RIPA buffer or co-IP buffer for 10 minutes. Cells were 
scraped off the tissue culture plastic using a disposable cell scraper and the lysate 
transferred to a microcentrifuge tube. The lysate was then clarified by centrifugation at 
14,000g for 15 minutes at 4°C. Protein concentration was determined using the Micro 
BCA Protein Assay Kit and light absorbance then measured with a DU 650 
spectrophotometer at a wavelength of 562 nm. 
3.11 Western blot analysis 
Laemmli sample buffer was added to lysates which were then boiled for 5 minutes. 
Protein separation was achieved by running the samples and molecular weight markers on 
an SDS-PAGE gel consisting of a short stacking gel and a longer resolving gel. The 
resolving gel contained 7% or 10% acrylamide depending on the size of the proteins being 
separated. Gels were typically run at 200V for 1 hour and 15 minutes. Following 
electrophoresis, the proteins were transferred onto a nitrocellulose membrane, while being 
buffered by 3MM filter paper saturated in transfer buffer, using semi-dry blotting 
apparatus at 20V for 45 minutes. After the proteins had been transferred onto 
nitrocellulose the membrane was blocked for one hour at room temperature in 5% low fat 
milk in TBS / 0.2% Tween 20. The primary antibody in 3% BSA / TBS / 0.2% Tween 20 
was then added for 1 hour at room temperature or overnight at 4°C (Table 3). The blots 
were then washed four times in TBS / 0.2% Tween 20 (10 minutes each) and incubated 
with horseradish peroxidase conjugated secondary antibodies at 1 in 10 000 in 5% low fat 
milk / TBS / 0.2% Tween 20 for 45 minutes. The blots were again washed four times in 
TBS / 0.2% Tween 20 (15 minutes each) and ECL reagent added for 1 minute. The 
proteins were then visualized using a Kodak X-OMAT 480 RA film processor. When 
necessary, blots were stripped using Re-Blot Plus Strong Antibody Stripping Solution and 
reprobed with additional antibodies. 
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Antibody Dilution 
Anti-actin 1: 500 
Anti-a-catenin 1: 400 
Anti- -catenin 1: 500 
Anti-y-catenin 1: 2000 
Anti-E-cadherin 1: 2000 
Anti-N-cadherin 1: 2500 
Anti-P-cadherin 1: 250 
Anti-CDC42 1: 1000 
Anti-EGFR 1: 5000 
Anti- hos ho-EGFR 1: 1000 
Anti-FAK 1: 1000 
Anti-HA tag 1: 500 
Anti-MAPK 1: 10 000 
Anti- hos ho-MAPK 1: 1000 
Anti-myc tag 9B 11 1: 1000 
Anti-p120 1: 1000 
Anti- 120- Y96 1: 1000 
Anti- 120- Y228 (monoclonal) 1: 5000 
Anti- 120- Y228 of clonal 1: 250 
Anti- 120- Y280 1: 250 
Anti- 120- Y291 1: 500 
Anti- 120- Y296 1: 5000 
Anti- 130C8S 1: 1000 
Anti-paxillin 1: 10 000 
Anti- hos hot osine PY20 1: 1000 
Anti-Rac 1 1: 1000 
Anti-RhoA 1: 500 
Anti-Src Kinase Domain 1: 5000 
Anti-Src- Y416 1: 1000 
Anti-STAT3 1: 1000 
Anti- hos ho-STAT3 1: 250 
Table 3 Primary antibodies used for Western blotting 
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3.12 Immunoprecipitation 
250-1000 µg of cleared lysate was incubated with the appropriate primary antibody at 4°C 
overnight (Table 4). Anti-mouse IgG-agarose or protein-G-agarose (for rabbit primary 
antibodies) was then added to immunoprecipitates for 1 hour at 4°C. Immunoprecipitates 
were washed three times, resuspended in Laemmli sample buffer, and boiled for 5 minutes. 
Where indicated immunoprecipitates were first washed in LAR reaction buffer then 
incubated with 2 µl / 10 units LAR phosphatase at 3 0°C for 30 minutes prior to addition of 
Laemmli sample buffer. Denatured proteins were separated by SDS-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes for immunoblotting. 
Antibody Dilution 
Anti-E-cadherin 1: 125 
Anti-HA tag 1: 125 
Anti-myc tag 1: 500 
Anti-p120 1: 250 
Table 4 Primary antibodies used for Immunoprecipitation. 
3.13 Rho-family GTPase activity assay 
E. Coli were transformed with the pGEX2TK vector encoding either the Rac- and Cdc42- 
binding region from human PAK1B (GST-PAK-CD) (104) or the Rho binding domain, 
from the Rho effector protein Rhotekin (GST-C21) (436) fused to GST. Cells were grown 
to OD600 0.3 and then induced to express the recombinant protein by the addition of 0.1 
mM IPTG for 2 hours. Cells were then harvested, resuspended in bacterial lysis buffer (50 
mM Tris-HC1 pH 7.5,1mM EDTA, 100 mM NaCl, 0.1% triton X-100,5% glycerol, 1 mM 
dithiothreitol, 1 µg/ml leupeptin, 1 gg/ml aprotinin, 1 mM benzamidine, and 1 mM PMSF) 
and sonicated for 2-3 minutes. Lysates were centrifuged at 4°C for 20 minutes at 10 000g 
and the supernatant incubated with glutathione-coupled Sepharose beads for 30 minutes at 
4°C with gentle agitation. Beads were then washed three times with lysis buffer (50 mM 
Tris-HCI, pH 7.4,2 mM MgC12,1% NP-40,10% glycerol, 100 mM NaCl, 1 mM 
benzamidine, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 pg/ml aprotinin, 1 mM DTT, 1 mM 
PMSF) and retained at 4°C until used. Cells were serum starved for 16 hours then 
stimulated with 100 ng/ml EGF or vehicle (10 µM acetic acid / 0.0001% BSA) for 5 
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minutes (Rae / Cdc42) or 15 minutes (RhoA), washed in ice-cold PBS (containing 1 mM 
MgC12 and 0.5 mM CaC12), incubated for 5 minutes on ice in lysis buffer, and then 
centrifuged for 5 min at 14 000 gat 4°C. Aliquots were taken from the supernatant to 
compare protein amounts. The remaining supernatant was incubated at 4°C with either 
GST-PAK beads for 30 minutes or GST-RBD beads for 60 minutes. Beads were then 
washed three times in lysis buffer, eluted in Laemmli sample buffer, and analyzed for 
bound Rho family molecules by Western blotting using anti-RhoA, anti-Racl, or anti- 
CDC42 antibodies as described in section 3.11. Films were scanned and the density of 
bands quantified using Total Labs software. 
3.14 Cell proliferation assay 
Proliferation was determined using the Ce1lTiter 96 Non-Radioactive Cell Proliferation 
Assay kit. Briefly, 1x 103 cells / well were plated per well on multiple 96-well plates in a 
volume of 100 µl. At 24 hour intervals 15µl of dye solution (3-(4,5-dimethytlthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide) was added. After a4 hour incubation at 37°C 100 µl of 
solubilization solution (an organic solvent, exact composition proprietary information of 
Promega) was added and the absorbance at 570 nm determined using a FlexStation 11 96 
well plate reader (Molecular Devices, CA, USA). Mean and S. D. values were calculated 
from quadruplicate wells. 
3.15 Cell motility assay 
1x 104 cells / well were plated on a 6-well plate and allowed to adhere for 8 hours. Images 
were then captured every 15 minutes using an Axiovert 200 M Zeiss microscope with a 
x20 objective and AQM Advance software (Kinetic Imaging, Nottingham, UK). The 
motility of individual cells was analysed using Tracking Analysis software (Kinetic 
Imaging). In all experiments the data was positively skewed and therefore data is reported 
as median and interquartile range and the non-parametric Mann-Whitney U test used for 
statistical comparison. 
3.16 Wound healing assay 
1x 106 cells / well were plated on 6 well plates. 24 hours later a wound was made with a 
single pass of a sterile pipette tip and images of cells migrating into the wound recorded by 
time-lapse video-microscopy at 15 minute intervals until complete wound closure. For 
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quantification, the distance travelled by the leading edge just prior to wound closure was 
measured and divided by time to calculate speed of migration. 10 individual points in two 
different wounds were measured and results expressed as mean +/- S. D. 
Alternatively cells were plated on glass chamber slides and grown to confluence prior to 
wounding with a sterile pipette tip. After 6 hours cells were fixed with 3.7% formaldehyde 
and immunofluorescence performed. 
3.17 Chemotactic migration assay 
Directional migration of cells in response to EGF was measured using the InnoCyte Cell 
Migration Assay Kit according to the manufacturer's instructions. Briefly, 5x 104 cells 
were resuspended in serum-free DMEM and plated on the upper surface of an uncoated 
transwell with 8 µm pore size. The lower surface of the transwell was placed in serum free 
DMEM with or without EGF (1-100 ng/ml). After incubation for 24 hours at 37°C in a 
humidified incubator the transwell was removed and placed in a fresh chamber containing 
Cell Detachment buffer and Calcein-AM solution. Following a 45 minute incubation at 
37°C the transwell was gently tilted back and forth to facilitate dislodgement of any cells 
still adherent to the lower surface of the transwell and then removed. The lower chamber 
was then incubated for a further 45 minutes at 37°C before determining the fluorescence 
with excitation 485 nm and emission 520 nm. Mean and S. D. values were calculated from 
triplicate wells. 
3.18 Matrigel invasion assay 
60 µl of growth factor-depleted Matrigel was added to the upper chamber of a Transwell 8 
µm pore size filter and allowed to set at 37°C for 90 minutes. Cells were trypsinised, 
washed and resuspended in DMEM at 1x 105 cells/ml. 100 µl of cell suspension was then 
placed on an inverted Transwell and the cells allowed to adhere for 4 hours. The Transwell 
was then carefully washed twice with serum-free DMEM before being placed in a well 
containing serum free DMEM with the cells adherent to the lower surface. Serum free 
DMEM with or without EGF (10 ng/ml) was then added to the centre of the Transwell and 
the plate left at 37°C in a humidified incubator for 72 hours. To stain cells Calcein AM 
(diluted in HEPES-buffered serum-free DMEM to a final concentration of 4 µM) was 
added to both upper and lower chambers and the plate returned to the 37°C incubator for 
60 minutes. Horizontal z-sections through the Matrigel were then taken at 15 pm intervals 
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using a Leica DM IRBE confocal microscope. The number of positive pixels in each 
image was determined using "Image J" software (NIH) using a value of 150 for 
background subtraction. The sum of the values obtained for individual z-sections 
(excluding the first section which corresponds to the upper surface of the filter) was then 
expressed as a percentage of the control cell value. For each experiment samples were run 
in duplicate and at least 4 z-series were taken per sample. 
3.19 Organotypic invasion assay 
pECFP was introduced into A431-Scr or A431-p120- cells using the AmaxaNucleofector 
System and pooled populations with uniform expression selected by FACS. These were 
plated on top of collagen/Matrigel (4 mg/ml collagen/2.5 mg/ml Matrigel) gels containing 
10% FBS. Where indicated 5x 105 tumour derived fibroblasts were added to the gel. After 
24 hours the gel was transferred onto a nylon filter and placed on a mesh support. This was 
partially submerged in media containing 10% FBS, while the rest of the gel including the 
A431 cells was in contact with air. After 5 days the gels were fixed with 4% 
paraformaldehyde / 0.25% gluteraldehyde / PBS, permeabilised with 0.2% Triton X- 
100/PBS and stained with TRITC-phalloidin. A multi-photon laser scanning microscope 
was used to take 5 optical xz sections of each gel and the area of non-invading cells and the 
total area over which cells had spread was measured. The invasion index =1- area of non- 
invading cells/total area over which cells had disseminated. Where indicated E-cadherin 
specific siRNA sequences (#1 GGAGAGCGGUGGUCAAAGAUU, #2 
ACCAGAACCUCGAACUAUAUU) or non-targeting control sequences were introduced 
into the cells using Oligofectamine according to the manufacturers instructions. All 
organotypic invasion assays were performed by Dr S Hooper in the laboratory of Dr E 
Sahai, London Research Institute. 
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4 Results: Generation and validation of novel p120 
phospho-specific antibodies. 
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4.1 Aim 
p120-catenin is phosphorylated on tyrosine residues following activation of RTKs 
including EGF, PDGF, CSF-1 and VEGF (181,182,184) and cytoplasmic tyrosine kinases 
such as Src (52). Using a 2-dimensional tryptic mapping approach eight tyrosine residues 
(at positions 96,112,257,280,291,296 and 302) which are phosphorylated in Src 
transformed fibroblasts have been identified (68). However the regulation and 
consequences of phosphorylation events occurring at each of these individual sites is 
largely unknown (176). 
Sequence-specific phosphorylation-state specific antibodies (hereafter referred to as 
phospho-specific antibodies) have proved useful tools in enabling the feasible dissection of 
signalling pathways and, specifically, in defining events occurring at individual residues 
rather than global phosphorylation of a protein. In addition, for the in-situ study of protein 
phosphorylation in tissues or cells phospho-specific antibodies are essential. At the outset 
of this work no p120 phospho-specific antibodies existed. We therefore aimed to produce 
novel phospho-specific antibodies to facilitate the study of p120 site-specific 
phosphorylation events occurring in response to receptor and non-RTK activation in cancer 
cell lines and tissues. 
4.2 Results 
4.2.1 p120 is phosphorylated in KM12C cells expressing 
constitutively active c-Src. 
To validate novel phospho-specific antibodies a source of phosphorylated p120 was 
required. Tyrosine phosphorylation of p 120 has been best defined in cell lines expressing 
the active form of the cytoplasmic tyrosine kinase Src (52,68). The generation of a 
KM12C colon carcinoma cell line with stable expression of a constitutively active Src527F 
mutant has previously been reported (257). The level and activity of Src (as measured by 
auto-phosphorylation of tyrosine-416) was dramatically increased in KM12C-Src527F 
cells as compared to the parental cell line (Figure 4-1 A). Using an antibody that 
recognises all tyrosine phosphorylation events, p120 immunoprecipitated from Src527F 
expressing cells was seen to be heavily phosphorylated on tyrosine residues as compared to 
p120 in the parental cells (Figure 4-1 B, upper panel). Equivalent levels of total p120 were 
present in the immunoprecipitates (Figure 4-1 B, lower panels). The presence of two 
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distinct bands reflects the presence of two dominant p120 isoforms in this cell line due to 
alternative splicing events which generate p120 isoform 3 with or without inclusion of the 
additional exons A, B or C. 
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Figure 4-1 Expression of active Src in KM12C cells causes tyrosine phosphorylation of 
p120. 
A) Lysates from KM12C cells or KM12C cells expressing constitutively active Src 
(KM 12C-Src527F) were prepared and analyzed by Western blotting with Src phospho- 
Y416 antibody. After removal of the phospho-specific antibody the blot was reprobed 
with Src antibody. Actin is a loading control. 
(B) p120 was immunoprecipitated from KM 12C or KM l2C-Src527F cells and analysed by 
Western blotting with a pan-phosphotyrosine antibody. The blot was stripped and reprobed 
with total p 120 antibody. 
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4.2.2 Production of antibodies. 
Serum was obtained from rabbits immunised with short peptides encompassing p120 
tyrosine residues 96,112,257,280,291,296 and 302. In each case the specific tyrosine 
residue had been phosphorylated at the time of synthesis and two rabbits were immunised 
with each peptide. We attempted to remove antibodies able to recognise non- 
phosphorylated peptide by immuno-affinity absorption and the remaining purified IgG 
fraction was then tested for its ability to immunoprecipitate p 120 from KM 12C-Src527F 
lysate (Figure 4-2 A). In addition, as KM12C cells express primarily isoform 3 which lacks 
tyrosine 96, exogenous p120 isoform 1A was co-expressed (see section 1.2.5) and used to 
test sera from rabbits immunised with peptide 89-102 (Figure 4-2 B). For each peptide at 
least one rabbit mounted a specific anti-p120 antibody response. The remainder of this 
chapter describes the validation performed to obtain robust evidence for the specificity of 
these antibodies. 
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Figure 4-2 Generation of phospho-specific antibodies. 
(A) p120 was immunoprccipitatcd from KMI2C-Src527F lysate using total p120 niAb or 
antisera from duplicate rabbits immunised with the p 120 phospho-peptides shown. The 
membrane was then probed with total p 120 antibody. (B) Exogenously expressed myc- 
tagged p120-1A was immunoprecipitated from KMI2C-Src527F cells with anti-myc 
antibody and the membrane probed with anti-phospho-Y96 antisera. 
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4.2.3 p120 is effectively de-phosphorylated by LAR phosphatase. 
Recombinant LAR phosphatase consists of the 350 amino acid soluble catalytic domain of 
the human transmembrane Leukocyte Antigen Related protein tyrosine phosphatase and is 
known to potently release phosphate groups from phospho-tyrosine residues in proteins 
(437). p120 immunoprecipitated from KM 12C-Src527F cells was fully de-phosphorylated 
by incubation with LAR phosphatase for 30 minutes prior to denaturation and gel 
electrophoresis as judged by loss of immuno-reactivity to a pan-phosphotyrosine antibody 
(Figure 4-3, top panel). Phospho-Y228, phospho-Y296 and phospho-Y302 antibodies 
failed to demonstrate reactivity with LAR phosphatase treated p120 indicating that the 
epitopes recognised were dependent on the presence of a phosphate group (Figure 4-3). In 
contrast anti-sera generated against tyrosine 112,257,280 and 291 were able to effectively 
immunoprecipitate dephosphorylated p120 indicating that they recognised epitopes 
independent of p 120 phosphorylation status and thus were not phospho-specific (Figure 4- 
3, bottom panel shows anti-phospho-Y280 as an example. ) 
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Figure 4-3 Phospho-Y228, -Y296 and -Y302 antibodies only detect phosphorylated p120. 
p120 was immunoprecipitated from KM12C-Src527F cell lysate and incubated with LAR 
phosphatase for 30 minutes prior to denaturation and electrophoresis. The membrane was 
probed with anti-phosphotyrosine, phospho-Y228, phospho-Y296, phospho-Y302 or 
phospho-Y280 antibodies. After removal of the phospho-specific antibody the blots were 
reprobcd with anti-p 120 antibody. 
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4.2.4 Phospho-Y228, -Y296 and -Y302 antibodies are sensitive to 
competition from phosphorylated but not non-phosphorylated 
peptide. 
Phospho-Y228, phospho-Y296 and phospho-Y302 antibodies were able to 
immunoprecipitate p120 from KM 12C-Src527F lysate. However, pre-incubation of the 
antibody with an approximately 10-fold excess of free phosphorylated peptide identical to 
that used to raise that antibody was sufficient to block immunoprecipitation (Figure 4-4). 
In contrast pre-incubation with peptides of identical sequence which were not 
phosphorylated did not interfere with the ability of each antibody to immunoprecipitate 
p 120 from KM 12C-Src527F lysate. This strongly suggested that phospho-Y228, phospho- 
Y296 and phospho-Y302 antibodies recognised epitopes specifically containing 
phosphorylated tyrosine-228, -296 or -302 respectively. 
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Figure 4-4 Immunoprecipitation of p120 by phospho-antibodies is specifically inhibited by 
pre-incubation with phospho-peptide. 
Phospho-Y228 (A), phospho-Y296 (B), or phospho-Y302 antibodies were used to 
immunoprecipitate p120 from KM12C-Src527F lysate (left lane). Alternatively, the 
antibodies were first incubated for one hour with an excess of phosphorylated (middle 
lane) or non-phosphorylated peptide (right lane) of identical sequence to the immunising 
peptide prior to immunoprecipitation. The membrane was probed with anti-p 120 antibody. 
95 
4.2.5 Generation of phosphorylation defective p120 constructs. 
Phenylalanine is an aromatic amino acid which differs from tyrosine only in that it lacks 
the reactive hydroxyl group in the ortho position on the benzene ring. Substitution of 
tyrosine with phenylalanine therefore has minimal effects on protein structure but prevents 
phosphorylation occurring (438). Therefore, substitution of a specific tyrosine residue with 
phenylalanine is a commonly used technique to prevent phosphorylation at a specific 
candidate residue. Myc-tagged p120 isoform IA constructs were generated in the 
bicistronic retroviral expression vector pLZRS-IRES-GFP. p120 eDNA was sited 
upstream, and GFP cDNA downstream, of an internal ribosomal entry site (IRFS). As a 
result translation of both p120 and GFP occurs from the same mRNA transcript and the 
levels of the two products are directly proportional (81). Site directed mutagenesis of all 
eight putative sites of tyrosine phosphorylation to phenylalanine was performed (p 120- 
IA/8F). In addition each tyrosine residue was mutated to phenylalanine in isolation (p120- 
I A/96F, p 120-1 A/228F, p 120-1 A/296F, p 120-1 A/302F). Stable expression of all 
constructs in KM12C-Src527F cells was achieved and single cell clones derived on the 
basis of GFP expression. Next we confirmed that all p120 constructs were correctly 
localised to the cell membrane as this is a prerequisite for significant phosphorylation of 
p120 to occur (Figure 4-5) (273). 
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Figure 4-5 Myc-tagged p120 localises to cell-cell contacts. 
Immunofluorescence using anti-myc antibody was performed on KM 12C-Src527F cells 
with stable expression of. (i) myc-tagged wt-pl20-lA, (ii) pl20-1A / 8F, (iii) p120-IA / 
96F, (iv) p120-1 A/ 228F, (v) p120-1A / 296F, (vi) p120-1A / 302F. Bar 20ýt n. 
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4.2.6 Phospho-Y228 and phospho-Y296 antibodies specifically 
recognise phosphorylated Y228 and Y296 respectively. 
Both phospho-Y228 (Figure 4-6 A) and phospho-Y296 (Figure 4-6 B) antibodies were able 
to recognise myc-tagged wild type p 120-1 A. Neither antibody was able to recognise p 120- 
1A in which all eight sites of tyrosine phosphorylation had been mutated to phenylalanine. 
Crucially, neither phospho-Y228 nor phospho-Y296 antibody recognised p 120 in which 
only tyrosine-228 or tyrosine-296, respectively, had been mutated to phenylalaninc. Thus 
both antibodies were truly specific for p120 only when phosphorylated on the specific 
residue intended and there was no cross-reactivity for other phosphorylated p 120 tyrosine 
residues. 
4.2.7 Phospho-Y96 and phospho-Y302 antibodies were not site- 
specific. 
Antibodies generated against phospho-Y96 (Figure 4-6 C) and phospho-Y302 (Figure 4-6 
D) were unable to recognise p 120- lA in which all eight sites of tyrosine phosphorylation 
had been mutated to phenylalanine. However, mutation to phenylalaninc of the individual 
tyrosine residue to which the antibody had been raised did not prevent immunoreactivity. 
Indeed no differential ability to recognise wild type versus mutant p120 was elicited 
despite the use of increasing dilutions of antibody (data not shown). Taken together with 
the results of the phosphatase and peptide competition experiments this suggested that 
these antibodies recognised phosphorylated tyrosine residues present in p 120 in addition to 
the specific target residue to which they had been raised. For this reason these antibodies 
were not used further. 
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Figure 4-6 Tyrosine to phenylalanine mutants are not recognised by phospho-Y228 and 
phospho-Y296 antibodies. 
Lysates prepared from KM 12C cell lines co-expressing constitutively active Src (KM 12C- 
Src527F) with myc-tagged wild type p 120-1 A (p 120-1 A) or p 120-1 Ain which either al 
eight tyrosine phospho-acceptor residues (p120-1 A/8F) or only the residue to which each 
antibody had been raised (p 120-1 A/96F, p 120-1 A/228F, p 120-1 A/296F and p 120- 
1 A/302F) were mutated to phenylalanine. Immunoprecipitations were performed with anti- 
myc antibody. Membranes were analysed by immuno-blotting with phospho-Y228 (A), 
phospho-Y296 (B), phospho-Y96 (C) or phospho-Y302 (D) antibodies. After removal of 
the phospho-specific antibody the blots were reprobed with anti-myc antibody. 
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4.3 Discussion 
4.3.1 Tyrosine phosphorylation of p120. 
The modification of proteins by the addition or removal of phosphate groups is involved in 
the regulation of nearly every aspect of cell biology. There are two main mechanisms by 
which phosphorylation can modify protein function. Firstly, phosphorylation may induce a 
conformational change leading, for example, to altered enzymatic activity. Secondly, 
phosphorylation may cause the formation of a novel binding site thus facilitating the 
formation of functional multi-molecular complexes (439). Increased phosphorylation of 
proteins on tyrosine residues is a common finding in cancerous cells and results from 
increased activity of receptor or non-RTKs or decreased activity of phosphatases (440). 
Increased tyrosine phosphorylation of p120 has been demonstrated in various tumour cell 
lines (176) although the physiological or pathological consequences of p120 
phosphorylation are largely undefined. 
An important initial contribution in understanding tyrosine phosphorylation of p120 was 
the mapping of eight individual tyrosine residues which are phosphorylated in a Src- 
dependent manner (68). Prior to this, studies of p120 tyrosine phosphorylation have relied 
on the use of pan-phosphotyrosine antibodies and studied global phosphorylation of the 
protein. However, many examples exist of differential regulation of individual tyrosine 
residues within a single protein and therefore attempts to correlate phenotype with changes 
in overall phosphorylation, rather than phosphorylation at individual sites, risk being 
uninformative. Indeed, a paradigm for this already exists for p120 in the regulation of 
serine / threonine phosphorylation. Activation of protein kinase C (PKC) in epithelial or 
endothelial cells was associated with dephosphorylation of p120 on serine / threonine 
residues using a general phospho-serine / threonine antibody (441,442). However, two- 
dimensional tryptic mapping techniques showed that PKC dependent de-phosphorylation 
of several p120 residues was, unexpectedly, accompanied by a potent increase in 
phosphorylation at serine-873 (69). Furthermore, a variety of kinases and phosphatases 
may impact on p120 phosphorylation and the extent to which individual tyrosine residues 
are independently regulated in response to varying stimuli or cellular context is unknown. 
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4.3.2 Generation of phospho-specific antibodies. 
The development of phospho-specific antibodies since the early 1990's has been a major 
technological advance in the study of protein phosphorylation (443). Earlier techniques 
employing 32P-radiolabelling are laborious, difficult to control, can use large amounts of 
radio-isotope and are not feasible methods to study individual events in proteins containing 
multiple phospho-acceptor residues. Drawbacks also exist with the use of general anti- 
phosphotyrosine antibodies. Firstly, to study phosphorylation of a particular protein the 
antibody must be used in conjunction with a protein-specific antibody, usually by 
incorporating a specific immuno-precipitation step and thus the study of phosphorylation 
in cells or tissues in-situ is not possible. Secondly, phosphorylation occurring at different 
residues within the molecule cannot be distinguished. Hence phospho-specific antibodies 
have several theoretical and practical advantages. Firstly, they allow the easy assessment 
by Western blotting of protein phosphorylation which has occurred in a cell. 
Phosphorylation events occurring at different residues within the same protein are readily 
distinguished. The sub-cellular localisation of phosphorylated proteins can be identified by 
immunofluorescence. Finally, the presence and localisation of phosphorylated proteins in 
tissues can be determined by immuno-histochemical analysis. 
To generate phospho-specific antibodies to p120 we utilised short peptides encompassing 
each of the eight tyrosine residues recently identified as sites of tyrosine phosphorylation. 
Peptides of 12-15 residues are long enough to form an epitope including the 
phosphorylated tyrosine but minimise the chances of providing other, phosphorylation- 
independent epitopes (444). Peptides of this length are poorly immunogenic and require to 
be linked to a carrier protein for efficient elicitation of an antibody response. For this 
reason our immunising peptides were conjugated to the carrier protein, keyhole limpet 
haemocyanin via the suflhydryl group of a cysteine residue which was added to the N- 
terminus. 
Both monoclonal and polyclonal phospho-specific antibodies can be successfully 
generated (444). Due to the relative simplicity of production we opted to produce 
polyclonal rather than monoclonal antibodies in the first instance. We conducted 
immunisations in rabbits which are easy to maintain and handle and in which polyclonal 
antibody production has been well characterised (445). An outbred strain was used in 
which the range of class II major histocompatibility molecules is greater and hence the 
likelihood of successfully generating an immune response is enhanced. 
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Despite the use of a short phosphorylated peptide for immunisations the sera obtained 
could theoretically still contain antibodies which recognised non-phosphorylated p120. For 
example, the immunising peptide may contain additional epitopes not encompassing the 
phosphorylated tyrosine residue. Alternatively, dephosphorylation of the peptide may 
occur in vivo following its subcutaneous injection with the creation of epitopes containing 
the non-phosphorylated tyrosine residue. 
4.3.3 Validation of phospho-specific antibodies. 
To identify potential phospho-specific antibodies we assayed the ability of sera to 
recognise p120 in which the phosphorylation state was experimentally manipulated. As a 
source of phosphorylated p120 we used both endogenous and exogenous myc-tagged p120 
from a colon cancer cell line expressing constitutively active Src. Although this approach 
tests the ability of sera to recognise the epitope in the context of the entire protein a 
possible weakness is the risk of rejecting a potentially useful antibody should the residue it 
recognises not undergo phosphorylation in this specific cellular context. However, all of 
the sites of interest are known to be good Src substrates both in vitro and in vivo (68) and 
there was no a priori reason to expect them not to be phosphorylated in KM12C-Src527F 
cells. Furthermore, this concern would primarily apply where antibodies were rejected as 
unsuccessful because they failed to demonstrate any reactivity with lysate from KM12C- 
Src527F cells. In fact, as discussed below unsuccessful antibodies were generally rejected 
due to their ability to recognise a specific tyrosine residue equally well when non- 
phosphorylated as phosphorylated or due to their ability to recognise phosphorylated 
tyrosine residues in a non-specific manner. 
Several techniques were used to identify sera which reacted with p120 only when 
phosphorylated on a specific tyrosine residue: 
1. As an initial screen p120 was fully dephosphorylated using recombinant LAR 
phosphatase. Antibodies which recognised p 120 equally well before and after 
phosphatase treatment (those generated to phospho-Y112, phospho-Y257 and 
phospho-Y280 and phospho-Y291) where considered not to be phospho-specific. 
2. The ability of sera to immunoprecipitate phosphorylated p120 from KM12C- 
Src527F lysate after pre-incubation with an excess of immunising antigen was then 
assessed. Phosphorylated but not non-phosphorylated peptide competitively 
inhibited immunoprecipitation of p 120 by phospho-Y228, phospho-Y296 and 
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phospho-Y302 antibodies. This suggested that these antibodies recognised the 
immunising peptide only when phosphorylated and did not recognise epitopes 
present on non-phosphorylated peptide. 
3. Antibodies were tested for their ability to recognise p120 in which the target 
tyrosine residue either individually, or in combination with all eight phospho- 
acceptor residues, had been mutated to phenylalanine. For phospho-Y228 and 
phospho-Y296 antibodies an isolated tyrosine to phenylalanine substitution was 
sufficient to prevent immuno-reactivity. In contrast phospho-Y96 and phospho- 
Y302 antibodies failed to recognise p120 in which all eight sites were mutated, yet 
maintained immuno-reactivity with p120 in which the specific tyrosine residue was 
mutated in isolation. These antibodies therefore demonstrated cross-reactivity with 
other phosphorylated tyrosine residues in p120 and were not used further. 
Thus antibodies were essentially rejected for one of two reasons. Firstly, because the 
antibody displayed immunoreactivity with dephosphorylated p 120 indicating that epitopes 
not dependent on the phosphorylation of the target tyrosine residue were recognised. The 
presence of such sera demonstrates that affinity absorption against column-bound non- 
phosphorylated peptide was not fully effective. In future, an additional affinity purification 
step could be performed in which the fraction adsorbed to column-bound phosphorylated 
peptide is retained. This may reduce background due to non-specific antibodies present in 
serum. However, as antibodies may still recognise any non-phosphorylation-dependent 
epitopes present on bound phosphorylated peptide it is not clear whether this would offer 
significant advantages. 
Secondly, as was the case for phospho-Y96 and phospho-Y302, the antibody appeared to 
have pan-phosphotyrosine activity as evidenced by the ability to recognise p120 in which 
the target residue was mutated to phenylalanine but not p 120 in which either all 8 residues 
were mutated or which had been enzymatically dephosphorylated. Interestingly a similar 
phenomenon was identified even for phospho-Y228 and phospho-Y296 antibodies when 
used at inappropriately high concentrations. However, in contrast to the phospho-Y96 and 
phospho-Y302 antibodies it was possible to identify dilutions of phospho-Y228 and 
phospho-Y296 antibodies at which this activity was effectively titrated out whilst 
maintaining strong reactivity for wild type phospho-p 120. 
When Western blotting cell lysates multiple non-specific bands were detected by both 
phospho-228 and phospho-296 antibodies. This may reflect cross reactivity with other 
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phosphorylated proteins due to homology between a specific p 120 phosphorylation site 
and the consensus sequence for that tyrosine kinase. Alternatively, this may indicate non- 
specific interactions with other antibodies present in rabbit serum at the time of sacrifice. 
For this reason phospho-Y228 and phospho-Y296 antibodies were primarily used in 
subsequent work for immunoprecipitation of p120 or for immunoblotting of 
immunoprecipitated p120 in preference to immunoblotting of whole cell lysate. 
Attempts to generate monoclonal phospho-specific antibodies were undertaken on our 
behalf by the Beatson Institute Antibody Production Service but were unsuccessful. 
However, during the time course of this work monoclonal phospho-specific antibodies to 
p120 tyrosine residues 96,228,280 and 291 became commercially available. 
For the remainder of this thesis the following p120 phospho-specific antibodies were used: 
monoclonal phospho-Y96; monoclonal phospho-Y228; monoclonal phospho-Y280; 
monoclonal phospho-Y291; rabbit polyclonal phospho-Y296. 
4.4 Summary 
Immunoglobulin was purified from rabbits immunised with chemically phosphorylated 
peptides encompassing each of the eight previously identified sites of p120 tyrosine 
phosphorylation. Several tests of validity were then employed to define antibodies which 
were truly phospho-specific. Firstly, phospho-specific antibodies were shown to recognise 
phosphorylated but not enzymatically de-phosphorylated p120. Secondly, phosphorylated 
but not non-phosphorylated immunising peptide competitively inhibited the ability of 
phospho-specific antibodies to immunoprecipitate p120. Finally, p120 in which specific 
tyrosine residues had been mutated to phenylalanine could not be recognised by phospho- 
specific antibodies. Using these criteria two polyclonal antibodies which specifically 
recognised p120 only when phosphorylated on tyrosine residues 228 or 296 were 
successfully produced. Concurrent with this work, p120 phospho-specific monoclonal 
antibodies to phospho-tyrosine-96, -228, -280 and -291 became commercially available. 
Together these facilitated a study of site-specific phosphorylation events in p120 as 
described in chapter five. 
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5 Results: Regulation of site-specific tyrosine 
phosphorylation events in p120. 
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5.1 Aim 
p120-catenin is phosphorylated on tyrosine residues in response to activation of both RTKs 
and the cytoplasmic tyrosine kinase, Src. Although eight potential sites of tyrosine 
phosphorylation have recently been mapped (68), the regulation of phosphorylation events 
at these individual sites is largely unknown (176). We therefore used the novel phospho- 
specific antibodies described in chapter four to define the p120 site-specific 
phosphorylation events occurring in response to Src activation in KM12C cells and to 
EGFR activation in the A431 cell line. 
5.2 Results 
5.2.1 The KM12C cell line provides a model system in which to 
study Src-dependent phosphorylation of p120. 
KM12C cells are derived from a human colorectal carcinoma (446) and have low 
endogenous Src family kinase activity (257). KM12C cells retain expression of core 
components of the AJ (Figure 5-1 A) and form functional AJs in culture (Figure 5-1 B). 
Previous work by this group has demonstrated disruption of the AJ, an increase in cell- 
matrix adhesion and expression of mesenchymal markers in response to increasing Src 
levels and activity in KM12C cells (257,447). In-keeping with p120's known status as a 
Src substrate, p120 immunoprecipitated from KM12C-Src527F lysate demonstrated a 
dramatic increase in phosphorylation on tyrosine as compared to p120 in cells transfected 
with empty vector alone (Figure 4-1 B). Thus KM12C cells provide an appropriate model 
in which to investigate the requirements for site-specific tyrosine phosphorylation of p120 
by Src in a carcinoma cell line. 
5.2.2 p120 is phosphorylated at multiple sites in Src527F- 
expressing KM12C cells. 
Using phospho-specific antibodies the expression of Src527F in KM12C cells was shown 
to increase phosphorylation of p120 at tyrosine residues 228,280,291 and 296 in 
comparison to cells expressing empty vector (Figure 5-4). As tyrosine-96 occurs only in 
p120 isoform 1 which is expressed at very low levels in KM12C cells phosphorylation at 
this site was not assessed. 
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Figure 5-1 KM12C cells form adherens junctions 
(A) KM 12C lysate was prepared and protein levels analysed by Western blotting using the 
antibodies indicated. 
(B) KM 12C cells were fixed and immunofluorescence performed using E-cadherin 
antibody. Bar 50ýtm. 
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5.2.3 Requirement of Src kinase activity for p120 
phosphorylation. 
The phosphorylation of a particular tyrosine residue which occurs when Src is over- 
expressed may be due, directly or indirectly, to the kinase activity of Src itself. 
Alternatively, over-expression of the non-catalytic SH2 and SH3 domains may be 
sufficient to cause phosphorylation independently of Src's kinase activity, presumably due 
to a scaffolding activity which enables the recruitment of additional kinase molecules. For 
example, over-expression of kinase-deficient Src causes increased phosphorylation of 
several tyrosine residues in FAK (448). It is not known whether the phosphorylation of 
p120 which occurs when Src is over-expressed in epithelial cells results from Src kinase 
activity or from a scaffolding function of the non-catalytic domains. Therefore, to define 
the specific role of Src's kinase activity in p120 phosphorylation in KM 12C cells we 
utilised both kinase-deficient Src constructs (Figure 5-3 and Table 5) and a novel and 
selective small molecule inhibitor of Src kinase activity. 
5.2.3.1 Pharmacological inhibition with AP23464 inhibits the 
phosphorylation of p120. 
AP23464 is a potent and selective ATP-based inhibitor of Src-family kinases, AhI and KIT 
(448-450). Using auto-phosphorylation at tyrosine-416 as a marker of Src's kinase activity, 
AP23464 was seen to fully inhibit Src at a concentration of 1 µM with no effect on protein 
levels (Figure 5-2 A). This correlated with complete inhibition of p120 phosphorylation at 
tyrosine residues 228,280 and 296 as well as inhibition of global phosphorylation of pl20 
as detected by a pan-phosphotyrosine antibody (Figure 5-2 B). Interestingly treatment of 
cells with AP23464 for as little as two minutes prior to lysis was sufficient to fully inhibit 
tyrosine phosphorylation of p 120 (Figure 5-2 C). 
5.2.3.2 Kinase-deficient Src promotes moderate phosphorylation of 
p120. 
Expression of either Src-251 (Figure 5-4 A) or Src-527F/K295M (Figure 5-4 B) was 
sufficient to increase tyrosine phosphorylation of p 120, albeit to a significantly lesser 
degree than that achieved by the expression of kinase-active Src. Levels of total p 120 were 
unaffected (Figure 5-4 A, B). All of the p120 tyrosine residues studied (Y228, Y280, Y291, 
Y296) were phosphorylated synchronously with no evidence of any differential regulation 
occurring at any site. Significantly, the tyrosine phosphorylation of other Src substrates 
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such as paxillin (451) and p130cas (452) was reduced in the presence of kinase-deficient 
Src (Figure 5-5). 
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Figure 5-2 Src-family kinase activity is required for phosphorylation of p120 in KM12C- 
Src527F cells. 
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Figure 5-2 Src family kinase activity is required for phosphorylation of p120 in 
KM12C-Src527F cells. 
(A) KM12C-Src527F cells were treated with vehicle (DMSO) or increasing concentrations 
of AP23464 for 60 minutes after which lysates were prepared and analyzed by Western 
blotting with Src phospho-Y416 antibody. After removal of the phospho-specific antibody 
the blot was reprobed with Src antibody. 
(B) and (C) KM12C-Src527F cells were incubated with 1 µM AP23464 for the time 
intervals shown prior to lysis. p120 was then immunoprecipitated and analysed by Western 
blotting with site specific phospho-p120 antibodies or anti-phosphotyrosine antibody. In 
each case after removal of the phospho-specific antibody the blot was reprobed with p120 
antibody. 
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Figure 5-3 Schematic diagram of Src constructs. 
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Name Comments 
(i) wt-Src Wild type c-Src. In the absence of an activating event 
intramolecular interactions render the kinase domain, SH2 and 
SH3 domain conformationally unavailable. 
(ii) Src527F Substitution of Y527 to F results in constitutive activity of the 
kinase domain and availability of SH2 and SH3 domains for 
protein protein interaction 
(iii) Src527F / As (ii) except substitution of W118 to A prevents SH3 domain 
W 118A interaction with its binding partners (453). 
(iv) Src527F / As (ii) except substitution of R175 to L prevents SH2 domain 
R175L interaction with its binding partners (454). 
(v) Src527F / Substitution of K295 to M abrogates kinase function therefore 
K295M kinase deficient (454). SH2 and SH3 domains available for 
protein protein interaction due to Y527 to F substitution. 
(vi) Src527F / As (v) except substitution of WI18 to A prevents SH3 domain 
K295M / interaction with its binding partners. 
W118A 
(vii) Src527F / As (v) except substitution of R175 to L prevents SH2 domain 
K295M / interaction with its binding partners. 
R175L 
(viii) Src-251 Entire kinase domain deleted and replaced with GFP therefore 
kinase deficient. SH2 and SH3 domains available for Protein- 
protein interaction due to deletion of intramolecular binding sites 
(455). 
Table 5 Characteristics of Src constructs 
All constructs were derived from chicken Src. 
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Figure 5-4 Expression of kinase-deficient Src promotes p120 phosphorylation. 
(A) p120 was immunoprecipitated from lysate prepared from KM12C cells transfected 
with empty vector (vector), constitutively active Src (KM12C-Src527F) or kinase-deficient 
Src (KM12C-Src251) and analysed by Western blotting with site specific phospho-p120 
antibodies or anti-phosphotyrosine antibody (left hand panels). 
(B) p120 was immunoprecipitated from lysate prepared from KM12C cells expressing 
empty vector, constitutively active Src or a second kinase-deficient Src (KM12C-Src527F / 
K295M) and analysed by Western blotting with site specific phospho-p120 antibodies or 
anti-phosphotyrosine antibody (left hand panels). 
In each case after removal of the phospho-specific antibodies the blots were reprobed with 
anti-p 120 antibody (right hand panels). 
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Figure 5-5 Kinase-deficient Src inhibits phosphorylation of Src substrates 
Paxillin (A) or p130`ä' (B) were immunoprecipitated from lysate prepared from KM 12C 
cells containing empty vector or two different kinase deficient Src constructs. Blots were 
probed with anti -phosphotyrosine antibody then stripped and reprobed with anti-paxillin 
(A) or anti-p 130`ß' antibody (B). 
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5.2.4 The Src SH2 but not SH3 domain is required for 
phosphorylation of p120. 
Previous work has identified a requirement for an intact Src myristylation site for Src- 
dependent phosphorylation of p120 to occur (52). In fibroblasts mutation of the Src SH2 
and SH3 domain was not reported to significantly alter tyrosine phosphorylation of p120 
(182). However, the requirement for particular structural elements within Src for p120 
phosphorylation in epithelial cells has not been defined. The expression of constitutively 
active and kinase-deficient Src constructs with function-abrogating point mutations in the 
SH2 or SH3 domain in KM12C cells has previously been reported (278,448). These 
constructs provided a means by which to test the requirement for the Src non-catalytic 
domains in p120 phosphorylation. Clones in which the levels of exogenous Src expression 
were broadly similar were used (Figure 5-6 A). Loss of a functional SH2 domain was 
associated with a significant reduction in p120 phosphorylation at all tyrosine sites studied 
(Figure 5-6 B). This reduction in p120 phosphorylation was seen for both constitutively 
active and kinase-deficient Src constructs harbouring the SH2 mutation as compared to the 
same constructs with a functional SH2 domain. In contrast, the function of the Src SH3 
domain appeared dispensable (Figure 5-6 B). 
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Figure 5-6 The Src SH2 domain is necessary for Src-dependent phosphorylation of p120. 
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Figure 5-6 The Src SH2 domain is necessary for Src-dependent phosphorylation of p120. 
(A) Lysates were prepared from KM12C cells transfected with empty vector (vector) or 
constitutively active Src (Src527F), constitutively active Src with a loss of function 
mutation in the SH3 (Src527F /W 118A) or SH2 domain (Src527F / R175L), kinase- 
deficient Src (Src527F / K295M) or kinase-deficient Src with a loss of function mutation in 
the SH3 (Src527F / K295M / W1 18A) or SH2 domain (Src527F / K295M / R175L) and 
analysed by Western blotting using anti-Src antibody and anti-actin antibodies. 
(B) p120 was immunoprecipitated from the same cell lines and analysed by Western 
blotting with site specific phospho-p120 antibodies or anti-phosphotyrosine antibody (left 
hand panels). In each case after removal of the phospho-specific antibodies the blots were 
reprobed with anti-p120 antibody (right hand panels). 
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5.2.5 Phosphorylation of p120 by EGF. 
Phosphorylation of p120 in response to growth factor stimulation has been reported in a 
variety of cell lines. However, treatment of KM12C cells with EGF did not cause a 
significant increase in total or site specific tyrosine phosphorylation of p120 (Figure 5-7 
A). This was despite the readily detectable phosphorylation of EGFR itself and of its 
downstream effector, MAPK (Figure 5-7 B). 
Therefore, to better define site specific phosphorylation events occurring due to EGF 
signalling we utilised the A431 cell line in which EGF-dependent phosphorylation of p120 
has previously been reported (176). A43 1 cells are derived from an epidermal squamous 
cell carcinoma and express high levels of EGFR due to a gene amplification event (456). In 
common with the KM12C cell line, A431 cells maintain all major components of the AJ 
and grow as epithelial colonies (described in chapter 6; Figure 6-10,6-11). Similarly, they 
predominantly express p120 isoform 3 (457) which does not contain tyrosine-96. 
Phosphorylation of p120 at tyrosine-228 in EGF-stimulated A431 cells has recently been 
identified (176). However, whether other sites are similarly regulated is unknown. 
Following EGF stimulation of A431 cells, EGFR phosphorylation (Figure 5-8 A) and 
simultaneous phosphorylation of p120 at tyrosine residues 228,280,291 and 296 (Figure 
5-8 B) occurred. Spatially, phosphorylation of p120 occurred mainly at AJs (Figure 5-8 C, 
dotted arrow) but also occurred at the leading edge of lamellipodia (Figure 5-8 C, filled 
arrow). 
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Figure 5-7 p120 is not phosphorylated in EGF stimulated KM12C cells. 
(A) KM12C cells were serum starved then stimulated with EGF (100 ng/ml) for 5,15 or 
30 minutes. p120 immunoprecipitated from cell lysates was analysed by immunoblotting 
with anti-phosphotyrosine or anti-p120 phospho-specific antibodies (left hand panels). In 
each case after removal of the phospho-specific antibodie the blot was reprobed with anti- 
p 120 antibody (right hand panels). 
(B, upper panels) EGFR was immunoprecipitated from cell lysates and immunoblotting 
performed with anti-phosphotyrosine antibody. (B, lower panels) Cell lysate was analysed 
by Western blotting with anti-phospho-MAPK antibody. 
In each case after removal of the phospho-specific antibodies the blots were reprobed with 
the corresponding non-phospho-specific antibody. 
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Figure 5-8 EGF stimulation results in phosphorylation of p120 at multiple sites. (A) 
A431 cells were serum starved overnight then stimulated with EGF (100 ng/ml) for 5 
minutes prior to lysis. Western blot analysis of cell lysates was carried out with phospho- 
EGFR antibody. After removal of the phospho-specific antibody the blot was reprobed 
with EGFR antibody. 
(B) A431 cells were serum-starved overnight and lysates prepared before or 5 minutes 
after stimulation with EGF (100 ng/ml). p 120 was immunoprecipitated from cell lysates 
and immuno-blotting performed with p120 phospho-specific antibodies (left hand panels). 
After removal of phospho-specific antibodies the blots were reprobed with anti-p 120 
antibody (right hand panels). 
(C) A431 cells grown on chamber slides were serum starved overnight then stimulated 
with EGF (100 ng/ml) for 5 minutes prior to fixation. Co-immunofluorescence was 
performed with p 120 phospho-Y228 (green) and p 120 (red) antibodies. Bar, 10 µm. 
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5.2.6 EGF induced phosphorylation of p120 requires an AP23464- 
sensitive kinase. 
As all 4 sites appeared to be phosphorylated in tandem, we used pharmacological inhibitors 
to investigate whether any differential regulation could be unmasked. As expected, 
treatment of A431 cells with AG1478, a specific inhibitor of EGFR kinase activity, 
prevented the EGF-dependent phosphorylation of p120 on all 4 sites (Figure 5-9 A). This 
corresponded with the ability of AG1478 to prevent phosphorylation of the EGFR 
following stimulation with EGF as well as inhibiting the activation of the well-defined 
EGF-dependent signalling pathways to MAPK and STAT3 (Figure 5-9 B). The EGF- 
dependent phosphorylation of p120 was also prevented in cells treated with AP23464, a 
selective inhibitor of Src family tyrosine kinases (Figure 5-9 A). The basal 
phosphorylation of p120 on residues 228 and 296 was also abrogated in AP23464 treated 
cells (Figure 5-9 A). Using phosphorylation of the auto-phosphorylation site of Src 
(tyrosine-416) as a measure of Src activity, we showed that Src activity was inhibited in 
A431 cells treated with AP23464 at the concentration (1 µM) used in these experiments 
(Figure 5-9 Q. AP23464 did not inhibit EGFR phosphorylation at the concentration used 
(Figure 5-9 D). Interestingly, pre-treatment with AP23464 was sufficient to block EGFR 
signalling to both p 120 and to STAT3, a known Src substrate, while phosphorylation of 
MAPK was not reduced (Figure 5-9 B). Thus p120 is phosphorylated on multiple residues 
in an EGF-and AP23464-sensitive kinase-dependent manner. 
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Figure 5-9 EGF induced phosphorylation of p120 is Src dependent. 
(A, B) A431 cells were serum starved overnight, incubated with AP23464 (1 ýtM) or 
AG1478 (300 nM) for I hour, then lysed before, or 5 minutes after, stimulation with FGF 
(100 ng/ml). p120 was immunoprecipitated from cell lysates and analysed by Western 
blotting with site specific phospho-p 120 antibodies or anti -phosphotyrosine antibody. 
Lysate was also analysed by Western blotting using phospho-EGFR, phospho-MAPK and 
phospho-STAT3 antibodies. In each case after removal of the phospho-specific antibodies 
the blots were reprobed with the corresponding non-phospho-specific antibodies. 
(C) A431 cells were treated with vehicle (DMSO) or increasing concentrations of 
AP23464 for 60 minutes after which lysates were prepared and analyzed by Western 
blotting with Src phospho-Y416 antibody. After removal of the phospho-specific antibody 
the blot was reprobed with Src antibody. 
(D) A431 cells were treated with vehicle (DMSO) or increasing concentrations of 
AP23464 for 60 minutes after which lysates were prepared and analyzed by Western 
127 
blotting with phospho-EGFR antibody. After removal of the phospho-specific. antibody 
the blot was reprobed with EGFR antibody. 
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5.3 Discussion 
p120 is an excellent Src substrate both in vitro and in vivo. However, whether the 
phosphorylation of individual tyrosine residues may be differentially regulated is 
unknown. Furthermore, the relative contributions of the Src catalytic domain and of the 
non-catalytic SH2 and SH3 domains have not been defined in epithelial cells. Finally, 
whether Src kinases are required to mediate RTK signalling to p120 is unclear. We 
therefore used the novel p120 phospho-specific antibodies described in chapter four to 
systematically study p120 phosphorylation in epithelial cancer cell lines in response to 
both Src and EGFR signalling. 
5.3.1 Src-dependent phosphorylation of p120. 
p120 was initially identified as a prominent phospho-protein in v-Src transformed chicken 
embryo fibroblasts (52). The phosphorylation of p120 correlated with, but was not 
necessary for, transformation (68). Src in which glycine at position 2 is mutated to alanine 
is unable to undergo myristylation, fails to localise to the plasma membrane and is unable 
to phosphorylate p120 (52). In keeping with this is the observation that p120 is not 
phosphorylated in cadherin-deficient cell lines (176,273). Thus, Src-dependent 
phosphorylation of p120 requires both molecules to co-localise at the cell membrane, Src 
via myristylation and p 120 via its interaction with the cadherin JMD. 
The rapidity with which p120 underwent dephosphorylation in AP23464 treated KM12C- 
Src527F cells was striking. Complete loss of tyrosine phosphorylation occurred after as 
little as two minutes of drug treatment suggesting that the phosphorylation state of p120 
may be highly dynamic. When over-expressing constitutively active Src in fibroblasts 
Mariner et al found that a five minute treatment with the phosphatase inhibitor pervanadate 
was required for the optimal detection of phosphorylation events suggesting that p 120 
tyrosine residues were subject to rapid dephosphorylation (68). A possible mediator is the 
cytoplasmic phosphatase, SHP-1, which interacts with phosphorylated p120 via its SH2 
domain and mediates its dephosphorylation (248). SHP-1 is itself phosphorylated and 
activated by Src and so its activity would be expected to be high in Src527F expressing 
KM12C cells (273). 
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5.3.1.1 Tyrosine phosphorylation of p120 is predominantly mediated 
via Src kinase activity. 
Although purified Src can phosphorylate p120 in vitro (68) it has not been shown, in vivo, 
whether Src-dependent phosphorylation of p120 is entirely mediated via Src's kinase 
activity or whether the recruitment of additional kinases to a signalling complex via the Src 
SH2 and / or SH3 domains may be involved. This is exemplified by another Src substrate, 
FAK, which undergoes phosphorylation at tyrosine residues 407,576,577 and 861 when 
kinase-deficient Src is over-expressed (448). Phosphorylation of these sites is not inhibited 
by AP23464 indicating that their phosphorylation is independent of Src's kinase activity. 
In contrast phosphorylation of FAK at tyrosine-925 specifically requires Src kinase 
activity. Understanding the relative contributions of Src kinase and non-kinase domains to 
signalling pathways is now particularly timely with the entry of Src inhibitors such as 
dasatinib into phase I clinical trials (458). In cancers both the absolute amount, as well as 
the activity, of Src may be increased (198) and drugs which competitively inhibit ATP 
binding to inhibit Src kinase activity would not necessarily be expected to block pathways 
aberrantly activated in response to over-expressed Src non-catalytic domains. 
To investigate the structural requirements for p120 phosphorylation in a colorectal cancer 
cell line we utilised both a novel small molecule Src inhibitor as well as a variety of over- 
expressed Src constructs. As expected, the over-expression of constitutively active c-Src in 
KM12C cells resulted in a dramatic increase in tyrosine phosphorylation of p120. This was 
evident at all tyrosine residues studied. Interestingly, the over-expression of Src constructs 
rendered kinase-deficient, either by introduction of a function-abrogating point mutation in 
the kinase domain or by deletion of the entire kinase domain, was sufficient to promote 
moderate tyrosine phosphorylation of p120. Again, this increase in phosphorylation was 
seen at all tyrosine residues studied albeit to a lesser extent than that achieved by 
constitutively active Src. Importantly, the phosphorylation events caused by kinase- 
deficient Src appeared to be selective rather than a non-specific effect involving all Src 
substrates as phosphorylation of the Src substrates paxillin and p 130ca$ was clearly reduced 
in the presence of kinase-deficient Src. Furthermore, as discussed above, our group has 
previously reported differential phosphorylation of FAK tyrosine residues in KM12C cells 
in the presence of kinase-deficient Src as discussed above (448). 
We next used AP23464 to pharmacologically inhibit Src kinase activity in KM12C cells 
expressing constitutively active Src. This resulted in rapid and complete dephosphorylation 
of p120 at all residues studied. No residual phosphorylation of p120 remained indicating 
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that in the presence of pharmacological inhibition of SFK kinase activity the over- 
expression of Src SH2 and SH3 domains is not sufficient to cause p120 phosphorylation. 
Taken together this data suggests that phosphorylation of p120 is primarily directly 
dependent on Src family kinase activity with a minor component attributable to over- 
expression of the non-catalytic domains. As this component was also inhibited by 
AP23464 it appears to represent recruitment or activation of an endogenous SFK or other 
AP23464-sensitive kinase. The only cytoplasmic kinase other than SFKs which has been 
shown to phosphorylate p120 in vitro and in vivo is Fer (276,459) although the sensitivity 
of this kinase to AP23464 has not been reported. Another potential cytoplasmic kinase 
might be Abl which interacts with and phosphorylates the p120 family member 6-catenin 
in neuronal cell lines (460) and which is also potently inhibited by AP23464 (450). 
However, SFKs activate Abl (461) and in other systems the expression of kinase-deficient 
Src has inhibited rather than activated Abi (462,463). Therefore we propose that the 
moderate increase in phosphorylation of p120 mediated by the over-expression of Src non- 
catalytic domains occurs via the recruitment and activation of either an endogenous SFK or 
unknown AP23464-sensitive kinase which can then phosphorylate p120. 
5.3.1.2 An intact SH2 domain is required for Src-dependent 
phosphorylation of p120. 
To define the role of the Src SH2 and SH3 domains in p120 phosphorylation we employed 
Src constructs with function-abrogating point mutations in the SH2 and SH3 domain. 
These mutations have been shown to prevent binding to a variety of SH2 and SH3 targets 
respectively (453,454). Loss of SH3 function did not interfere with Src's ability to 
phosphorylate p120. However, for both constitutively active and kinase-deficient Src 
proteins loss of function of the SH2 domain was associated with a significant reduction in 
p120 phosphorylation. 
In contrast to our results, an early study reported no reduction in p120 phosphorylation in 
response to mutation of the Src SH2 or SH3 domain (182). There are at least two plausible 
explanations for the discrepancy between this result and our work. Firstly, the earlier work 
was performed in chick embryo fibroblasts which represent a very different cellular 
context to KM12C colon cancer cells. In particular, the structure of the actin cytoskeleton 
and of cell-cell junctions as well as the localisation and activation of endogenous kinases 
may be fundamentally different in these two cell types. Secondly, the constructs used in the 
earlier work contained short deletions of residues 92-95 (c-Src d192, SH3 domain) or 155- 
157 (c-Src d1155, SH2 domain), neither of which overlap the W118A or R175L point 
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mutations we used. These constructs cannot, therefore be regarded as synonymous and it is 
possible that the spectrum of proteins to which binding is perturbed does not fully overlap. 
Expression of the c-Src d192 and d1155 constructs in KM12C cells could help to answer 
this question. However, it is clear that the possession of a functional SH2 domain is 
important for Src to cause phosphorylation of p120 in this epithelial cancer cell line. 
5.3.2 EGFR-dependent phosphorylation of p120. 
Stimulation of KM12C cells with EGF did not result in significant changes in p120 
tyrosine phosphorylation despite evidence of receptor activation as determined by EGFR 
phosphorylation and robust activation of other downstream signalling pathways. A more 
tractable model for studying the regulation of EGFR-dependent phosphorylation of p120 
was therefore provided by the A431 epidermal squamous cell carcinoma cell line. 
Stimulation of A431 cells with EGF resulted in the simultaneous phosphorylation of p120 
at all tyrosine residues studied. As expected this was completely abrogated by inhibition of 
EGFR kinase activity with AG1478. Treatment with AP23464 was also sufficient to fully 
block EGF-dependent phosphorylation of p120, thus implying a signalling pathway from 
EGFR to p120 involving an AP23464-sensitive kinase. This data contradicts work recently 
published by Mariner et al who reported EGFR signalling to p120 tyrosine-228 (176). 
They reported no reduction in phosphorylation of p120 tyrosine-228 in EGF-stimulated 
A431 cells which had been pre-treated with an alternative Src inhibitor, SU6656 (464). 
Several possible explanations exist for this discrepancy. Firstly, inappropriate 
concentrations of inhibitor may have been used by one or other group. Mariner chose a 
concentration of SU6656 based on its ability to inhibit Src kinase activity in an in vitro 
kinase assay. The strength of this approach is that it provides a direct measure of 
biochemical inhibition. However, the relationship between extracellular and intracellular 
concentration of inhibitor is not known and therefore it cannot be assumed that a dose 
based on inhibition in a cell free system will be equally potent against intracellular Src. In 
contrast we defined the concentration of AP23464 to be used on the basis of inhibition of 
Src auto-phosphorylation at tyrosine-416 which has been widely used and validated as a 
surrogate marker of Src activity (465). However, it is conceivable that a small molecule 
Src kinase inhibitor which occupies the ATP binding cleft may block kinase activity whilst 
allowing Y416 to remain in a phosphorylated state. If this were the case we could 
potentially have used an excessively large dose of inhibitor, in which case "off-target" 
inhibition of additional kinases might occur. A second explanation would be that both 
inhibitors were used at appropriate concentrations but that Src family kinases are not 
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involved in EGFR signalling to p120. Rather an unidentified kinase targeted by AP23464 
but not SU6656 would be the mediator of p120 phosphorylation. Abi is activated 
downstream of EGF signalling (461) and AP23464 is approximately equipotent in its 
inhibition of Abl and Src. In contrast SU6656 is 6-fold more potent for Src than Abl (466). 
However, it is not known if p120 is a substrate of Abl. Our demonstration that EGFR 
signalling to STAT3, a known Src substrate, was inhibited whilst signalling to MAPK was 
unaltered strongly suggests that the concentration of AP23464 used demonstrated 
selectivity and did not globally inhibit EGFR signalling. It also suggests that an AP23464- 
sensitive kinase operates downstream of EGFR rather than being required to co-operate in 
EGFR activation. Further work is required to definitively identify the kinase recruited by 
EGFR activation to phosphorylate p120. If this kinase is indeed Src then the over- 
expression of kinase-deficient Src protein might be expected to inhibit this in a dominant- 
negative fashion. However, as we have demonstrated the overexpression of Src non- 
catalytic domains may, in itself, promote a degree of p120 phosphorylation. Alternatively, 
RNAi-mediated depletion of Src would be possible but might be confounded by 
redundancy with other SFKs within this cell type. A head to head comparison of various 
Src inhibitors with known IC50s for a variety of kinases may be useful to suggest potential 
non-SFK candidates. 
5.4 Summary 
Tyrosine phosphorylation of p120 by Src in epithelial cells is dependent on Src's kinase 
activity and SH2 domain. However, two different kinase-deficient Src constructs were able 
to induce moderate p 120 phosphorylation suggesting that over-expressed Src non-catalytic 
domains may recruit endogenous Src-family kinases or other AP23464-sensitive kinase to 
a signalling complex. EGFR-dependent phosphorylation of p 120 appears to be indirect via 
a pathway sensitive to inhibition by AP23464. Whether this reflects inhibition of Src or an 
as yet unidentified AP23464-sensitive kinase warrants further investigation. 
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6 Results: An investigation of the effects of p120 
phosphorylation on cell-cell adhesion. 
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6.1 Alm 
Despite p120's initial identification 16 years ago as a major phospho-protein in Src 
transformed cells the biological sequelae of its phosphorylation on tyrosine have proved 
enigmatic. In cancer cell lines increased activity of Src or EGFR, which often correlates 
with disruption of cell-cell adhesion and increased invasiveness, also causes prominent 
phosphorylation of p120. However, whilst p120 can profoundly influence the AJ and the 
motile phenotype of a cell it is not known whether the tyrosine phosphorylation state of 
p120 has any role in this regulation. We therefore used phosphorylation-defective p120 
constructs to specifically define the role of p120 tyrosine phosphorylation in cell-cell 
adhesion in KM12C and A431 cell lines. 
6.2 Results 
6.2.1 p120 is phosphorylated at tyrosine-228 in nascent AJs. 
Tyrosine phosphorylation appears to have a dual function at the AJ with tightly regulated 
phosphorylation of AJ proteins occurring as a physiological event during the formation of 
AJs, whilst deregulated kinase activity is often associated with disruption of AJs. The 
extracellular domain of E-cadherin must bind calcium to stabilise its conformation and 
facilitate adhesive interaction with the cadherin molecule of an adjacent cell (2). A 
common experimental manipulation involves the reduction of calcium in tissue culture 
media to 0.03 mM which results in rapid loss of cell-cell adhesion and redistribution of E- 
cadherin to a diffuse pattern around the membrane. On subsequent re-addition of calcium 
to achieve a concentration of 1-2 mM AJs reform. This type of "calcium switch" was 
utilised to study the phosphorylation of p120 by endogenous kinases in KM12C cells 
during AJ formation. 
Following a switch from low to high calcium, tyrosine phosphorylation of p120 was most 
apparent at residue 228 (Figure 6-1). The temporal kinetics of phosphorylation were 
identical to those of morphological AJ formation as determined by the recruitment of p120 
to linear areas of cell-cell contact (Figure 6-2). Phosphorylation was not detectable at 
residues 280 and 291. Basal phosphorylation of tyrosine 296 was identified but was not 
altered during the time course of AJ formation. These phosphorylation events required 
long exposures for detection and hence were of a significantly lower order of magnitude 
than that seen constitutively in Src527F expressing cells. Spatially, the phosphorylated 
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p120 was localised at nascent junctions as determined by immunofluorescence with 
phospho-Y228 antibody (Figure 6-2A). In low calcium medium p120 was localised 
primarily at the membrane with a diffuse distribution. In contrast E-cadherin was localised 
both at the membrane and internalised in apparent vesicular structures in the cytoplasm 
(Figure 6-2B). This observation is consistent with previous reports that dissociation of 
p120 from cadherin is an early event during cadherin internalisation (75). 
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Figure 6-1 p120 is phosphorylated during AJ formation. 
KM12C cells were maintained in low calcium-containing medium (KGM supplemented 
with 0.03 mM CaCI2) for 24 hours then cell lysate prepared before or 15,30,60 or 120 
minutes after being switched to high calcium-containing medium (KGM supplemented 
with 1.5 mM CaCl2). p120 was immunoprecipitatcd and immuno-blotting performed with 
a pan-phosphotyrosine antibody (left upper panel) or with the site-specific phospho-p120 
antibodies shown (left remaining panels). After removal of the phospho-specific antibodies 
each blot was reprobed with anti-p 120 antibody (right panels). 
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Figure 6-2 p120 tyrosine-228 is phosphorylated at nascent junctions. 
KM12C cells grown on chamber slides in low calcium-containing medium (KGM 
supplemented with 0.03 mM CaC12) for 24 hours were fixed prior to, or 15,30 or 60 
minutes after being switched to high calcium-containing medium (KGM supplemented 
with 1.5 mM CaC12). Co-immunofluorescence was performed with (A): p120 phospho- 
Y228 (red) and p120 (green) antibodies; or (B): E-cadherin (green) and p120 (red) 
antibodies. Bar, 20 pm. 
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6.2.2 p120 is a major Src-dependent target at the AJ. 
Our group has previously identified an "adhesion-switch" phenotype in KM12C colorectal 
carcinoma cells when constitutively active Src (Src527F) is expressed (257,278,447). 
Specifically, Src527F blocks the proper assembly of AJs after cells are switched from 
media containing low levels of calcium to media containing high levels of calcium. In 
parallel there is an increased prominence of cell-matrix adhesions and increased expression 
of mesenchymal markers such as vimentin. As described in chapter five, the expression of 
Src527F in KM12C colorectal cancer cells is associated with a marked increase in the 
phosphorylation of several p120 tyrosine residues. Tyrosine phosphorylation of E-cadherin 
and ß-catenin in cell lines expressing active Src has previously been reported (180). To 
identify whether these other components of the AJ were similarly phosphorylated in 
KM12C cells expressing Src527F (and the other Src constructs described in chapter five) 
E-cadherin and ß-catenin were immunoprecipitated and analysed by immunoblotting with 
an anti-phosphotyrosine antibody. Expression of Src527F was associated with increased 
phosphorylation of E-cadherin (Figure 6-3). Interestingly, and in contrast to p120, the 
introduction of an SH2 function abrogating mutation did not reduce the ability of Src527F 
to cause phosphorylation of E-cadherin. As is the case for p120, the expression of kinase- 
defective Src caused a small but consistent increase in phosphorylation of E-cadherin. 
However, for all Src constructs the relative increase in E-cadherin phosphorylation above 
that in parental KM12C cells was far less than that for p120 (Fig. 6-3). No alteration in ß- 
catenin phosphorylation was detected. In all cases total levels of the proteins were not 
changed. Thus p120 appeared to be the most prominently phosphorylated major 
component of the AJ in KM12C cells expressing Src527F. 
6.2.3 Expression of active Src in KM12C cells perturbs formation 
of AJs. 
KM12C cells grown in low calcium containing medium readily reformed junctions on re- 
addition of calcium (76.7% at 4 hours) as judged by localisation of E-cadherin to linear 
areas of cell-cell contact (Figure 6-4 A). The expression of Src527F potently inhibited the 
reformation of AJs (12.6% at 4 hours) (Figure 6-4 A) with most E-cadherin remaining 
diffusely localised around the cell membrane and internalised in the cytoplasm (Figure 6-4 
B). 
140 
Treatment of KM12C-Src527F cells with concentrations of AP23464 which inhibit SFK 
kinase activity abrogated the negative impact of expression of Src527F on calcium-induced 
AJ formation in a dose dependent manner (Figure 6-4 A, B). The concentrations of 
AP23464 were similar to those in which tyrosine phosphorylation of p120 was inhibited 
(Figure 5-5). Thus increased Src kinase activity in KM12C cells caused deregulation of the 
AJ and this correlated with phosphorylation of p120. Conversely, pharmacological 
inhibition of Src kinase activity effectively blocked Src induced inhibition of AJ formation 
and this similarly correlated with prevention of p 120 hyper-phosphorylation. 
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Figure 6-3 p120 is a major phosphorylated protein at the AJ. 
p120, E-cadherin and (3-catenin were immunoprecipitated from KM12C cells expressing 
empty vector (vector) or constitutively active Src (Src527F), constitutively active Src with 
a loss of function mutation in the SH3 (Src527F /W 118A) or SH2 domain (Src527F / 
R175L), kinase-deficient Src (Src527F / K295M) or kinase-deficient Src with a loss of 
function mutation in the SH3 (Src527F / K295M /W 118A) or SH2 domain (Src527F / 
K295M / R175L). Western blotting with anti-phosphotyrosine antibody was performed 
(left hand panels). After removal of the phosphotyrosine antibody the blots were reprobed 
with E-cadherin, p 120, or P-catenin antibody (right hand panels). 
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Figure 6-4 Src induces deregulation of the AJ which is reversed by AP23464. 
(A) KM12C cells or KM 12C cells expressing constitutively active Src (Src527F) were 
plated for 24 hours in high calcium-containing medium (MEM), further maintained for 24 
hours in low calcium-containing medium (KGM supplemented with 0.03 mM CaC12) then 
switched to high calcium-containing medium (KGM supplemented with 1.5 mM CaCl2) 
with or without increasing concentrations of AP23464. After 4 hours cells were fixed and 
stained with E-cadherin antibody. For quantification, 100 cells were assessed for their 
ability to form AJs as assessed by contacts with adjacent cells delineated by E-cadherin 
staining. Results represent the mean +/- S. D. of three independent experiments. (B) 
Representative confocal images demonstrating prominent accumulation of E-cadherin at 
cell-cell contacts (arrows) in KM12C-Src527F cells switched from low to high calcium in 
the absence (i) or presence (ii) of 0.5 pM AP23464. 
143 
6.2.4 Co-expression of Src527F and phosphorylation-defective 
p120. 
Src has many downstream targets and it is therefore difficult to attribute a cellular 
phenotype to phosphorylation of any one substrate. To determine whether the correlation 
seen between p120 phosphorylation and AJ deregulation indicated a causal relationship it 
was necessary to interfere specifically with the tyrosine phosphorylation of p120 in 
isolation. The replacement of tyrosine phospho-acceptor residues with phenylalanine 
renders a protein "phosphorylation-defective" and hence the relative contribution of its 
phosphorylation to the overall Src-induced phenotype may be ascertained. Therefore, 
Src527F and either wild type HA-tagged murine p120 isoform 1A or murine p120-1A in 
which all eight sites of tyrosine phosphorylation were mutated to phenylalanine (p120- 
lA/8F) were co-expressed in KM12C cells with the aim of achieving a dominant negative 
effect. In common with most epithelial cells, the predominant p 120 isoform in KM 12C 
cells is isoform 3 (58-60). Thus exogenous p120-1A appears as a slightly slower migrating 
additional band (Figure 6-5 A, arrow). Expression of p120-1A or p120-1A/8F did not alter 
the levels of other core components of the AJ (Figure 6-5 A). Both wild-type and p120-8F 
constructs localised correctly to the cell membrane, specifically at sites of cell-cell contact 
(Figure 6-5 B). An anti-HA antibody was used to immunoprecipitate only exogenous p120 
which was then analysed by immuno-blotting with an anti-phosphotyrosine antibody. As 
expected, significant phosphorylation on tyrosine was detected for wild type p120-1A but 
not p120-1A/8F (Figure 6-5 Q. Immunoprecipitation with an antibody which recognises 
both endogenous and exogenous p120 demonstrated that expression of p120-1A/8F was 
associated with a significant reduction in phosphorylation of endogenous p 120 suggesting 
a dominant negative effect was at least partially achieved (Figure 6-5 D). 
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Figure 6-5 Expression of HA-tagged p120 constructs in KM12C-Src527F cells. 
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Figure 6-5 Expression of HA-tagged p120 constructs in KM12C-Src527F cells. 
(A) Lysates were prepared from KM12C cells expressing empty vector (vector), 
constitutively active Src (Src527F), Src527F and HA-tagged p120-1A, or Src527F and 
HA-tagged p120-1A in which eight tyrosine phospho-acceptor residues were mutated to 
phenylalanine (p120-1A/8F). Western blotting with anti-p120, anti-E-cadherin, anti-ß- 
catenin and anti-a-catenin antibodies was performed. Arrow indicates exogenous p120-1A. 
(B) KM12C-Src527F / p120-1A (i) and KM12C-Src527F / p120-1A/8F (ii) cells were 
fixed and immunofluorescence was performed with anti-HA antibody. Bar, 10 µm. 
(C) Exogenous p120 was immunoprecipitated from KM12C-Src527F / p120-1A and 
KM12C-Src527F / p120-1A/8F cell lysates and analysed by Western blotting with anti- 
phosphotyrosine antibody. After removal of anti-phosphotyrosine antibody the membrane 
was reprobed with anti-HA antibody. 
(D) p120 was immunoprecipitated from KM12C cells expressing empty vector or 
Src527F, Src527F and p120-1A or Src527F and p120-1A/8F and analysed by Western 
blotting with anti-phosphotyrosine antibody. After removal of the anti-phosphotyrosine 
antibody the membrane was reprobed with anti-p 120 antibody. 
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6.2.5 Phosphorylation-defective p120 does not reverse Src- 
induced inhibition of AJ formation. 
We predicted that if increased tyrosine phosphorylation of p120 was an important 
mechanism of Src-induced inhibition of AJ formation then expression of pl20-1A/8F, 
which we had shown to act in a dominant-negative manner to prevent phosphorylation of 
p 120, should abrogate the Src-induced phenotype. Therefore, the ability of p120-1A/8F to 
reverse the Src-induced inhibition of cell-cell contact formation in response to a calcium 
switch was determined (Figure 6-6). KM12C cells containing empty vector readily 
reformed cell-cell contacts (82% +/- 8.6% of cells at 4 hours). Expression of Src527F 
potently reduced the percentage of cells forming cell-cell contacts (10.3% +/- 1.7%) but 
co-expression of pl20-1A/8F did not abrogate the effect of Src527F (5% +/- 2.5%). Co- 
expression of wild type p120-1A, included as a control, also had no discernable effect 
(2.7% +/- 1.9%). 
6.2.6 Phosphorylation-defective p120 does not inhibit 
disassembly of AJs. 
As the expression of phosphorylation-defective p120 did not alter Src's ability to inhibit 
cell contact formation we asked whether phosphorylation-defective p120 might interfere 
with the initial disassembly of the AJ occurring when KM12C cells are switched from high 
to low calcium-containing medium. After four hours in low calcium-containing medium 
34.7% +/- 15.3% of KM12C cells containing empty vector retained cell-cell contacts. In 
cells expressing Src527F approximately 10.2% +/- 12.3% of cells retained cell-cell 
contacts and the co-expression of p120-1A/8F (12.0% +/- 13.1%) or wild type p120-1A 
(12.5% +/- 6.75%) did not influence this process (Figure 6-7). 
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Figure 6-6 Phosphorylation-defective pt20 does not reverse the Src-induced adhesion 
defect. 
(A) KM 12C cells containing empty vector (i), Src527F (ii), Src527F / p120-1 A (iii), or 
Src527F / p120-lA/8F (iv) were maintained in low calcium-containing medium (KGM 
supplemented with 0.03 mM CaCl2) for 24 hours then switched to high calcium-containing 
medium (KGM supplemented with 1.5 mM CaCl2). After 4 hours cells were fixed and 
stained with anti-E-cadherin antibody. Bar 50 pm. (B) For quantification 100 cells were 
assessed for their ability to form AJs as assessed by contacts with adjacent cells delineated 
by E-cadherin staining. Results represent the mean +/- S. D. of three independent 
experiments. 
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Figure 6-7 p120-8F does not interfere with disassembly of AJs. 
(A) KM12C cells containing empty vector (i), Src527F (ii), Src527F / p120-1A (iii), or 
Src527F / pl20-lA/8F (iv) were plated for 24 hours in high calcium-containing medium 
(MEM), then switched to low calcium-containing medium (KGM supplemented with 
0.03mM CaCl2) for 4 hours. After fixation cells were stained with anti-E-cadherin 
antibody. Bar 40 µm. (B) For quantification 100 cells were assessed for their ability to 
form Ms as assessed by contacts with adjacent cells delineated by E-cadherin staining. 
Results represent the mean +/- S. D. of four independent experiments. 
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6.2.7 Functional Src non-catalytic domains are required for 
disruption of the AJ. 
Although the phosphorylation state of p 120 correlated with Src's ability to inhibit AJ 
formation in KM 12C-Src527F cells the preceding experiments suggested there was not a 
causal link. Interestingly, the introduction of a function abrogating point mutation in the 
SH2 (Src527F / R175L) or SH3 (Src527F / WI I8A) domain rendered Src unable to inhibit 
cell-cell contact formation in response to a calcium switch (Figure 6-8, data courtesy of Dr 
E Avizienyte (278)). However, both of these Src constructs caused an increase in tyrosine 
phosphorylation of p 120 which, in the case of Src527F /WI 18A, was as great as Src527F 
(Figure 5-6). 
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Figure 6-8 Loss of function of the Src SH2 or SH3 domain blocks inhibition of AJ formation. 
(A) KM 12C cells containing Src527F (i), Src527F /W 118A (ii), or Src527F / R175L (iii) 
were maintained in low calcium-containing medium (KGM supplemented with 0.03 mM 
CaCl2) for 24 hours then switched to high calcium-containing medium (KGM 
supplemented with 1.5 mM CaCl2). After 4 hours cells were fixed and stained with anti-F- 
cadherin antibody. Bar, 20 Fun. (B) For quantification 100 cells were assessed for their 
ability to form Ms as assessed by contacts with adjacent cells delineated by E-cadherin 
staining. Results represent the mean +/- S. D. of three independent experiments. 
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6.2.8 RNAi-mediated depletion and reconstitution of p120 in A431 
cells. 
To further investigate the role of p120 phosphorylation in cell-cell adhesion, we utilised a 
powerful RNAi-based substitution system recently described by Mariner et a1 (176). The 
magnitude of RNAi effect was cell line specific and, although a potent reduction in p120 
levels was achieved in A431 cells, significant knockdown of p 120 could not be achieved in 
KM 12C cell lines (data not shown). Importantly, this system avoids the potential 
confounding factor of sub-cellular mis-localisation of over-expressed p 120 due to 
saturation of cadherin binding sites and hence facilitates direct comparison of the function 
of different p120 constructs expressed at physiological levels. Human-specific p120 RNAi 
sequences (which do not alter the stability of murine p120) or a scrambled control 
sequence (A43I-Scr) were stably expressed in A431 cells using the retroviral vector 
pRetroSuper and a number of single cell clones with significant reduction in p120 levels 
obtained (A431-pl20f)(Figure 6-9 A shows results from two independent clones). As 
expected, there was a concurrent reduction in E-cadherin and P-cadherin (Figure 6-9 A). In 
addition, levels of other components of the AJ such as P-catenin and a-eatenin were also 
reduced (Figure 6-9 A), reflecting the known effects of p120 on AJ stability. There were 
no alterations in levels of EGFR, Src or FAK following knock-down of p 120 (Figure 6-9 
B). 
Subsequently, constructs encoding wild type and phosphorylation defective murine p 120 
isoform 3A were reintroduced into a single cell clone in which a high level of knockdown 
of endogenous p120 had been achieved (clone 7) using. Unlike isoform 1, p120 isoform 3 
does not contain tyrosine-96 but does contain tyrosines 112 - 302. Therefore the 
corresponding phosphorylation defective mutant was labelled "7 F" in contrast to the 
isoform IA "8F" mutant described in chapter four. We also introduced isoform 4A which 
lacks the entire N-terminal regulatory domain containing all identified sites of tyrosine and 
most sites of serine/threonine phosphorylation (Figure 6-9 C) (69). This isoform 
undergoes no detectable tyrosine phosphorylation in A431 cells (data not shown). Due to 
the presence of an intra-ribosomal entry site in the pLZRS-IRES-GFP vector the 
expression of p 120 and GFP was directly proportional. This facilitated the selection of 
pooled populations with stable expression of p 120 at levels similar to parental A431 cells 
by FACS according to GFP expression. Re-introduction of isoform 3A, 3A/7F or 4A 
restored levels of cadherins and catenins to those seen in the control cells (Fig. 6-9 A). 
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Figure 6-9 RNAi-mediated depletion and reconstitution of p120. 
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Figure 6-9 RNAi-mediated depletion and reconstitution of p120. 
(A, B) A431 cell lines expressing either a human p120 specific RNAi hairpin (A431-p120") 
or scrambled sequence (A431-Scr) were generated. Subsequently wild type murine p120 
isoform 3A (A431-p120"/p120-3A), 4A (A431-p120"/p120-4A) or phosphorylation 
defective isoform 3A (A431-p120"/p120-3A/7F) were reintroduced. Lysates were prepared 
and analysed by Western blotting with p120, E-cadherin, P-cadherin, ß-catenin, a-catenin, 
EGFR, FAK and Src antibodies. 
(C) Schematic diagram of p120 constructs. Isoform 3A is identical to the predominant 
isoform in parental A431 cells and contains 7 sites of tyrosine phosphorylation (red 
circles). The "p120-7F" construct is isoform 3A in which all sites of tyrosine 
phosphorylation were mutated to phenylalanine (grey circles). Isoform 4A lacks the N- 
terminal regulatory domain and contains no sites of tyrosine phosphoryation. 
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6.2.9 Depletion of p120 causes loss of morphological cell-cell 
cohesion. 
As depletion of p 120 resulted in a significant reduction in cadherins and other AJ proteins 
we predicted that morphological cell-cell cohesion would be impaired due to an inability to 
form AJs. Indeed, whilst parental A431 cells form epithelial colonies when cultured on 
tissue culture plastic, cells in which p120 was depleted grew in isolation and were unable 
to form colonies (Figure 6-10). Even when grown at high density morphological cell-cell 
cohesion did not occur as judged by actin staining (Figure 6-11). Unlike parental cells 
which adopted a typical cobblestone morphology the p120 depleted cells showed marked 
variation in shape with no evidence of intercellular coordination of actin organisation. This 
phenotype was reversed by reconstitution with p120 isoform 3A, 3A/7F or 4A (Figure 6- 
10). Importantly the ability of A431 cells reconstituted with p120-3A/7F or p120-4A to 
form cell-cell junctions appeared unimpaired suggesting that the phosphorylation of p120 
at tyrosine-228 occurring in nascent junctions (section 6.2.1) was not a necessary event in 
AJ formation. 
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Figure 6-10 Depletion of p120 specifically prevents morphological cell-cell cohesion. 
(A) Phase contrast micrographs of A431 cells expressing a scrambled control RNAi 
sequence (i) or a human p 120-specific RNAi sequence (ii - v). p 120-depleted cells were 
reconstituted with murine p120-3A (iii) or murine p120-4A (iv) or murine p120-3A/ 7F (v) 
(Magnification x 10; Bar 50 µm). 
158 
Figure 6-11 Depletion of p120 causes loss of cell-cell adhesion. 
A431 cells expressing a scrambled control RNAi sequence (A43 I -Scr) or a human p 120- 
specific RNAi sequence (A431-p 120-) were grown to confluence then fixed and actin 
stained with phalloidin-TRITC. Bar, 20 µm. 
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6.2.10 The p120 regulatory domain is required for growth 
factor induced scattering. 
Unlike KM12C-Src527F cells, virtually all A431 cells formed cell-cell contacts after 
switch from low to high calcium containing media. This was not influenced by the 
expression of pl20-4A or p120-3A/7F (data not shown). However, small colonies of A431 
cells are known to undergo scattering in response to EGF (397). This process involves the 
disassembly of AJs followed by migration of individual cells away from the colony in a 
random fashion. As we had demonstrated phosphorylation of p 120 at multiple tyrosine 
residues in EGF-stimulated A431 cells we wished to ask whether the phosphorylation state 
of p120 was important for EGF-induced scattering. The ability of EGF to induce scattering 
of colonies of A431-p120- cells reconstituted with wild type p120-3A, pl20-3A/7F or wild 
type p120-4A was assessed by time-lapse microscopy (Figure 6-12). The addition of EGF 
to A431-p120- cells reconstituted with wild type p120-3A resulted in complete dissolution 
of virtually all colonies. This phenotype was identical to that of parental A431 cells (data 
not shown). In contrast the addition of EGF to A431-p 120- /p 120-4A colonies caused 
some contraction and rounding of cells which is characteristic of the A431 cytoskeletal 
response to EGF but did not disrupt the morphological cohesion of the colony. A subtle but 
consistent difference was observed for EGF treated A431-p120- / p120-3A/7F colonies 
which adopted an intermediate phenotype with a less compact appearance and with some 
scattering but in which complete disruption of morphological cohesion was rare. 
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Figure 6-12 p120 isoform influences EGF induced cell scattering. 
48 hours 0 hours 
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Figure 6-12 p120 isoform influences EGF induced cell scattering. A431-p120" cells 
reconstituted with p120-3A, p120-3A/7F, or p120-4A were sparsely plated and maintained 
in complete medium until small colonies had formed. They were then serum starved 
overnight and phase contrast micrographs taken immediately before and 48 hours after the 
addition of EGF (10 ng/ml). Representative examples of two colonies per cell line are 
shown (x20 magnification; Bar 50 µm). 
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6.3 Discussion 
The consequences arising from phosphorylation of p120 on tyrosine are largely unknown. 
This is perhaps surprising given the progress made in understanding the role of tyrosine 
phosphorylation in other contemporaneously discovered Src substrates such as FAK (467) 
and cortactin (468) (reviewed in (236)). Alterations in cell-cell adhesion and motility often 
occur in association with increased Src or RTK activity and are properties which p120, a 
prominent substrate of such kinases, is in a pivotal position to influence. We set out to 
investigate the significance of the p120 phosphorylation events we had identified in 
KM12C and A431 cell lines, with particular reference to intercellular adhesion. Increased 
activity of Src or EGFR also correlates strongly with the acquisition of a more motile or 
invasive phenotype and this is addressed separately in chapter seven. 
6.3.1 Phosphorylation of p120 at nascentAJs. 
Src family kinases are enriched at AJs (194) and their regulated activity is necessary for AJ 
formation (138), perhaps via the activation of PI 3-K and Rae (179,252). It is not then 
surprising that p120, as a prime SFK substrate, should undergo phosphorylation during AJ 
formation. Indeed, the tyrosine phosphorylation of p120 has previously been reported to be 
increased during Ai formation (138,176) and, conversely, to be reduced in mature 
junctions (251). We extend these previous reports to demonstrate that phosphorylation of 
p120 at nascent AJs appears to occur at tyrosine-228 without significant phosphorylation at 
tyrosine residues 280,291 or 296. Whether tyrosine-228 represents the sole site of 
phosphorylation or whether residues such as 112,257 and 302 may similarly undergo 
phosphorylation remains undetermined. Interestingly, phosphorylation of p 120 at tyrosine- 
228 does not appear to be a necessary event for AJ formation in A431 cells as no gross 
defect was seen in the ability of cells reconstituted with p120-4A to form cell-cell 
adhesions. This is in-keeping with similar observations published by the Reynolds group 
(176). 
In contrast to the other work described in this chapter which utilised cells over-expressing 
exogenous Src or a cell line which over-expresses EGFR to high levels, the demonstration 
of p120 phosphorylation at nascent AJs provided proof-of-principle that p120, and 
specifically tyrosine-228, is a bona fide substrate of endogenous kinases in epithelial cells. 
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6.3.2 Phosphorylation of p120 by oncogenic kinases. 
In contrast to the spatio-temporally regulated phosphorylation of p 120 described above, the 
stable expression of active Src in the KM12C cell line was associated with constitutive 
hyper-phosphorylation of p 120. Indeed p 120 was more prominently phosphorylated than 
either E-cadherin or ß-catenin, the two other major kinase substrates at the AJ. Thus, p120 
was a prominent phospho-protein in KM12C-Src527F cells in which cell-cell junction 
formation is impaired. Furthermore, inhibition of Src kinase activity with the selective 
inhibitor AP23464 prevented p120 phosphorylation and this correlated with reversal of 
Src-dependent deregulation of the AJ. This prompted us to ask whether tyrosine 
phosphorylation of p120 was a necessary event for Src-dependent deregulation of AJs in 
KM12C cells. The hypothesis that tyrosine phosphorylation of p120 provides a means of 
exerting dynamic modulation over its key role in the regulation of cadherin trafficking is 
attractive but remains lacking in direct evidence. For example, Aono et al investigated the 
adhesive defect seen in the Colo 205 cell line which expresses normal levels of E-cadherin 
and catenins but which is unable to form AJs (272). Treatment with the kinase inhibitor 
staurosporine or the expression of a p120 construct lacking the regulatory domain (deletion 
of residues 1-324) was sufficient to promote cell-cell adhesion suggesting that constitutive 
signalling events impacting on the p 120 N-terminal region were the cause of impaired 
adhesion. However, this approach did not distinguish tyrosine phosphorylation from other 
events occurring at the p120 N-terminus. Indeed, the major phosphorylated p120 residue in 
Colo 205 cells was, in fact, serine rather than tyrosine. Secondly, Ozawa et al 
demonstrated that that the ability of Src to disrupt AJs in E-cadherin transfected L cells (a 
cadherin-deficient mouse fibroblast line) was abrogated by the co-expression of p120 
lacking most of the N-terminal region (deletion of residues 29-233) (273). Again, this 
provided circumstantial evidence for p120 tyrosine phosphorylation but, importantly, did 
not exclude a role for other regulatory events involving the p120 regulatory domain or 
coiled-coil domain. Both of these studies predated the identification of the sites of p120 
tyrosine phosphorylation, a development which now makes it possible to definitively test 
the specific role of p 120 tyrosine phosphorylation via the use of p120 phosphorylation- 
defective mutants. Consequently we have used both a phosphorylation-defective p120 
construct (p120-3A/7F) and p120-4A which lacks the entire N-terminal region containing 
all sites of tyrosine phosphorylation and most sites of serine/threonine phosphorylation. 
We over-expressed phosphorylation-defective p120 in KM12C cells with the aim of 
achieving a dominant negative effect by competing out endogenous phosphorylation- 
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competent p120. Although this widely used approached is often instructive it is important 
to acknowledge its limitations. Firstly, there is no guarantee that a dominant negative effect 
can be achieved, particularly if only small amounts of phosphorylated protein are sufficient 
to exert a phenotype. Secondly, even if a dominant negative effect is achieved an excess of 
over-expressed protein may itself alter the cells phenotype by mechanisms entirely 
unrelated to phosphorylation. This is a particular concern for p120 where a series of 
mutually exclusive regulatory interactions with various binding partners occur which may 
be perturbed with dramatic effect in the presence of an excess of over-expressed p120. 
Specifically, over-expressed p 120 may saturate cadherin binding sites then accumulate in 
the cytoplasm where it would be free to regulate Rho GTPase and Kaiso activity. 
Consequently, wild type p120 was also over-expressed as an essential control to 
differentiate effects caused by altered p120 phosphorylation status from effects simply 
caused by excess p 120. Recently a more elegant and powerful methodology which is likely 
to supersede the traditional dominant negative approach has been described (176). In brief, 
this approach exploits non-homology between human and murine cDNA to generate a 
human-specific RNAi hairpin. Having achieved good knockdown of endogenous human 
protein, the cell line is then reconstituted with murine cDNA which is unaffected by the 
human specific RNAi hairpin. An alternative approach to evade RNAi-mediated 
destruction would be to reconstitute a cell line with cDNA of the same species but in which 
silent nucleotide substitutions had been introduced. Regardless, the reconstituted cell is 
forced to use the exogenous protein which can be expressed at levels identical to those of 
the parental cell. This facilitates a direct and more physiological comparison of protein 
function. This system was first described by Mariner et al in the context of their work on 
p120 and we have used it in A431 cells without modification other than to include a 
scrambled control sequence as an additional control (176). 
Using a dominant negative approach we could not identify any requirement for p120 
phosphorylation in mediating Src-dependent deregulation of cell-cell contacts in KM12C 
cells. This data is open to at least two interpretations. Firstly, we should acknowledge that 
the degree of dominant negative effect achieved may simply have been insufficient. 
Although we demonstrate a clear reduction in phosphorylation of endogenous p120 it is 
possible that the effect of p120 phosphorylation was in fact so potent that phosphorylation 
of even a minority of molecules was sufficient to impair AJ formation. In this regard it is 
unfortunate that the RNAi-mediated substitution system applied effectively to A431 cells 
was unsuccessful in KM12C-derived cell lines. 
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A second interpretation would regard phosphorylation of p120, at least for this specific 
cell-cell adhesive defect, as an epiphenomenon. Supporting this is the finding that mutation 
of the SH3 domain abrogated the ability of Src527F to deregulate the AJ without any 
impairment of its ability to phosphorylate p120. In other words, tyrosine phosphorylation 
of p120 was not sufficient for Src induced disruption of the AJ. 
In contrast, tyrosine phosphorylation of p120 was involved in the scattering of EGF- 
stimulated A431 cells. Substitution of 7 prominent sites of tyrosine phosphorylation with 
phenylalanine partially abrogated EGF induced scattering. However, a greater inhibitory 
effect was seen in the presence of p 120 isoform 4A. This suggested that additional events 
in the p120 N-terminal region, perhaps growth factor induced serine / threonine 
phosphorylation were required for the maximal effect of EGF. This data is in-keeping with 
that of Cozzolino et al who demonstrated an inhibitory effect of over-expressed p 1204A 
in the HGF induced scattering of MDCK cells (131). Finally, the observation that the 
motility of A431 cells was unaltered by the substitution of wild type with phosphorylation 
defective p120 (see section 7.2.3) suggested that the defect in scattering seen in A431 cells 
expressing phosphorylation defective p 120 was due to increased stability of adhesions 
rather than reduced motility. 
There are several mechanisms not requiring p120 phosphorylation by which Src may 
disrupt AJs in KM12C cells. Recent work has demonstrated that the ability of Src to inhibit 
junction formation in KM12C cells is at least partially explained by events originating not 
at the AJ but at cell-matrix adhesions (278). Specifically, elevated Src activity in KM12C 
cells was associated with localised activation of ERK, MLCK and ROCK at integrin-based 
cell-matrix adhesions and accumulation of phospho-myosin at these sites (278). Blockade 
of ERK, ROCK or MLCK activity inhibited accumulation of phospho-myosin and was 
sufficient to allow AJs to form. Thus, a major mechanism of Src's inhibitory effect on 
junction formation in KM12C cells may be via the generation of contractile forces which 
are unfavourable to junction formation. 
As was the case in the present work, p120 is generally the most heavily phosphorylated 
protein at the AJ. Despite this, recent work suggests that phosphorylation of cadherins or 
ß-catenin may be mechanistically more important. For example, phosphorylation of VE- 
cadherin at tyrosine-658 causes dissociation of p120 (89) and this appears to "unmask" a 
sequence motif for constitutive endolysosomal processing (75). Thus, the critical role of 
p120 in maintaining endothelial AJ stability is influenced by tyrosine phosphorylation, but 
of VE-cadherin rather than p120 itself. 
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The recent identification of Hakai, a novel E3 ubiquitin ligase, provides a further 
mechanism for tyrosine kinase mediated AJ disruption (11). Hakai specifically binds the 
juxtamembrane domain of phosphorylated E-cadherin, targeting it for ubiquitination and 
endocytosis with a resulting decrease in cell-cell adhesion. These residues are within the 
p 120-binding cadherin JMD so, reminiscent of the situation for VE-cadherin, it has been 
suggested that p120 may act to limit access of Hakai and hence stabilise E-cadherin. 
A potential confounding factor in the work undertaken in KM12C cells was the use of 
p120 isoform 1A. Although this isoform is expressed at low levels in KM12C cells the 
predominant isoform, in common with most epithelial cell lines is isoform 3. Isoform 1 is 
preferentially found in more motile cells types (59), associates preferentially with N- 
cadherin (381), and is upregulated in snail-driven EMT (172). However, the consequence 
of this p120 isoform switch, if any, for the AJ is unknown. In p120 deficient SW48 colon 
carcinoma cells both isoform 1 and 3 were equally able to stabilise cadherin and 
reconstitute the AJ (81). In addition expression of p120 isoform 1 in Caco-2 colorectal 
cancer cells which predominantly express lower molecular weight isoforms did not cause 
any alteration in morphology of cell-cell contacts or any defect in epithelial barrier 
function (469). Therefore we think it unlikely that we would have obtained different results 
had we used isoform 3 rather than isoform 1. 
Finally, the requirement for p120 tyrosine phosphorylation in EGFR induced scattering of 
A431 cells but not in Src driven inhibition of AJ formation in KM12C cells likely reflects 
important differences in the biology of these two processes. Specifically these two models 
utilised different kinases (Src and EGFR), tested their effects on established (A43 1) versus 
nascent (KM12C) AJs and compared sustained steady state kinase activity (stable 
expression of Src527F) with the acute onset of kinase activity (EGF stimulation of serum 
starved A431 cells). It is interesting to speculate that kinase driven elevation in acto- 
myosin contractility may be in itself sufficient to prevent the formation of new junctions as 
occurred in KM12C cells. Conversely in the presence of established AJs, such as in 
colonies of A431 cells, additional phosphorylation events involving p120 may be 
necessary for AJ disruption. 
6.4 Summary 
p120 underwent transient and low level phosphorylation of tyrosine-228 during AJ 
formation. This does not appear to be a necessary event for AJ formation and its 
significance is undetermined. In contrast, p120 was hyper-phosphorylated in KM12C cells 
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expressing Src527F or upon stimulation of A431 cells with EGF. The tyrosine 
phosphorylation of p 120, along with other functions attributable to the N-terminal region 
were required to mediate EGF-dependent scattering of A431 cells. However, the 
deregulation of AJ formation in Src-expressing KM12C cells appeared to be due to 
mechanisms other than p120 phosphorylation. 
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7 Results: Role of p120 in the motility and 
invasion of Squamous Cell Carcinoma cells. 
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7.1 Aim 
The ability of tumour cells to invade is a key step in the metastatic process and loss of E- 
cadherin-mediated cell-cell junctions has often been associated with increased invasive 
capacity and poor patient survival. p120 has emerged as a key player in regulating cadherin 
stability, actin re-modelling and cell motility and is a prominent substrate of oncogenic 
kinases whose activity often correlates with invasion and metastasis. It has been postulated 
that p120 may be able to either positively or negatively regulate invasion depending on the 
cellular context. However, the potential role of p 120 in invasion has not yet been 
experimentally tested. 
The A431 epidermal squamous cell carcinoma line over-expresses EGFR and invades a 3- 
dimensional extracellular matrix in response to an EGF gradient, providing a tractable 
reductionist system in which to investigate cancer cell invasion (397). In chapter five we 
demonstrated the phosphorylation of p120 at tyrosine residues 228,280,291 and 296 in 
A431 cells exposed to EGF. We therefore set out to define the role, if any, of p120 and its 
tyrosine phosphorylation in A431 cell motility and invasion. 
7.2 Results 
7.2.1 Src kinase activity is required for motility. 
Inhibition of SFK activity is associated with the inhibition of cellular motility in 2- 
dimensional culture as well as with the inhibition of invasion, a process occurring in 3- 
dimensions (335,384,388-394). Here we describe the effect of the specific Src kinase 
inhibitor AP23464 (448) on A431 cell motility whilst the effect of AP23464 on invasion is 
described in section 7.2.7. Concentrations of AP23464 which blocked SFK activity and 
inhibited phosphorylation of p120 (described in section 5.2.6) reduced the median speed 
of A431 cells sparsely plated on tissue culture plastic from 6.33 µm/hr (interquartile range: 
4.1 - 11.4 µm/hr) to 0.9 µm/hr (interquartile range: 0.4 - 1.6 µm/hr) As the data was not 
normally distributed we utilised the non-parametric Mann-Whitney U test to demonstrate 
this to be a statistically significant reduction (p < 0.0001) (Figure 7-1). 
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Figure 7-1 AP23464 Inhibits motility and invasion of A431 cells. 
The migration of sparsely plated A431 cells with or without the addition of 1 µM AP23464 
to the culture media was analysed by time-lapse video microscopy. For quantification of 
migration 50 individual cells were tracked for 16 hours. Migration is represented as 
median speed. 
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7.2.2 Depletion of p120 causes increased motility in 2- 
dimensions. 
p120 has been reported to promote or inhibit the 2D motility of various epithelial cell lines 
in an isoform and cell context-specific manner (128,130,131). The depletion of all p120 
isoforms in A431 cells caused an increase in 2-dimensional motility as measured by time 
lapse video-microscopy of sparsely cultured cells (Figure 7-2 A). The median speed was 
increased 3.5 fold from 8.0 µm / hr (interquartile range: 3.5 - 14.4 µm / hr) in A431-Scr 
cells to 27.3 µm / hr (interquartile range: 14.1- 51.6 µm / hr) in A431-p120" cells. The 
increased motility was confirmed in two clones (clone 3 and 7). This increase was 
statistically significant (p<0.0001, Mann-Whitney U test). 
Next we determined the motility of cells plated on Matrigel-coated tissue culture plastic. 
The speed (Figure 7-2 B) of both A431-p120' cells and of control cells was increased in 
comparison to identical cells plated on uncoated tissue culture plastic. The increased 
motility of p120 depleted cells (77.8 µm / hr, interquartile range: 62.4 - 95.2 µm / hr) 
compared to control cells (61.2 µm / hr, interquartile range: 52.3 - 76.3 µm / hr) was less 
apparent than for cells plated on plastic but remained significant (p < 0.001, Mann- 
Whitney U test). The increased motility in p120 depleted cells was reversed by 
reconstitution with wild type p120-3A indicating that the phenotype observed was due 
specifically to loss of p120 and not a clonal or "off-target" effect. For qualitative purposes 
the tracks of 10 individual cells are shown (Figure 7-2 C) 
7.2.3 The ability of p120 to be phosphorylated does not influence 
motility. 
As concentrations of AP23464 which inhibited phosphorylation of p120 were sufficient to 
block motility we wished to determine whether this correlation might indicate any causal 
relationship. To answer this question we measured the motility of individual A431-p120' 
cells reconstituted with wild type or phosphorylation-defective p120-3A or with p120-4A. 
There was no significant difference in median motility whether p120-3A (59.7 µm / hr, 
interquartile range: 44.5 - 72.6 µm / hr), p120-3A / 7F (60.6 gm / hr, interquartile range: 
48.0 - 72.5 µm / hr), or p 120-4A (64.7 gm / hr, interquartile range: 51.1 - 77.3 µm / hr) 
were expressed (Figure 7-3). Thus we concluded that the ability of p 120 to undergo 
tyrosine phosphorylation did not influence the motility of A431 cells. 
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Figure 7-2 Depletion of p120 increases motility of A431 cells. 
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Figure 7-2 Depletion of p120 increases motility of A431 cells. 
(A) A431-Scr and A431-p120- cells were sparsely plated and migration analysed over a5 
hour period by time-lapse video microscopy. For quantification of migration 100 
individual cells per cell line were tracked for 5 hours. Migration is represented as median 
speed. Results are representative of 3 independent experiments. 
(B) A431-Scr, A431-p120- and A431-p120- cells reconstituted with p120-3A were sparsely 
plated on Matrigel-coated plastic and the migration of 50 cells analysed over a5 hour 
period by time-lapse video microscopy 
(C) Representative migratory paths are shown for 10 cells. Bar 100 µm. 
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Figure 7-3 The ability of p120 to undergo tyrosine phosphorylation does not Influence 
motility. 
A431-p120- cells reconstituted with p120 isoform 3A, 3A/7F or 4A were sparsely plated 
on Matrigel-coated plastic and migration analysed over a5 hour period by time-lapse video 
microscopy. Results represent the median speed of migration of 50 individual cells per cell 
line and are representative of two independent experiments. 
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7.2.4 Wound closure by p120-depleted cells is disorganised. 
A431 cells migrated into a "wound" created in a confluent monolayer by scratching with a 
pipette tip. Migration occurred in a collective manner as a confluent sheet of cells with a 
uniform vector of movement. This was associated with the formation of lamellipodia at the 
leading edge and with the retention of cell-cell morphological cohesion (Figure 7-4 A, left 
panel and movie 1). In contrast single A431-p120- cells could clearly be seen to migrate 
independently into the denuded area. Unlike parental cells, A431-p120' cells appeared to 
fill the defect by the random movement of single cells. (Figure 7-4A, right panel and 
movie 2). Staining for actin confirmed that A431-Scr cells retained cell-cell junctions 
whilst A431-p120' cells adopted an elongated morphology with no apparent cell-cell 
contacts. However, despite the different mode of migration into the wound the actual 
speed with which wound closure occurred was not significantly different between the 
A431-Scr (20.57 +/- 2.26 µm / hour) and A431-p120- cells (18.14 +/- 2.98 pm / 
hour)(Figure 7-4 B, C). 
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Figure 7-4 Wound closure by p120-depleted cells is disorganised. 
(A) A431-Scr (left panel) or A431-p120- (right panel) cells were fixed and stained with 
phalloidin-FITC 6 hours after a wound was made in a confluent monolayer. Arrow 
indicates direction of migration (x40 magnification). 
(B) A wound was made in a confluent monolayer of A431-Scr or A431-p120- cells using a 
sterile pipette tip and images recorded at 0 and 9 hours. Bar, 400 µm. 
(C) The rate of migration into the wound was quantified for 5 locations per wound on 
duplicate wounds and presented as mean speed +/- S. D. Results are representative of three 
independent experiments. 
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7.2.5 Depletion of p120 does not influence proliferation. 
The depletion of p 120 was previously reported to cause a significant reduction in growth in 
a pancreatic cancer cell line (470). However, no difference in proliferation was seen 
between A431-Scr and A431-p120' cells over 6 days (Figure 7-5). 
7.2.6 Loss of p120 and the AJ does not impair major EGFR 
signalling pathways. 
Depletion of p120 was not associated with any alteration in the protein levels of EGFR or 
of other kinases involved in motility and invasion including Src and FAK (Figure 6-9). 
However as bidirectional cross talk exists between the AJ and the EGFR (471) we 
investigated the effects of depleting p120, and hence the AJ, on signalling to MAPK and 
STAT3 which represent two of the major downstream pathways of EGFR activation. As 
well as providing a readout of EGFR activity both the MAPK (472) and STAT3 (473) 
pathways are themselves implicated in motility and invasion. Importantly, the EGF- 
dependent phosphorylation of MAPK and STAT3 was seen in both p120 knock-down and 
control cells (Figure 7-6). This suggested that EGFR signalling to at least two of its major 
downstream effector pathways was not perturbed by depletion of p120. 
We then turned to Rho-family GTPases which have previously been shown to be activated 
in EGF stimulated A431 cells (397), are implicated in motility and invasion (474), and 
which are known to be regulated by p120 (475). The activation of RhoA, Rac and Cdc42 in 
response to EGF stimulation was not reduced in A431-p120- cells when compared to 
control cells (Figure 7-7). A reduction in basal levels of active RhoA and Cdc42, but not 
Rac was noted in p 120-depleted cells. 
Taken together these results suggested that depletion ofp120 did not introduce defects in 
EGFR signalling to Rho GTPases or to the MAPK or STAT3 pathways, at least in a 2- 
dimensional context. 
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Figure 7-5 Depletion of p120 does not influence cellular proliferation. 
A431-Scr 
  A431-p120- 
A43 I -Scr or A43I-p 120- cells were plated at a density of Ix 10; cells / well in 96 well 
plates. At 24 hour intervals the number of viable cells was determined using a colorimetric 
MTT assay where absorbance at 570 nm is directly proportional to cell number. Results 
are plotted as mean absorbance +/- S. D. for quadruplicate wells. 
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Figure 7-6 p120 is not required for major EGFR signalling pathways. 
A431-Scr and A431-p 120- cells were serum starved overnight then stimulated with EGF 
(100 ng/ml) for 5 minutes prior to lysis. Western blot analysis was carried out with 
phospho-MAPK and phospho-STAT3 antibodies. In each case after removal of the 
phospho-specific antibodies the blots were reprobed with the corresponding non-phospho- 
specific antibodies. 
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Figure 7-7 p120 is not required for EGF induced Rho GTPase activation. 
(A) Serum starved cells were stimulated with EGF (100 ng / ml) for 5 minutes (Rae! / 
Cdc42) or 15 minutes (RhoA) then lysed and pull-down assays performed. Immunoblotting 
of cell lysate was also performed to ensure equivalent levels of protein were present. 
(B) For quantification the amount of active Rho-family GTPase was determined by band 
densitometry and the mean fold activation relative to serum starved cells displayed for 
three independent experiments +/- S. D. 
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7.2.7 AP23464 inhibits invasion into Matrigel. 
We next utilised a quantitative in vitro invasion assay to assess the ability of A431 cells to 
invade into Matrigel in response to EGF. Matrigel is a commercially available preparation 
consisting primarily of collagen IV and laminins purified from the extracellular matrix 
produced in vivo by a mouse sarcoma cell line (476). The Matrigel invasion assay is 
hypothesised to recapitulate three critical steps of invasion: adhesion, proteolytic 
dissolution of the matrix and migration (477). Invasion only occurred in the presence of an 
EGF gradient and was maximal for 10 ng/ml (EGF concentrations from 1-100 ng/ml were 
tested, data not shown). The maximum depth of invasion into Matrigel was typically 60-75 
µm. Cells which invaded into the Matrigel appeared to do so collectively, forming multi- 
cellular clusters rather than invading as isolated cells. The addition of AP23464 to culture 
media was sufficient to reduce invasion by 93% in comparison to untreated cells (Fig 7-8 
A, B). Thus Src was a necessary effector of EGF-induced invasiveness of A431 cells. 
7.2.8 p120 is required for invasion into Matrigel. 
As we had demonstrated that depletion of p120 in A431 cells resulted in loss of cell-cell 
contacts and increased 2-dimensional motility we hypothesised that A431-p12O'cells 
would have a greater capacity for invasion than parental cells. Surprisingly, knock-down of 
p120 protein resulted in a marked reduction in invasion into Matrigcl over 72 hours in 
comparison to the A431-Scr cells (Figure 7-9 A, B). Quantification showed a 76% 
reduction in invasion in A431-p120" clone 3 and 71% reduction in A431-p120' clone 7 
cells (Figure 7-9). Importantly, the ability of reconstituted p120-3A to reverse the invasion 
defect confirmed that this phenotype was specifically due to p120 depletion. 
7.2.9 The requirement for p120 in EGF-stimulated invasion is 
phosphorylation-independent. 
In chapter five we demonstrated the phosphorylation of p 120 at tyrosine residues 228,280, 
291 and 296 in EGF-stimulated A431 cells. As invasion only occurred in the presence of 
EGF and could be inhibited by concentrations of AP23464 which also blocked the EGF 
induced phosphorylation of p120, we hypothesised that the requirement of p120 for 
invasion would specifically depend on its ability to be phosphorylated. However, 
reconstitution with p120 isoform 4A, which lacks all sites of tyrosine phosphorylation, 
restored the invasion defect in the A431-p120' cells to a level seen in the control cells 
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(Figure 7-9 A). Thus, tyrosine phosphorylation of p120 (or other events occurring in the 
regulatory domain such as serine/threonine phosphorylation) were not required for 
invasion in response to EGF. 
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Figure 7-8 AP23464 inhibits invasion into Matrigel 
(A) Cells were seeded on Transwell filters in the presence or absence of AP23464 and 
allowed to invade into Matrigel towards an EGF gradient. After 72 hours cells were 
labelled with calcein AM and visualised in the Matrigel at 15 µm intervals. A 
representative z series is shown for qualitative purposes. 
(B) Quantification of invasion is shown for a representative experiment in a series of two. 
Values are mean +/- S. D. 
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Figure 7-9 p120 is required for invasion in a phosphorylation-independent manner. 
(i) (ii) (iii) (iv) 
188 
Figure 7-9 p120 is required for Invasion in a phosphorylation-independent manner. 
(A) Cells were seeded on Transwell filters and allowed to invade into Matrigel towards an 
EGF gradient. After 72 hours cells were labelled with calcein AM and visualised in the 
Matrigel at 15 µm intervals. Representative z-series are shown for (i) A431-Scr, (ii) A431- 
" p 120" Clone 3, (iii) A431-p 120- Clone 7, (iv) A431-p 120"/p 120-3A and (v) A431-p120 
/p 120-4A. 
(B) Quantification of invasion is shown for a representative experiment in a series of four. 
Values are mean +/- S. D. 
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7.2.10 p120 is required for invasion in an organotypic assay. 
The reduced ability of A431-p120- cells to undergo invasion was further characterised 
using an organotypic invasion assay. This 3D environment more closely resembles the in 
vivo situation and measures invasion of cells exposed to air into a collagen I/ Matrigel 
matrix containing tumour derived fibroblasts (478,479). Depletion of p l. 20 caused a 71% 
reduction in invasion in comparison to control cells expressing a scrambled p120 sequence 
(Figure 7-10). The fibroblast-derived factors which may stimulate invasion in the 
organotypic assay are poorly defined but may include EGF (480), KGF (481), GM-CSF 
(481), IGF (482) and TGF-ß (480). These fibroblast-derived growth factors were 
necessary to stimulate invasiveness of A431 cells as there was almost no invasion of 
control or p120 knock-down cells in the absence of fibroblasts (Figure 7-10). 
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Figure 7-10 pl20 is required for organotypic invasion. 
CFP-labelled cells (blue) were seeded on collagen / Matrigel gels in the presence or 
absence of fibroblasts and after 5 days the gels were fixed and labelled with phalloidin- 
TRITC (red). Quantification of invasion relative to A431-Scr control cells from three 
separate experiments is shown where values are mean +/- S. D. 
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7.2.11 A431 cells utilise a collective mode of invasion. 
Malignant cells may adopt diverse strategies for invasion including mesenchymal or 
amoeboid invasion of single cells or collective invasion of co-ordinated columns or sheets 
of cells (410,420). To characterise the mode of invasion utilised by A431 cells 
reconstructed confocal images of A431-Scr cells invading in the organotypic assay were 
generated. A431-Scr cells invading 5 or 30 µm into the gel did so as cohesive groups of 
cells consistent with a collective mode of invasion (Figure 7-11, upper panels). Thus A431 
cells invaded collectively in both the Matrigel and organotypic invasion assays. 
7.2.12 Invading p120-depleted A431 cells retain cell-cell 
cohesion. 
In 2-dimensions depletion of p120 was sufficient to entirely ablate morphological cell-cell 
cohesion (Figure 6-10). However the intercellular adhesive phenotype in two dimensions 
does not necessarily predict the nature of cell-cell adhesion in a three dimensional 
environment (95). We wished to define whether the A431-p 120' cells which invaded a 
short distance into the gel did so collectively or as single cells. In fact, A431-p120" cells 
which invaded superficially into the gel (to a depth of 5 µm) did so as collective strands 
(Figure 7-11, lower panels). The cells seen in the 30 µm section are fibroblasts rather than 
invading A431-p 120" cells. 
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Figure 7-11 A431 cells invade in a collective manner. 
A431-Scr or A431-p120- cells were seeded on collagen / Matrigel gels in the presence of 
fibroblasts and after 5 days the gels were fixed and labelled with phalloidin-TRITC. 
Confocal images of cells invading approximately 5 µm (left panels) and 30 µm (right 
panels) are shown. 
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7.2.13 E-cadherin is not required for the collective invasion of 
A431 cells. 
As the requirement for p 120 in mediating EGF-induced invasion did not map to its N- 
terminal regulatory domain it was possible that p120 was acting to stabilise E-cadherin and 
hence facilitate the intercellular adhesion implicit in collective cell invasion. To test this 
hypothesis E-cadherin was transiently knocked down in A431-Scr cells using two separate 
RNAi duplexes (Figure 7- 12). As a control for non-specific effects two duplexes 
(irrelevant 1 and 2) containing at least 4 mismatches with all known human genes and 
which have been shown on microarray analysis to have minimal targeting of known human 
genes were also used. A high level of knockdown of E-cadherin was achieved (Figure 7-12 
A). The depletion of E-cadherin did not alter the ability of the A431 cells to invade (Figure 
7-12 B, C). This suggests that the ability of p120 to regulate invasion is via a mechanism 
independent of its ability to stabilise E-cadherin and that the collective invasion of A431 
cells is not dependent on E-cadherin mediated cell-cell junctions. This is supported by the 
formation of collective strands of invasive cells in the small number of A431-p120- cells 
that invade a small distance into the collagen gels (Figure 7-11). 
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Figure 7-12 E-cadherin is not required for invasion. 
(A) A431-Scr cells were transiently transfected with either of two E-cadherin-specific 
duplexes (ECAD 1/2) or with either of two control non-targeting duplexes (Irrelevant 1/2) 
and Western blotting of protein levels performed after 72 hours. Membranes were also 
probed with anti-tubulin antibody as a loading control. 
(B) CFP-labelled cells (blue) were seeded in collagen gels in the presence of fibroblasts 
and after 5 days the gels were fixed and labelled with phalloidin-TRITC (red). 
(C) Quantification of invasion from three separate experiments is shown where values are 
mean +/- S. D. The invasion by cells transfected with irrelevant duplex 1 was defined as 
100% and the other values normalised to this. 
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7.2.14 Reduced invasion is not due to a defect in 
chemotactic migration. 
The invasive defect seen in p120-depleted A431 cells could represent either a general 
failure to recognise or respond to a chemotactic EGF gradient or could signify a loss of 
functions more specifically related to invasion. To discriminate between these two 
possibilities the migration of A431-Scr and A431-pl20' cells across a Transwell filter 
which had not been coated with extracellular matrix was determined (Figure 7-13). In the 
presence of endogenous or reconstituted p120 a basal level of migration occurred which, 
surprisingly, was not increased in the presence of EGF. In contrast, cells in which p120 had 
been depleted showed significantly increased migration in response to EGF (p = 0.037, 
Two-sample T-Test) and this was maximal for 10 ng/ml EGF, a concentration identical to 
that used in the Matrigel invasion assays (concentrations of 1-100 ng/ml tested, data not 
shown). Thus, the depletion of p120 was associated with enhanced rather than diminished 
chemotactic migration of A431 cells in response to EGF. 
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Figure 7-13 p120 is not required for chemotactic migration to an EGF gradient. 
Cells were seeded on uncoated Transwell filters and allowed to migrate across the filter 
with or without an EGF gradient. After 24 hours cells which had crossed to the lower 
surface of the filter were detached and labelled with a fluorescent dye. Results are plotted 
as mean absorbance +/- S. D. for triplicate filters. 
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7.3 Discussion 
As a prominent substrate of pro-invasive kinases with the ability to regulate the AJ, Rho 
GTPases and transcription, p120 appears well placed to integrate and disseminate signals 
leading to invasion. However, the potential role of p120 in invasion has not been 
experimentally tested. We utilised the RNAi-based substitution system described in 
chapter six to recapitulate two distinct scenarios where p120 function may be deregulated 
in invasive human cancers in vivo: 1) Complete loss of p120 which is a relatively 
infrequent but consistent finding across multiple immunohistochemical studies; and 2) 
deregulated tyrosine phosphorylation of p120 which is seen in several neoplastic cell lines 
and which may occur in tumours with upregulated kinase activity. The first question was 
addressed by RNAi-mediated depletion of p 120. The second, by determining whether 
tyrosine phosphorylation of p120 correlated with invasiveness and then specifically 
interfering with p120 phosphorylation by replacing wild type p120 with the 
phosphorylation deficient truncated isoform, p120-4A. 
7.3.1 p120 and 2-dimensional motility. 
The depletion of p120 in A431 cells was associated with a significant increase in two 
dimensional motility. This contrasts with previous reports in which depletion of p120 by 
RNAi in a colorectal (130) and lobular breast cancer (128) cell line was associated with 
increased RhoA activity and decreased motility. However, in both of these cell lines p120 
was constitutively cytoplasmic. The depletion of p 120 from a cadherin deficient cell line in 
which p120 is constitutively cytoplasmic and apparently causing tonic inhibition of RhoA 
may differ from depleting p120 in a cell line such as A431 where it is predominantly 
membranous. In this regard the effects of depleting p120 on motility may be highly 
dependent on the specific cellular context. Interestingly, expression of a dominant negative 
cadherin construct (a substitution of tryptophan to alanine at position 2 leads to an inability 
of the mutant protein to form trans dimers) was previously reported to cause increased 
motility of A431 cells (483). It has been suggested that, by sequestering p120, dominant 
negative cadherins may partially phenocopy the effects of p120 depletion (271). Viewed in 
this light these findings would be consistent with our current data. 
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7.3.1.1 Tyrosine phosphorylation of p120 is not necessary for cell 
motility. 
We found that the lower rate of motility in p120 expressing cells, compared to cells in 
which p120 had been depleted, was independent of the ability of the reconstituted p120 to 
be phosphorylated. This finding is in-keeping with previous reports that expression of p120 
isoform 4 in primary keratinocytes did not influence motility as compared to control cells 
(131). In contrast the motility of HGF stimulated MDCK cells was reported to be inhibited 
by the expression of p120-4A and increased by expression of p120-1A (131). It is possible 
that this represents differing requirements for p120 phosphorylation intrinsic to various 
epithelial cell lines. Alternatively, this may represent distinct pathways activated in 
response to EGF, HGF, or to the growth factors present in foetal bovine serum (FBS). We 
found that motility in A431 cells was significantly reduced in serum free medium (median 
speed 1-2 pm / hour) as compared to complete medium (6-8 µm / hour). However, on 
addition of even low concentrations of EGF a very high percentage of sparsely plated 
A431 cells rapidly detached making a direct analysis of EGF-stimulated motility 
impossible. However, the motility in all cell lines was increased to the same extent in 
serum containing versus serum free medium suggesting there was no difference in the 
ability of A431 cells to respond to the growth factors present in FBS regardless of the p120 
isoform expressed. 
The finding that Src kinase activity was required for motility was in-keeping with the 
known pro-migratory function of this kinase (484). Previous work has identified the 
importance of tyrosine phosphorylation of specific Src substrates such as FAK and 
cortactin in cell migration (236). However, the Src substrate p120 appears to differ in this 
regard as its ability to undergo phosphorylation did not influence the motile abilities of the 
cell. 
7.3.1.2 A431 cells favour collective migration in 2-dimensional culture. 
Striking differences were seen in the mode of wound-closure adopted by control and p120 
depleted A431 cells. Unlike control cells which moved as a co-ordinated and coherent 
sheet, p120 depleted cells migrated into the denuded area independently without evidence 
of multicellular organisation. Interestingly, despite the 3 fold increase in random motility 
seen in p120 depleted cells there was no difference in the time taken to achieve wound 
closure as compared to control cells. This apparent discrepancy is partially explained by 
the persistent vector of motion displayed by the coherent epithelial sheet. In contrast p120- 
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depleted cells filled the wound less efficiently as individual cells migrated in various 
directions rather than uniformly into the defect. Furthermore, the speed of the collective 
sheet (20.57 µm / hour) was greater than the speed achieved by sparsely plated individual 
A431 cells (8.0 µm / hour). This suggests that collective motility is a more efficient means 
of migration for the A431 cell line. 
7.3.2 p120 and invasion. 
7.3.2.1 Increased 2-dimensional planer migration is not predictive of 
increased invasiveness. 
Intuitively, one might expect the depletion of p120 (which caused increased motility in two 
dimensions and downregulation of the invasion suppressor E-cadherin) to increase 
invasiveness. On the contrary, p120 depletion was associated with a dramatic reduction in 
invasiveness both in Matrigel and in collagen gels in an organotypic assay. The finding 
that two-dimensional planer motility is not predictive of invasion has been seen in other 
model systems. For example, a study characterising the genotype-phenotype relationship of 
various E-cadherin germline mutations identified in hereditary diffuse-type gastric cancer 
demonstrated that 2-dimensional motility was neither necessary nor sufficient for invasion 
(344). Clearly the ability to invade a 3-dimensional matrix may demand phenotypic 
changes of a cell in addition to motility such as expression of matrix degrading enzymes or 
altered expression of cell-matrix adhesion molecules. Furthermore, a cell which is poorly 
motile in 2-dimensions may become highly motile in a 3-dimensional microenvironment. 
Indeed molecular signalling pathways leading to invasion or motility have been 
experimentally dissected. For example, blockade of MAPK signalling in N-cadherin 
expressing MCF-7 breast cancer cells resulted in the inhibition of FGF-2 induced invasion 
and MMP-9 production without inhibiting motility (378). Thus caution should be exercised 
when attempting to infer invasiveness from 2-dimensional studies. 
7.3.2.2 p120 is required for the collective invasion of A431 cells. 
Visualisation of invading cells within a collagen gel clearly revealed that A431 cells 
invaded collectively as groups of cells. This type of invasion is common in tumours in vivo 
and is characterised by the retention of cell-cell contacts, dependence on proteolysis and on 
integrin-based cell matrix attachments. The cell and molecular biology of collective 
invasion is poorly defined and we have not yet elicited the mechanism by which p120 is 
required. However, several plausible explanations may be proposed: 
201 
1. Loss of p120 (or other AJ proteins) interferes with EGF signalling. 
Various reports have linked the AJ or its component proteins to either positive or 
negative regulation of growth factor receptor signalling. For example E-cadherin and 
VE-cadherin dependent cell-cell adhesion has been reported to inhibit EGFR (471, 
485) or VEGFR (486) signalling respectively. Conversely a transient increase in 
EGFR activity has been reported at nascent AJs (137) and the AJ-dependent but EGF 
independent activation of EGFR appears to be important in the prevention of anoikis 
in clusters of squamous cell carcinoma cells (425). N-cadherin has been shown to 
cooperate directly with FGFR in inducing invasiveness and p120 has been implicated 
in the growth factor dependent activation of RhoA. It was possible then that loss of 
p120 and the AJ may in some way impair EGF signalling and thus the ability of 
A431 cells to respond to an EGF gradient. Although, we demonstrated no defect in 
the activation of major pathways downstream of EGFR signalling such as the STAT3 
and MAPK pathways in 2-dimensional culture this does not exclude such a defect 
occurring within the 3-dimensional environment of an invasion assay. 
We demonstrated that A431-p120' cells were able to migrate through an uncoated 
Transwell towards an EGF gradient; in other words the defect seen was specifically 
of invasion rather than of chemotactic migration. Interestingly, chemotactic 
migration of p120 expressing cells was not seen in this system. Clearly, they have the 
ability to respond chemotactically as evidenced by invasion through a Transwell into 
Matrigel in response to EGF. It is likely that the intact AJ inhibits migration of cells 
from a confluent monolayer through the Transwell and that this inhibition is lost in 
the p120 depleted cells. The addition of Matrigel to the Transwell must provide 
additional signals which cooperate with EGF to facilitate collective migration and 
invasion of p120 expressing cells. 
2. Loss of p120 alters Rho GTPase activity 
As discussed earlier p120 regulates Rho GTPases, signalling molecules whose 
involvement in motility and invasion are well documented. Previous work has 
implicated p120 in growth factor dependent activation of RhoA (131). Our failure to 
detect any difference in the ability of RhoA, Rae or Cdc42 to be activated following 
EGF stimulation in A431-p 120' cells as compared to control cells does not fully 
eliminate modulation of Rho-GTPase activity as being of relevance. Firstly, it is not 
clear how the activation of Rho GTPases following 5-15 minutes of stimulation with 
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EGF in a tissue culture dish compares to the chronic stimulation achieved over 
several days as in an invasion assay. In this regard the reduction in constitutive 
activity of RhoA and Cdc42 in serum starved A431-p120- cells in comparison to 
control cells may be of relevance. This observation at least raises the possibility that 
a differential activation of Rho GTPases might occur when cells are exposed to lower 
levels of EGF over a more prolonged time period. Secondly, the regulation of Rho 
GTPases differs in two and three dimensions. For example, fibroblasts maintained in 
a 3-dimensional fibronectin matrix have a lower level of Rac activity than when 
plated in 2 dimensions on fibronectin coated tissue culture plastic (487). Thus, the 
ability of cells to respond to EGF in two dimensional tissue culture may not 
necessarily replicate events occurring in a three dimensional extracellular matrix. 
Furthermore, we measured the global changes in GTPase activity following 
stimulation of all cells in culture. For collective invasion, polarised activation of Rho 
GTPases may be required such as in the pathfinder cells at the leading edge and a 
subtle defect in the spatial regulation of Rho GTPase activity cannot be excluded. 
Therefore we conclude that there is no gross defect in the ability of EGF to activate 
Rho GTPases but cannot confidently reject alterations in Rho GTPase signalling as a 
mechanism by which depletion of p120 inhibits the collective invasion of A431 cells. 
3. Loss of p120 alters transcription. 
p120 directly links events at the cell surface to gene transcription via the 
transcriptional repressor Kaiso (144). The physical interaction of p120 with Kaiso 
negatively regulates the ability of Kaiso to inhibit transcription. Theoretically the 
depletion of p 120 from a cell may therefore cause increased Kaiso-mediated 
repression of target genes some of which, such as MMP7, may be important for 
collective invasion. Conversely, in the absence of the AJ ß-catenin may also 
accumulate in the nucleus causing increased transcription of TCF target genes 
involved in invasion, some of which, such as MMP7, are co-ordinately regulated by 
Kaiso. However, in A431 cells the APC pathway of ß-catenin degradation appears to 
be intact as, rather than accumulating in the cytoplasm or nucleus, ß-catenin levels 
are reduced in parallel with other AJ components. Furthermore the levels of MMP7 
transcripts were unaltered in A431-p120- cells compared to control cells (A Serrels, 
unpublished data). This does not exclude altered transcription as the cause of 
impaired invasion and future work should test this further by the use of TCF and 
Kaiso reporter constructs. 
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Members of the AP-1 family of transcription factors are required for the EGF- 
induced invasion of A431 cells (397). However, expression of a dominant negative 
cadherin construct in A431 cells increased rather than decreased AP-1 activity 
although whether loss of E-cadherin function via depletion of p 120 would have an 
identical or effect on AP-1 activity is unknown (483). Future work should therefore 
also clarify the effects of p120 depletion on AP-1 family transcriptional activity. 
4. p120 is required to maintain cadherins other than E-cadherin. 
E-cadherin was not required for the collective invasion of A431 cells as RNAi 
mediated depletion of E-cadherin neither increased nor diminished invasiveness. 
However, A431 cells were shown to also express P-cadherin, which has been 
reported to have pro-invasive properties in other systems (372). If the collective 
invasion of A431 cells required pro-invasive cadherins such as P-cadherin then a 
requirement for p 120, without which all cadherins are degraded, would be expected. 
This hypothesis should be testable by RNAi-mediated depletion of P-cadherin. 
Should knockdown of P- cadherin inhibit invasion then this would strongly suggest 
that this is mechanism of p120 action. Conversely, the forced over-expression of P- 
cadherin in p 120-deficent cells might reverse the invasive defect. However, as 
alluded to above the forced expression of cadherins in the absence of p 120 may not 
replicate the physiological state due to rapid turnover of AJs and impaired cadherin- 
activated signalling pathways in which p120 is involved. This type of experiment 
would also be confounded if A431 cells were to express other less well defined 
cadherins which may also exhibit pro-invasive activity such as cadherin-1 1 (488). 
7.4 Summary 
Using an RNAi based substitution system p120 knock-down resulted in loss of AJs and 
increased motility of A431 cells. This correlated with inhibition of EGF-dependent 
invasion which was restored by reconstitution of wild type p 120. A truncated isoform of 
p120, which cannot be phosphorylated, was equally able to restore invasive capacity 
indicating that p120 phosphorylation is not required for EGF-dependent invasion of A431 
cells. Visualisation of invading cells within a collagen gel revealed that A431 cells 
invaded collectively as groups of cells. Knock-down of E-cadherin protein levels by RNAi 
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demonstrated that this was not dependent on E-cadherin mediated cell-cell adhesion. Thus 
we identify a requirement for p120 to regulate collective tumour cell invasion which is 
independent of its known effects on E-cadherin stability and, surprisingly, is independent 
of its ability to undergo tyrosine phosphorylation. 
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8 Concluding remarks. 
206 
The data presented and discussed in this thesis raise several points for further 
consideration: 
8.1 Is the tyrosine phosphorylation of p120 increased in 
cancer? 
As a substrate of oncogenic kinases the phosphorylation of p120 might be expected to be 
increased in human cancers. Whether, and with what frequency, this may occur has not yet 
been defined. A single study has suggested that increased phosphorylation of p120 may be 
a common occurrence in lung cancer (177). However, a biochemical approach as was 
utilised in this study is time consuming and constrained by the availability of fresh-frozen 
tissue. The development of p120 phospho-specific antibodies, as described in this thesis, 
should now facilitate the direct immunohistochemical study of p120 tyrosine 
phosphorylation in human tumour specimens. However, we would argue that the study of 
protein tyrosine phosphorylation in archival tumour specimens should be performed with 
caution. Tyrosine phosphorylation is a highly dynamic process and, as a consequence, 
artefactual alterations in protein phosphorylation may occur (443). Indeed, the snapshot 
provided by immunohistochemical analysis may be more revealing of factors surrounding 
tissue collection than of the true phosphorylation status of the protein in vivo. For example, 
dephosphorylation of a protein may occur due to a predominance of phosphatase activity 
(which is ATP-independent) over ATP-dependent kinase activity in the face of diminishing 
cellular energy stores in devascularised tissue. Indeed, a reduction in protein tyrosine 
phosphorylation correlates with increasing time to fixation. Conversely, transient increases 
in tyrosine phosphorylation may also occur. This presumably reflects profound and rapid 
cellular responses to devascularisation. An example of such changes is the rapid increase in 
expression of acute phase response genes shown to occur in prostate tissue derived from 
radical prostatectomy (in which the median time from ligation of arterial supply to fixation 
was 28 minutes) as compared to that obtained by a more rapid biopsy procedure (489). The 
size of specimen is also of relevance with a common finding being maintained 
phosphorylation in tissue from the rim but not the centre of larger specimens due to the 
time taken for penetration of the formalin fixative (443) For these reasons the use of 
existing tumour arrays, in which the provenance of samples is largely unknown, to address 
the frequency of protein tyrosine phosphorylation risks being uninformative or even 
misleading. Ideally biopsy derived material collected according to a validated protocol 
should be preferred for this type of study. For this reason we have not yet performed a 
survey of p120 tyrosine phosphorylation in human tumours. 
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However, recent work utilising the APCM"/+mouse model of colorectal carcinogenesis has 
provided proof-of-principle that p120 hyper-phosphorylation may occur during in vivo 
oncogenesis (0 Sansom and G Ashton, unpublished observations). A marked increase in 
tyrosine phosphorylation of p120 at tyrosine-228 was detected by immunohistochemical 
examination in 10 out of 10 colonic adenomas in comparison to adjacent normal colonic 
mucosa (Figure 8-1). Levels of p120 protein were unchanged (data not shown). Critically, 
this shows p120 phosphorylation to occur in a realistic model of oncogenesis which is 
likely to be predictive of events in human colorectal neoplasia. The nature of the kinases 
involved is suggested by recent work identifying activation of both EGFR and Src in this 
model (490). That increased phosphorylation of p120 should occur at such an early point in 
oncogenesis is intriguing. By definition adenomas are non-invasive. Thus, in the APCM"'/+ 
mouse model increased tyrosine phosphorylation of p120 is not sufficient to confer 
invasive growth. 
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Figure 8-1 p120 is hyper-phosphorylated in colonic adenomas. 
Colonic adenomas arising in the APCM'"'+ mouse were fixed and stained with pl 20- 
phospho-Y228 antibody. Of ten adenomas examined all exhibited increased phospho-Y228 
staining. Examples of two adenomas demonstrating strong staining with phospho-Y228 
antibody are shown (filled arrows). For comparison, an area of morphologically normal 
mucosa in which only a low level of phospho-Y228 is detectable is shown (upper panel, 
dotted arrow). In eight of ten adenomas examined a uniform pattern of increased staining 
was seen, with a patchy increase seen in the remaining two cases. An example of patchy 
staining is shown in the lower panel where an area of adenoma not displaying elevated 
phosphorylation of p120 is present (lower panel, dotted arrow). 
(unpublished data, courtesy of G Ashton and 0 Sansom, Beatson Institute) 
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8.2 What are the physiological consequences of p120 
tyrosine phosphorylation? 
The tyrosine phosphorylation of AJ proteins such as cadherins and ß-catenin appears to 
provide a rapid and reversible means of regulating the AJ. Whether phosphorylation of 
p120 may similarly influence AJ function has been less clear. Indeed evidence for a critical 
modulatory role for tyrosine phosphorylation has been lacking for any of p120's accepted 
functions. Our data support a role for p120 tyrosine phosphorylation in modulating AJ 
function, at least in some contexts. Specifically, we have shown that p120 phosphorylation 
is required for the scattering induced by EGFR signalling and that interfering with this 
phosphorylation inhibits scattering, most probably via stabilisation of the Ai rather than by 
inhibiting motility. Further work is now required to identify whether this property maps to 
the phosphorylation state of one or more specific tyrosine residues or, as is the case for the 
interaction of SHP-1 with p120, is a property dependent on the total number of residues 
phosphorylated. This issue is directly testable using p120 constructs with individual and 
combined tyrosine to phenylalanine substitutions. In addition, our finding that p120 
isoform 4 inhibited scattering more fully than the p120-3A/7F construct suggests that other 
events occurring in the regulatory domain are important. One possibility is phosphorylation 
on serine which has been shown to occur in response to EGFR activation (181). The role of 
serine / threonine phosphorylation would similarly be amenable to study by targeted 
substitution of the appropriate residues. 
It is interesting to speculate in what way the role of p120 phosphorylation in two- 
dimensional scattering may reflect the function of p 120 phosphorylation in 3-dimensional 
culture or, ultimately, in vivo. The effects of growth factor treatment in 2 and 3-dimensions 
may be markedly different. For example, small colonies of MDCK cells cultured in 2- 
dimensions rapidly dissociate in response to HGF. In contrast, the same cells cultured in a 
3-dimensional collagen matrix form small cysts which, on exposure to HGF, develop 
branching tubules in which cell-cell adhesion is maintained (491). Furthermore, over- 
expression of EGFR in oesophageal squamous cells was associated with increased 
association of p120 with E-cadherin and increased cell-cell adhesion in 3-dimensional 
organotypic culture (492). Therefore, whilst a role for p120 phosphorylation in the 
dynamic modulation or remodelling of cell adhesions appears plausible, it is clear that 
effects observed in 2-dimensional culture are not necessarily directly representative of 
events occurring in vivo. 
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Studies incorporating greater spatio-temporal resolution are necessary to further define the 
consequences of p120 phosphorylation at the AJ. In particular this may address the 
relevance of p120 phosphorylation at tyrosine-228 which occurs in nascent Ms but which 
does not appear to be required for AJ formation. Specifically, the use of GFP-labelled 
p 120, E-Cadherin and actin may allow the detection of more subtle defects in the kinetics 
of AJ formation or turnover. 
As was acknowledged in the title of a recent review article, the consequences of p120 
phosphorylation remain an unresolved issue (493). However, as our knowledge of p120 
biology increases we may be able to better design experiments to test the involvement of 
tyrosine phosphorylation in various aspects of p 120 function. 
8.3 Might a requirement for p120 define collective 
invasion? 
Despite the recognition that many common solid tumours invade collectively, the 
molecular mechanisms underlying this type of invasion are poorly understood. The extent 
to which cadherins may be involved in collective invasion, either by facilitating cell-cell 
adhesion or by the generation of specific pro-invasive signals, is not known. Although the 
AJ is required for cell-cell adhesion in tissue culture this does not appear to be an absolute 
requirement in 3-dimensional culture (86) or in vivo (95) and so it cannot be assumed that 
collective invasion is necessarily cadherin (and by implication p120)-dependent. 
Our demonstration that p 120 was required for the invasion of A431 cells was at first 
surprising. Indeed, as depletion of p120 caused downregulation of E-cadherin, a frequent 
invasion suppressor, and increased 2-dimensional motility we had predicted that invasion 
would be increased and, most likely, associated with a collective to mesenchymal switch. 
However, A431 cells did not appear able to exhibit plasticity in their mode of invasion in 
response to depletion of p120. Interestingly, the phosphorylation of p120 was neither 
required for collective invasion of A431 cells into collagen or Matrigel, nor was sufficient 
to cause invasion in adenomas in the APCM'"'+mouse. 
Previous work in A431 cells has shown that EMT induced by the forced expression of 
Snail caused loss of E-cadherin and increased invasiveness, although whether these cells 
invaded collectively or displayed mesenchymal single cell invasion was not determined 
(494). Thus it appears that it is the underlying mechanism by which E-cadherin is lost, 
211 
rather than simply its presence or absence, which determines invasiveness. Three distinct 
scenarios can be considered: 
1. Loss of E-cadherin in isolation. 
In our hands loss of E-cadherin due to RNAi-mediated depletion had no significant 
effect, either positive or negative, on invasiveness. It should be noted, however, that 
effects of transient and long term knockdown of E-cadherin may differ. For example 
expression of a DN-cadherin in A431 cells caused a switch in intermediate filaments 
from cytokeratin to vimentin consistent with EMT but this occurred over a period of 
weeks rather than days (483). Thus it is possible that stable rather than transient 
knockdown of E-cadherin may have yielded different results. 
2. Loss of E-cadherin secondary to depletion of p120. 
The depletion of p120 significantly reduced invasiveness. As depletion of E-cadherin 
had no effect this indicates that the contribution of p120 to invasiveness was 
unrelated to its role in stabilising E-cadherin. In this regard observations made in 
biopsies of oral squamous cell carcinomas are intriguing. Some collectively invading 
oral squamous cell carcinomas appear to lose expression of E-cadherin yet retain 
membranous expression of p120 (Figure 8-2). As cadherins are necessary and 
sufficient for the recruitment of p120 to the membrane this implies that in the 
absence of E-cadherin the expression of other cadherins is maintained. This could 
suggest a model where p120 is required for the stability and function of pro-invasive 
N- or P-cadherins. However, the potential role of various cadherins in collective 
invasion awaits definition. 
3. Loss of E-cadherin due to transcriptional downregulation in the context of EMT. 
Snail induced EMT was reported to increase invasiveness in A431 cells (494). 
Although this was associated with downregulation of E-cadherin other transcriptional 
events such as increased MMP2 production may underlie the increase seen in 
invasion. An important question to be addressed is whether Snail induced EMT is 
able to override the requirement for p120 for A431 cell invasion. 
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Although the invasion of A431 cells reconstituted with p120 isoform 3 or 4 was equal it 
would be informative to test the effect of reconstitution with p120 isoform 1. Over- 
expression of this isoform has been associated with increased 2-dimensional motility (131), 
although as discussed previously this does not necessarily have predictive value for 
invasion. In addition, however, p120 isoform 1 is upregulated in some metastatic cell lines 
(171), associates preferentially with pro-invasive N-cadherin (381) and is also upregulated 
in EMT (172). These observations raise the possibility that a switch from p120 isoform 3 
to 1 might increase invasiveness. Again, this hypothesis could be readily tested using the 
methods described in this thesis. 
It is also interesting to speculate that the requirement for p120 in the collective invasion of 
A431 cells may in some way recapitulate the requirement for p 120 in morphogenetic 
movements in vertebrate embryogenesis. In Xenopus the effects of loss of p120 could be 
corrected by carefully titrated expression of DA-Rac and cadherin (56). Whether such 
manipulations could rescue invasiveness in this system could be readily tested. 
A matter of priority is to determine whether the requirement identified for p120 in the 
collective invasion of A431 cells exists in other cell lines which are known to utilise a 
collective mode of invasion. Should this be the case then it would be appropriate to test the 
role of p120 in invasion in vivo. However, several difficulties may hinder this approach. 
Invasion, by definition, influences and is influenced by tissue micro-architecture. 
Therefore, invasion should be studied in tumours arising within their tissue of origin; a 
xenograft approach is likely to be of limited relevance. For this reason a genetic model of 
carcinogenesis or, alternatively, a chemical carcinogenesis model should be used. 
Unfortunately targeted deletion of p120 may have profound effects on the development of 
that tissue and indeed, as in the case of the GI tract, may be lethal. This might be 
circumvented, at least in part, by developing an inducible targeted knockout of p120. For 
example, a floxed-p 120 transgenic mouse could be crossed with a transgenic mouse 
expressing ER-Cre recombinase under the control of a keratin promoter. p 120 could then 
be deleted from the skin in a temporally and spatially controlled manner by the direct 
application of tamoxifen. In combination with a well defined two stage chemical 
carcinogensis model (495) the results of knocking out p120 at various stages of 
carcinogenesis could be determined. 
In conclusion, further study to unravel the mechanisms by which p120 is involved in 
collective invasion is likely to increase our understanding of the complex biology of this 
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process. Ultimately, this understanding may have an impact on our ability to 
therapeutically target this particular hallmark of malignancy. 
(A) 
(B) 
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Figure 8-2 E-cadherin deficient squamous cell carcinomas display membranous p120. 
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Figure 8-2 E-cadherin-deficient squamous cell carcinomas retain membranous p120. 
Biopsies of non-cancerous oral mucosa (A) or invasive squamous cell carcinoma (B) were 
fixed and stained with E-cadherin (red) or p120 (green) antibodies or with Alexa633 
coupled phalloidin (blue) to visualise actin. Single images are shown with merged images 
(top right hand panels). Membranous co-localisation of E-cadherin and p120 occurs in 
non-cancerous mucosa. Note areas of collectively invading tumour in which E-cadherin is 
downregulated but membranous localisation of p120 is retained (arrows). (C) Higher 
magnification view of boxed area demonstrating membranous p120. 
(unpublished data, courtesy of Dr E Sahai, London Research Institute) 
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SUPPLEMENTARY MATERIAL 
Compact disc containing: - 
Movie 1: Wound closure by A431-Scr cells. 
A wound was made in a confluent monolayer of A431-Scr cells using a sterile pipette tip 
and images recorded at 15 minute intervals over a 10 hour period by time-lapse 
videomicroscopy (x10 magnification). Images were combined using AQM advance 
software to create the movies shown. 
Movie 2: Wound closure by A431-p120" cells. 
A wound was made in a confluent monolayer of A431-p120' cells using a sterile pipette tip 
and images recorded at 15 minute intervals over a 10 hour period by time-lapse 
videomicroscopy (x10 magnification). Images were combined using AQM advance 
software to create the movies shown. 
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p120-catenin is required for the collective invasion of squamous cell 
carcinoma cells via a phosphorylation-independent mechanism 
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Loss of E-cadherin-mediated cell-cell junctions has been 
correlated with cancer cell invasion and poor patient 
survival. p120-catenin has emerged as a key player in 
promoting E-cadherin stability and adherens junction 
integrity and has been proposed as a potential invasion 
suppressor by preventing release of cells from the 
constraints imposed by cadherin-mediated cell-cell adhe- 
sion. However, it has been proposed that tyrosine 
phosphorylation of p120 may contribute to cadherin- 
dependent junction disassembly during invasion. Here, we 
use small interfering RNA (siRNA) in A431 cells to show 
that knockdown of p120 promotes two-dimensional 
migration of cells. In contrast, p120 knockdown impairs 
epidermal growth factor-induced A431 invasion into three- 
dimensional matrix gels or in organotypic culture, 
whereas re-expression of siRNA-resistant p120, or a 
p120 isoform that cannot be phosphorylated on tyrosine, 
restores the collective mode of invasion employed by A431 
cells in vitro. Thus, p120 promotes A431 cell invasion in a 
phosphorylation-independent manner. We show that the 
collective invasion of A431 cells depends on the presence 
of cadherin-mediated (P- and E-cadherin) cell-cell con- 
tacts, which are lost in cells where p120 expression is 
knocked down. Furthermore, membranous p120 is main- 
tained in invasive squamous cell carcinomas in tumours 
suggesting that p120 may be important for the collective 
invasion of tumours cells in vivo. 
Oncogene advance online publication, 5 March 2007; 
d oi: 10.103 8/sj . onc. 1210334 
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Introduction 
Invasion, the ability of neoplastic cells to breach tissue 
barriers, is a hallmark of malignancy and an attractive 
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process to target therapeutic strategies (Hanahan and 
Weinberg, 2000). Several lines of evidence implicate 
E-cadherin, a cell adhesion molecule, as a powerful 
suppressor of invasion. For example, invasive human 
cancers often display reduced expression of E-cadherin 
(Hajra and Fearon, 2002). E-cadherin suppresses meta- 
static potential when expressed in cadherin-deficient 
invasive cell lines (Vleminckx et al., 1991) and expres- 
sion of a dominant-negative E-cadherin is sufficient to 
cause early invasion and metastasis in a mouse 
transgenic pancreatic cancer model (Perl et al., 1998). 
Conversely, intracellular contacts may be maintained 
resulting in the invasion of coherent clusters or sheets of 
cells, a phenotype known as collective invasion (Friedl 
et al., 2004). This allows the migration and invasion of 
differentiated tumours that have retained cell-cell 
junctions. It also allows the passive movement of non- 
migratory cells within these clusters, thus increasing 
their invasive and metastatic potential. 
The extracellular domain of E-cadherin forms homo- 
dimers with cadherin molecules of an adjacent cell, 
whereas the cytoplasmic domain interacts with binding 
partners called catenins to form a functional unit known 
as the adherens junction (AJ) (Wheelock and Johnson, 
2003). Rather than simply acting as a physical `glue' it is 
now clear that multiple signalling pathways originate 
from the AJ and that a bidirectional cross talk exists 
with growth factor receptors (Wheelock and Johnson, 
2003; Brunton et al., 2004). The AJ intimately links 
events at the cell surface to gene transcription via the 
ß-catenin/T-cell factor (TCF) (Peifer and Polakis, 2000) 
and the p120-catenin/Kaiso pathways (Daniel and 
Reynolds, 1999; Kelly et al., 2004), whereas deregulation 
of the AJ in cancer has been frequently linked to 
transcriptional repression of E-cadherin (Strathdee, 
2002). Alternatively, post-translational mechanisms 
and in particular the tyrosine phosphorylation of 
cadherins or catenins by kinases such as the epidermal 
growth factor (EGF) receptor, or Src can occur and this 
correlates strongly with invasion in model systems 
(Mareel and Leroy, 2003). 
p120-catenin (hereafter p120) has emerged as a critical 
regulator of the AJ, both in vitro (Ireton et al., 2002; 
Davis et al., 2003; Xiao et al., 2003) and in vivo (Davis 
and Reynolds, 2006; Perez-Moreno et al., 2006). Speci- 
fically, in the absence of a physical interaction with p120, 
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classical cadherins (e. g. E-, VE-, N- and P-cadherin) are 
rapidly endocytosed and targeted for degradation. 
Reduced expression of p120 is frequently observed in 
human cancers and so this may represent one mechanism 
by which tumours downregulate E-cadherin (Thoreson 
and Reynolds, 2002). Hence, it has been hypothesized 
that p120 may act as an invasion suppressor via its ability 
to stabilize E-cadherin. Alternatively, when the primary 
event is the loss of E-cadherin expression, cytoplasmic 
accumulation of p120, which is relatively stable, may 
occur. Again, this appears to be a common histopatho- 
logical finding in human cancer specimens (1'horeson and 
Reynolds, 2002) and has been linked to a pro-invasive 
role for p120, which was mediated via the regulation 
of Rho-family GTPase signalling (Yanagisawa and 
Anastasiadis, 2006). 
A431 cells, derived from a vulval squamous cell 
carcinoma (SCC), invade a three-dimensional matrix in 
response to an EGF gradient and this provides a 
tractable reductionist system to investigate cancer cell invasion (Malliri et al., 1998). We therefore set out to 
test the role of p120 in invasion in cells that retain 
E-cadherin expression, by reducing the absolute amount 
of p120 and also by interfering with its phosphorylation. 
p120 was first identified as an Src substrate and is 
heavily phosphorylated in Src-transformed cells and 
also in response to receptor tyrosine kinase activation. However, the role of tyrosine phosphorylation of p120 
remains uncertain. Depending on the cellular context, 
the p120 N-terminal regulatory domain, which contains 
all known sites of tyrosine phosphorylation, can 
negatively modulate cell-cell adhesion (Aono et al., 1999; Ozawa and Ohkubo, 2001). Furthermore, a p120 isoform lacking the N-terminal region can act in a dominant-negative manner to inhibit growth factor- dependent motility (Cozzolino et al., 2003). 
We demonstrate here that loss of AJ caused by 
depletion of p120 protein inhibits, rather than promotes, invasion of A431 cells. Thus, in this system, p120 does 
not have an invasion-suppressor role. Surprisingly, 
despite being phosphorylated at several tyrosine residues 
in response to EGF, the requirement for p120 in EGF- 
induced invasion is not dependent on its ability to be 
phosphorylated. We show that A431 cells invade in a 
collective manner, which is dependent on the presence of 
cadherin-mediated cell-cell contacts, which in turn are 
dependent on the presence of p120. 
Results 
Activation of EGFR causes phosphorylation of p120 at 
multiple tyrosine residues 
We initially set out to address whether phosphorylation 
of p120 was important for tumour cell invasion. A431 
SCC cells overexpress EGF receptor and undergo specific 
changes in response to EGF stimulation including 
activation of Rho-family GTPases, actin reorganization 
and invasion of an extracellular matrix (Malliri et al., 
1998; Kurokawa et al., 2004). p120 is a prominent 
phospho-protein in EGF-stimulated epithelial cells (Lim 
et al., 2003; Thelemann et al., 2005) and is an attractive 
candidate molecule to mediate, or co-ordinate, some of 
these responses. Phosphorylation of p120 at tyrosine-228 
in EGF-stimulated A431 cells has recently been reported 
(Mariner et al., 2004). However, whether other sites are 
similarly regulated is unknown. Site-specific phospho- 
antibodies are also available to tyrosine-280 and tyrosine- 
291, and here we describe the generation of a new 
polyclonal antibody that specifically recognizes p120 
when phosphorylated on tyrosine-296. Before using this 
antibody to analyse the EGF-dependent phosphorylation 
events in A431 cells, we wished to verify its specificity. To 
do this we utilized KM12C colon carcinoma cells stably 
transfected with a c-Src construct, which is constitutively 
active because of mutation of the negative regulatory 
tyrosine-527 to phenylalanine (Src527F) (Avizienyte 
et al., 2002). Using an antibody that recognizes all 
tyrosine phosphorylation events, p120 immunoprecipi- 
tated from Src527F-expressing cells was seen to be 
heavily phosphorylated on tyrosine residues when 
compared with p120 in the parental cells (Figure la, 
upper panel). A similar result was seen when the 
immunoprecipitates were blotted with the phospho- 
Y296-specific antibody. Equivalent levels of total p120 
were present in the immunoprecipitates (Figure la, lower 
panel). The presence of two distinct bands reflects the two 
dominant p120 isoforms in this cell line. Phospho 
specificity of the phospho-Y296 antibody was validated 
in several ways. First, the ability of the antibody to 
recognize p120 immunoprecipitated from KM12C- 
Src527F cells was abrogated by dephosphorylation of 
the immunoprecipitate with leukocyte antigen-related 
(LAR) phosphatase (Figure lb). Second, the ability of 
phospho-Y296 to immunoprecipitate p120 from 
KM12C-Src527F lysates was blocked by preincubation 
with an excess of phosphorylated but not non-phos- 
phorylated immunizing peptide (Figure l c). Finally, myc- 
tagged wild-type p120 isoform 1A (p 120- l A) or p 120- lA 
in which tyrosine-296 was mutated to phenylalanine 
(p120-1A/296F) were expressed in KM 12C-Src527F cells. 
Immunoprecipitation of only the exogenously expressed 
myc-tagged proteins showed that wild-type pl20-lA but 
not pl20-1A/296F was recognized by the phospho-Y296 
antibody (Figure l d). 
Using the panel of phospho-specific antibodies 
described above we identified simultaneous phosphor- 
ylation of p120 at tyrosine residues 228,280,291 and 
296 following EGF stimulation (Figure 2a). As all four 
sites appeared to be phosphorylated in tandem, we used 
pharmacological inhibitors to investigate whether any 
differential regulation could be unmasked. Treatment of 
A431 cells with AG1478, a specific inhibitor of EGF- 
receptor tyrosine kinase activity, prevented the EGF- 
dependent phosphorylation of p120 on all four sites 
(Figure 2b). This corresponded with the ability of 
AG1478 to prevent the phosphorylation of the EGF 
receptor following stimulation with EGF as well as 
inhibiting the activation of the well-defined EGF- 
dependent signalling pathways to MAPK and STAT3 
(Figure 2c). AP23464 is a selective inhibitor of Src 
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family tyrosine kinases (Brunton er a/., 2005) and the 
EGF-dependent phosphorylation of p120 was also 
prevented in AP23464-treated cells (Figure 2b). Phos- 
phorylation of p120 on residues 228 and 296 was 
reduced to levels below that of basal phosphorylation in 
unstimulated cells (Figure 2b). Using phosphorylation 
of the autophosphorylation site of Src (tyrosine-416) as 
a measure of Src activity, we showed that Src activity 
was inhibited in cells treated with AP23464 at the 
concentration (I /IM) used in these experiments 
(Figure 2d). Interestingly, pre-treatment with AP23464 
was sufficient to block signalling to both p120 and 
STAT3, it known Src substrate, whereas phosphoryla- 
tion of MAPK was not reduced (Figure 2c). Thus p120 
is phosphorylated on multiple residues in an EGF- and 
Src-dependent manner, but this pathway does not 
mediate signalling from the EGF receptor to the MAPK 
cascade. 
RNAi-mediated knockdown and reconstitution ojp120 
To investigate the role of p120 in EGF-dependent events, 
particularly invasion, we utilized a powerful RNAi-based 
substitution system first described by Mariner et at. 
(2004). Importantly, this system avoids the potential 
confounding factor of subcellular mis-localization of 
overexpressed p120 due to saturation of cadherin- 
binding sites, and hence facilitates direct comparison of 
the function of different p120 constructs expressed 
at physiological levels. Human-specific p120 RNAi 
sequences, which do not alter the stability of murine 
p120, or a scrambled control sequence 0431-Scr) were 
stably expressed in A43 I cells and a number of single-cell 
clones with significant reduction in p120 levels were 
obtained (A431-p120 ) (Figure 3a, upper panel shows 
results from two independent clones). As expected, there 
was a concurrent reduction in E-, P-cadherin and other 
components of the AJ such as /3- and x-catenin 
(Figure 3a), which corresponds to the known effects of 
p120 on AJ stability. As a control we showed no 
alterations in levels of Src following knockdown of p 120 
(Figure 3a, lower panel). 
Owing to alternative splicing events and the use of 
alternative start colons, four major isoforins of' 1-1120 
exist (Figure 3b, start colons marked 1-4) (Keirsehilck 
et al., 1998). A431 cells in common with most epithelial 
cells, predominantly express p120 isoform 3 (Ishizaki 
cl al., 2004). Therefore constructs encoding murine } 120 
isoform 3A were reintroduced into cells in which p120 
had been knocked down. Pooled populations with stable 
expression of p120 at levels similar to parental A431 
cells were selected by fluorescence-activated cell sorting 
(FACS) sorting. We also introduced isoform 4A which 
lacks the entire N-terminal signalling domain containing 
all identified sites of tyrosine and most sites of serine 
threonine phosphorylation (Figure 3b) (Xia el al., 
2003). This isoform undergoes no detectable tyrosine 
phosphorylation in A43I cells (data not shown). 
Re-introduction of either isoform 3A or isoform 4A 
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restored E-cadherin levels to those seen in the control 
cells (Figure 3a). In parallel, the loss of cell cohesion 
resulting from knockdown of p120 was reversed by 
reintroduction of either p120 isoform (Figure 3c). 
As cross talk exists between the AJ and the EGF 
receptor (Qian et al., 2004), we investigated the effects 
of depleting p120 and hence the AJ on major 
EGF signalling pathways. Importantly, in A431-p120 
cells, there was no defect in EGF-signalling as the 
EGF-dependent phosphorylation of MAPK and 
STAT3 was seen in both p120 knockdown and control 
cells (Figure 3d). 
p12() regulates motility 
p120 has been reported to promote or inhibit the 
motility of various epithelial cell lines in a isoform and 
cell context-specific manner (Cozzolino et al., 2003; 
Shibata et al., 2004; Bellovin et al., 2005). In A43I cells, 
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the RNAi-mediated depletion of p120 was associated 
with an increase in two-dimensional motility of sparsely 
cultured cells as measured by time-lapse video-micro- 
scopy. The median speed was increased 3.5-fold from 
8.0µm/h (interquartile range: 3.5-14.4 µm/h) in A431-Scr 
cells to 27.3 Eim, h (interquartile range: 14.1-51.6 pm/h) 
in A431-p120 cells (Figure 4a). As the data were not 
normally distributed, we utilized the non-parametric 
Mann-Whitney U-test to demonstrate this to be a 
statistically significant increase (P<0.0001). 
Using a wound assay to monitor migration of cells 
from a confluent monolayer into a denuded area, we 
were also able to see qualitative differences in the mode 
of migration (Figure 4b and movies in Supplementary 
material). The A431-Scr cells moved as a sheet of cells 
keeping contact with adjacent cells in the monolayer 
(Movie 1, Supplementary Material). In contrast, the 
movement of A431-p120 was more disorganized with 
b 
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U? ä 
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individual cells moving into the denuded area (Movie 2, 
Supplementary Material). Cells were fixed and stained 
with phalloidin to visualize the actin cytoskeleton as they 
migrated into the wound (Figure 4b). A431-Scr cells 
maintained tight cell-cell contacts, whereas A431-pl20- 
cells at the edge of the wound had broken away from the 
neighbouring cells and had become more elongated. 
Although the individual A431-p120 cells moved more 
rapidly than the A43 I -Scr cells, the lack of directionality 
meant that the speed of wound closure was unaltered 
between the A431-Scr and A431-pl20 cells (A431-Scr 
20.57±2.26 and A431-p120 18.14±2.98µm/h). 
As regulation of Rho family GTPase activity by 
cytoplasmic p120 has been associated with a more 
motile phenotype, we measured GTP loading of RhoA, 
Racl and Cdc42 in A431-Scr and A431-p120 cells 
(Figure 4c). There was no difference in the basal levels of 
GTP-loaded RhoA, Racl and Cdc42 in the A431-Scr 
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and A431-p120- cells. Furthermore, the increase in 
GTP-bound RhoA, Racl and Cdc42 following EGF 
treatment was unaltered in cells lacking p120. The 
quantitation of the fold activation following EGF 
treatment is shown from densitometry measurements 
of three independent experiments (Figure 4c). EGF 
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receptor activation in A431 cells leads to the Racl- 
mediated formation of membrane ruffles (Malliri et al., 
1998) and as an additional approach to look for changes 
in Racl activation, the ability of cells to ruffle in 
response to EGF was measured. Treatment of A431-Scr 
cells with EGF resulted in a dramatic rearrangement of 
the actin cytoskeleton resulting in the formation of 
membrane ruffles in around 70% of cells. There was no 
difference in the A431-p120 cells (Figure 4d). 
p120 is required for invasion 
A431 cells are able to invade an extracellular matrix 
in response to an EGF gradient (Malliri et a!., 1998). As 
we demonstrated that depletion of p120 in A431 
cells resulted in loss of E-cadherin and increased 
two-dimensional motility, we hypothesized that A431- 
p120 cells would have a greater capacity for invasion 
than parental cells. We therefore utilized a quantitative 
a 
in vitro invasion assay to assess the ability of A431 cell 
lines to invade into Matrigel in response to EGF. 
Invasion only occurred in the presence of an EGF 
gradient and was maximal for lO ng/ml (EGF concen- 
trations from I to 100 ng/mI were tested; data not 
shown). Surprisingly, knockdown of p120 protein 
resulted in a marked reduction in invasion into Matrigel 
over 72h in comparison to the A431-Scr cells 
(Figure 5a). Quantification showed that there was a 
76% reduction in invasion in the A431-p120- cells 
(Figure 5a). This reduction in invasion was confirmed 
for two different A431-pl20 cells clones (clones 3 and 
7). Importantly, the ability of reconstituted p120-3A to 
reverse the invasion defect confirmed that this pheno- 
type was specifically due to p120 depletion and not a 
clonal or 'off-target' effect. 
As stimulation of A431 cells with EGF results in 
phosphorylation of p120 at multiple tyrosine residues, 
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Figure 5p 120 is required for invasion. (a) Cells were seeded on Transwell filters and allowed to invade into Matrigel towards an EGF 
gradient. After 72 h, cells were labelled with calcein AM and visualized in the Matrigel at 15µm intervals. Composite images of 
invading cells are shown for (i) A431-Scr. (ii) A431-p120- Clone 3, (iii) A431-p120- Clone 7, (iv) A431-p120 pI20-3A and (v) A431- 
p120 /p120-4A cells. Quantitation of invasion is shown for a representative experiment in a series of four. Values are mean±s. d. 
(b) CFP-labelled cells (blue) were seeded in collageniMatrigel gels in the presence or absence of fibroblasts, and after 5 days the gels 
were fixed and labelled with TRITC-phalloidin (red). Quantitation of invasion is shown where values are mean±s. d. collated from 
three experiments. (c) A43l-Scr or A43I-p120- cells were plated at a density of Ix 103 cells, well in 96-well plates. At 24 h intervals, the 
number of viable cells was determined using a colorimetric MTT assay where absorbance at 570 nm is directly proportional to cell 
number. Results are plotted as mean absorbance±s. d. for quadruplicate wells. (d) Adherent (i) A431-Scr, (ii) A431-p120 Clone 3, 
(iii) A431-pl20 Clone 7, (iv) A431-pI20 p120-3A and (v) A431-pI20 /p120-4A cells were quantified after adhesion to Matrigel 
for 30 min. Values are mean ±s. d. of quadruplicate wells taken from a representative experiment. 
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we hypothesized that this requirement of p120 for 
invasion would specifically depend on its ability to be 
phosphorylated. However, reconstitution with p120 
isoform 4A, which lacks all sites of tyrosine phosphor- 
ylation, restored the invasion defect in the A431-p120- 
cells to a level seen in the control cells (Figure 5a). Thus, 
tyrosine phosphorylation of p120 (or other events 
occurring in the regulatory domain such as serine/ 
threonine phosphorylation (Xia et al., 2003)) was not 
required for invasion. 
The reduced ability of A431-p120- cells to undergo 
invasion was further characterized using an organotypic 
invasion assay (Figure 5b). This 3D environment more 
closely resembles the in vivo situation and measures the 
invasion of cells into collagen/Matrigel gels co-cultured 
in the presence of tumour-derived fibroblasts. There was 
a marked reduction in invasion of the p120 knockdown 
cells when compared with cells expressing scrambled 
p120 sequences (Figure 5b). There was no invasion of 
control or p120 knockdown cells in the absence of 
fibroblasts. 
A proliferation assay was carried out to exclude the 
possibility that the effects on invasion were due to 
reduced proliferation in the A431-p120 cells. No 
difference in proliferation was seen between the A431- 
Scr and A431-pl20 cells (Figure 5c). To address 
whether integrin function was altered in the cells lacking 
p120, adhesion assays were carried out. There was no 
difference in the adhesion of the A431-Scr and A431- 
p120 cells or the cells in which p120 had been re- 
introduced (Figure 5d). 
Invasion is dependent on the ability of cells to form 
cell-cell contacts 
Malignant cells may adopt different strategies for 
invasion including mesenchymal or amoeboid invasion 
of single cells or collective invasion of co-ordinated 
columns or sheets of cells (Friedl et a!., 2004; Sahai, 
2005). Reconstructed confocal images of A431-Scr cells 
invading in the organotypic assay demonstrated inva- 
sion of groups of cells consistent with a collective mode 
of invasion (Figure 6a). Given the reduced levels of 
cadherins present in the A431-p120 cells (Figure 3a) 
and the collective nature of the invasion observed in the 
organotypic assays, we hypothesized that the critical 
role of p120 in collective invasion was to stabilize cell- 
cell contacts through stabilization of cadherins at the 
cell surface. E-cadherin is the predominant cadherin 
expressed in A431 cells; however, transient knockdown 
of E-cadherin in A431-Scr cells using RNAi duplex 
oligonucleotides (Figure 6b) did not alter the ability 
of the A431 cells to invade (Figure 6c). A431 cells 
also express P-cadherin, but we were unable to detect 
N-cadherin in any of the conditions tested (results not 
shown). Knockdown of P-cadherin alone had no effect 
on the invasion of A431 cells; however, combination 
of P- and E-cadherin knockdown significantly reduced 
the ability of A431 cells to invade in the organotypic 
assay (Figure 6c). Further analysis demonstrated that 
P-cadherin levels were upregulated when E-cadherin was 
knocked down (Figure 6d), suggesting that there is 
interplay between both cadherin types to maintain cell- 
cell contacts required for invasion. 
To address this we looked at cell-cell contacts in the 
cells. Loss of either E- or P-cadherin alone did not alter 
the morphology of the A431 cells and cell-cell contacts 
were still visible where p120 was present (Figure 7a). 
However, combined loss of E- and P-cadherin resulted 
in a loss of cell-cell contacts and p120 was localized 
diffusely in the cytoplasm. This was similar to the 
morphology of the A431-p 120 - cells, which had also lost 
cell-cell contacts (Figure 7a, right-hand panels) asso- 
ciated with downregulation of both E- and P-cadherin 
(Figure 3a). Taken together, these data suggest that the 
pro-invasive role of p120 is at cell-cell contacts where it 
functions to maintain cadherin-mediated cell junctions 
that are required for the collective invasion of the A431 
cells. Consistent with this we observe that p120 is 
localized to cell-cell contacts in collectively invading 
A431 cells (Figure 7b). 
SCC of the head and neck often invade in collective 
clusters and strands and our results indicate that this 
type of invasion would be dependent on p120. In a small 
study we found that p120 expression was maintained in 
7 out of 7 human SCCs examined including two high- 
grade tumours (Figure 8). Furthermore, p120 remained 
localized at cell-cell contacts as we observed in the 
organotypic assay, even in the high-grade tumours 
where small groups of cells had collectively invaded 
the surrounding stromal tissue (Figure 8e and f, arrow 
heads). These data demonstrate that our finding that 
p120 is required for the collective invasion of A431 SCC 
cells is consistent with the expression pattern and sub- 
cellular distribution of p120 in head and neck SCC. 
Discussion 
Most cancer deaths result from locally invasive or 
metastatic disease, which is not amenable to curative 
surgical resection and for which systemic anti-cancer 
therapy is required. Understanding the biology of these 
processes, therefore, provides key information that may 
aid the development of therapeutic strategies to prevent 
the spread of disease. There are numerous reports in the 
literature that describe decrease or loss of p120 in a 
range of epithelial tumours. In some cases, this is linked 
to late-stage disease and decreased survival suggesting 
that p120 may act as an invasion or metastasis 
suppressor (Thoreson and Reynolds, 2002). However, 
we have identified a novel role for p120 in promoting 
collective invasion of epithelial tumour cells as knock- 
down of p120 by small interfering RNA (siRNA) 
inhibits invasion of A431 SCC cells into both Matrigel 
and collagen gels. 
The collective movement of tumour cells describes the 
migration and invasion of groups of tumour cells which 
have maintained cell-cell junctions. It allows the 
migration of and invasion of differentiated tumours 
that have retained cell-cell junctions and also allows the 
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Figure 6 Cell-ell contacts are required for invasion. (a) Phalloidin staining of A431-Scr and A431-p120 cells invading as collective 
strands in organotypic invasion assay. (b) A431-Scr cells were treated with two independent E-cadherin-specific or two control 
(irrelevant) RNAi oligonucleotides and lysates prepared. Western-blot analysis was carried out with anti-E-cadherin antibody and 
anti-tubulin antibody used as a loading control. (c) A431-Scr cells treated with either E- or P-cadherin-specific or control RNAi 
oligonucleotides were seeded in collagen'Matrigel gels in the presence of fibroblasts and the invasion index calculated after 5 days. 
Values are mean ±s. d. from a representative experiment in a series of three. (d) A43 I -Scr cells were treated with either E- or P-cadherin- 
specific or control RNAi oligonucleotides and lysates prepared. Western-blot analysis was carried out with p120, P- and E-cadherin 
antibodies, and anti-tubulin antibody was used as a loading control. 
passive movement of non-migratory cells within these 
clusters. The mechanisms involved in this type of 
invasion are not fully understood. It shares a number 
of properties with single-cell migration such as integrin 
and matrix metalloproteinase requirements, but the 
extent to which cadherins are involved in collective 
invasion is not well defined (Fried) et al., 2004; Sahai, 
2005). 
Here we show that retention of cadherin-mediated 
cell-cell contacts is required for the collective invasion 
of A431 cells. Reduction in both P- and E-cadherin 
expression is required for loss of cell-cell contacts and 
an inhibition of invasion of cells, which is consistent 
with redundancy of function between these two epithe- 
lial cadherins (Jensen et a!., 1997). In vitro studies using 
either a p120-deficient colon epithelial cell line or 
siRNA-mediated knockdown of pI20 demonstrated 
that p120 plays a key role in the stability of the AJ by 
regulating the internalization and subsequent degrada- 
tion of E-cadherin (Ireton et a!., 2002; Davis et al., 2003; 
Xiao et a!., 2003), and the loss of both E- and P- 
cadherin in the A431-p120 cells supports a pro-invasive 
role for p120 in collective invasion by maintaining 
integrity of cadherin-mediated cell-cell contacts. 
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Figure 7 Cell-cell contacts require cadherins. (a) A431-Scr cells treated with either E- or P-cadherin-specific or control RNAi 
oligonucleotides were fixed and stained with anti-p120 antibody or TRITC-phalloidin. (b) p120 and DAPI staining of A431-Scr cells 
insading as collectise strands in organotypic invasion assac. 
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differentiated non-kcr tinizing tumour, (d) non-kcratinizing tumour, (e) high-grade tumour with occasional keratin nests, (f) high- 
grade tumour. Panels a and fare 500 x 500 µm and panels b-e are 250 x 250 µm. 
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Furthermore, the presence of p120 at cell-cell contacts 
in high-grade invasive tumours suggest that this may be 
important mechanism of invasion in vivo. 
Recently, a requirement for p120 in the invasion of 
E-cadherin deficient cell lines, which do not have 
functional cell-cell junctions, has been demonstrated 
by Yanagisawa and Anastasiadis (2006). In this situa- 
tion, p120 appears to act by stabilizing expression of the 
mesenchymal cadherins, N-cadherin and cadherin 11, 
which have been shown to have pro-invasive functions 
in other cell types (Islam et al., 1996; Hazan et al., 2000). 
Regulation of Rho family GTPase activity by cytoplas- 
mic p120 has been associated with a branching 
morphology and more motile phenotype (Anastasiadis 
and Reynolds, 2000; Noren et al., 2000; Grosheva et al., 
2001; Cozzolino et al., 2003) and has been proposed as 
the mechanism by which p120 may act to promote 
invasion. In these reports, no direct measurements of 
invasion were made but a more motile phenotype was 
proposed to be associated with a more invasive 
phenotype. However, Yanagisawa and Anastasiadis 
(2006) went on to demonstrate that the effects of p120 
on invasion of the E-cadherin deficient cells were 
mediated via activation of Racl and inhibition of RhoA 
signalling. However, in our experiments, Racl activity 
was unaltered in cells where p120 was knocked down 
suggesting that invasion of A431 cells is not regulated 
via activation of Racl. The differences between our own 
study and that by Yanagisawa and Anastasiadis (2006) 
probably reflect differences in the mode of invasion 
employed by the different cells. We are measuring 
collective invasion of cells that retain cell-cell contacts, 
whereas the other study was looking at invasion of 
individual cells that are known to involve different 
signalling pathways. Furthermore, the ability of p120 to 
regulate Racl activity is dependent on its cytoplasmic 
localization and we have shown that p120 is predomi- 
nantly localized at cell-cell junctions in collectively 
invading cells. It is possible that p120 has an additional 
role in A431 invasion that involves regulating the levels 
of phosphorylated myosin light chain as we saw a small 
reduction in levels of MYPTI and MLC phosphoryla- 
tion in A431-p120- cells (results not shown). However, 
this is unlikely to be mediated through RhoA as we were 
unable to detect any significant changes in RhoA-GTP 
levels in our system. Our own work and that of 
Yanagisawa and Anastasiadis (2006) both define a key 
role for p120 in tumour cell invasion through stabiliza- 
tion of cadherins, although the downstream signalling 
pathways are different. Our demonstration that it is 
important for the collective invasion of tumour cells 
suggests that p120 may play a pivotal role in tumour cell 
invasion which show considerable plasticity in terms of 
their mode of invasion. 
Tyrosine phosphorylation of p120 by oncogenic 
Src and growth factor receptors has been well docu- 
mented and a number of phosphorylation sites have 
been mapped to the N-terminal portion of the protein 
(Mariner et al., 2001,2004). Use of phosphorylation 
defective mutants has suggested a requirement for 
p120 phosphorylation in promoting cell motility. For 
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example, heregulin-stimulated migration of breast can- 
cer cell lines requires p120 and is associated with 
tyrosine phosphorylation of p120 (Shibata et al., 
2004), whereas HGF-dependent cell scattering and 
migration of MDCK cells is prevented by expression 
of a p120 mutant lacking the N-terminal domain 
phosphorylation sites (Cozzolino et al., 2003). In 
this case, activation of RhoA by HGF was also 
abrogated. The same phosphorylation defective mutant 
was also able to partially suppress cell scattering in v- 
Src-transformed cells (Ozawa and Ohkubo, 2001), 
whereas increased motility in keratinocytes upon over- 
expression of p120 was dependent on EGF (Cozzolino 
et al., 2003), suggesting a role for phosphorylation. 
Taken together, these observations indicate that p120 
may act in concert with growth factor receptors to 
regulate cell motility via modulation of phosphorylation 
and/or Rho GTPase signalling. In contrast, it appears 
that although phosphorylation of p120 occurs upon 
junction formation, it is not required for their assembly 
in epithelial cells (Mariner et al., 2004). In the present 
study, we show that although p120 is phosphorylated in 
EGF-stimulated cells, this is not required for their 
invasion. Thus, the processes involved in cell-cell 
adhesion, motility and invasion can be separated 
mechanistically and the ability of p120 to act as an 
invasion promoter is more complex and cannot be 
accounted for solely by alterations in RhoGTPase 
activity or a requirement for phosphorylation events. 
The transcription factor Kaiso was first identified in a 
complex with p120 and is a member of a family of BTB/ 
POZ proteins whose target genes include a number that 
are involved in tumourigenesis (van Roy and McCrea, 
2005). Kaiso acts as a transcriptional repressor and p120 
binding to Kaiso relieves this repression. It has therefore 
been proposed that the aberrant expression of p120 in 
tumour cells may result in deregulated Kaiso activity. 
Interestingly, known Kaiso targets include the metallo- 
proteinase, MMP7 (Spring et al., 2005), whereas Kaiso 
can also repress Wnt gene targets (Park et al., 2005), 
many of which are known to be involved in tumour cell 
invasion. This provides an attractive mechanism where- 
by p120 may regulate tumour cell invasion and this 
requires further investigation. 
Collective migration of tumours has been documented 
by histologists for many years, although the mechanisms 
involved are not fully understood. It allows the 
migration and invasion of differentiated tumours that 
have retained cell-cell junctions. It also allows the 
passive movement of non-migratory cells within these 
clusters, thus increasing their invasive and metastatic 
potential. The movement of tumour cell clusters in 
contrast to individual tumour cells may also provide 
increased survival and migratory signals through auto- 
crine production of such factors. Hence, the collective 
movement and invasion of tumour cells presents several 
advantages to the progression of an aggressive invasive 
tumour. Understanding the signalling pathways that 
regulate collective cell movement and invasion, such as 
the role of p120, may present exciting new opportunities 
to target this process. 
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Materials and methods 
cDNA constructs 
Full-length human p120 isoform IA with a C-terminal myc tag 
was generated by polymerase chain reaction (PCR) using 
pEFBOS-p120-1A as a template (van Hengel eta!., 1999) (a gift 
from J van Hengel, Flanders Interuniversity Institute for 
Biotechnology, Belgium) and the 5' primer TTACCCTGCCC 
TGCGGCGGCTCCGC and the 3' primer CGGTCGACTTA 
CAGATCCTCTTCTGAGATGAGT=GTTCAATCTTC 
TGCATC AAGGG. The PCR product was cloned into pCR- 
Blunt II-TOPO (Invitrogen, Paisley, UK) and sequenced to 
ensure that no mutations had occurred during amplification. 
The insert was then subcloned into the bicistronic retroviral 
vector pLZRS-IRES-GFP (a gift from AB Reynolds, Vander- 
bilt University Medical School, Nashville, TN) using the EcoRI 
sites to generate pLZRS-p120-lA-IRES-GFP (Ireton et a!., 
2002). Alternatively, site-directed mutagenesis of tyrosine-296 
to phenylalanine was performed using the QuickChange Site- 
directed mutagenesis kit (Stratagene, La Jolla, CA, USA) 
before subcloning to generate pLZRS-pl20-IA/296F-IRES- 
GFP and the sequence verified. pRetroSuper constructs 
containing either a human-specific p120 RNAi sequence 
(GCCAGAGGTGGTTCGGATA) or a scrambled control 
sequence (GATAAGGTGCTGCGTGGAC) were generated 
as described previously (Davis et al., 2003). 
Cell lines 
Generation of KM 12C cells (a gift from IJ Fidler, University 
of Texas, MD, USA; Anderson Center, Houston, TX, USA) 
expressing constitutively active Src (SrcY527F) was as 
described previously (Avizienyte et al., 2002). A431 cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM) 
containing L-glutamine and 10% fetal bovine serum (FBS). 
Retroviral infection of KM12C-Src527F or A431 cells was 
performed as described previously (Avizienyte et a!., 2002), 
and cells with stable retroviral integration were selected on the 
basis of GFP expression (KM12C-Src527F-pLZRS-p120 
constructs) or with 2µg/ml puromycin (Sigma Chemical Co., 
Poole, UK) (A431-pRetroSuper constructs). pLZRS-IRES- 
GFP encoding cDNA for murine p120 isoform 3A or 4A (gifts 
from AB Reynolds) were introduced to single-cell A431 clones 
with knockdown of p120 using the Amaxa Nucleofector 
System (Amaxa GmbH, Cologne, Germany) and pooled 
populations selected according to GFP expression by FACS. 
Growth factors and drugs 
Human recombinant EGF (R&D Systems, Abingdon, UK) 
was used at concentrations of 10 or 100 ng/ml. For all 
experiments, cells were first serum-starved overnight and then 
stimulated with the appropriate concentration of EGF in 
serum-free medium. AP23464 (ARIAD Pharmaceuticals, 
Cambridge, MA, USA) was dissolved in dimethylsulphoxide 
(DMSO) to a stock concentration of 10 mm. Immediately 
before use it was diluted in medium to achieve a final 
concentration of 1 µ1M AG1478 (CN Biosciences Ltd, Notting- 
ham, UK) was dissolved in DMSO to a stock concentration of 
10 mm and was further diluted in medium to a final 
concentration of 300 nm immediately before use. 
Immunoprecipitation and immunoblotting 
Cells were washed and then lysed in ice-cold radioimmuno- 
precipitation assay buffer (50 mm Tris, pH 7.4,150 mM NaCl, 
1% Triton X-100,0.5% deoxycholate, 0.1% sodium dodecyl 
sulphate (SDS), 100µN[ sodium orthovanadate, 2mm phenyl- 
methylsulfonyl fluoride (PMSF), 10µg/ml aprotinin, 500µM 
NaF). About 250-1000µg of cleared lysate was then immu- 
noprecipitated with 1µg anti-p120 (BD Biosciences, Oxford, 
UK), 4µl rabbit anti-p 120-pY296 or 4µl anti-myc clone 9B I1 
(New England Biolabs, Hertfordshire, UK). Where indicated, 
immunoprecipitates were first washed in reaction buffer 
(25 mm Imidazole, pH 7.0,50 mm NaCl, 2.5 mm Na-EDTA, 
5 mm DTT, 100 µg/ml bovine serum albumin (BSA)) and then 
incubated with 2µl LAR phosphatase (CN Biosciences Ltd) at 
30°C for 30 min before the addition of Laemmli sample buffer. 
Denatured proteins were separated by SDS-polyacrylamide 
gel electrophoresis and transferred to nitrocellulose. Mem- 
branes were blocked and probed with 1: 1000 anti-p 120,1: 5000 
anti-p120-pY228,1: 250 anti-p120-pY280,1: 500 anti-p120- 
pY291,1: 5000 anti-EGFR, 1: 1000 anti-phospho-EGFR, 
1: 1000 PY20 (anti-phosphotyrosine), 1: 2000 anti-E-cadherin, 
1: 500 anti-ß-catenin (all from BD Biosciences, Oxford, UK), 
1: 10 000 anti-MAPK, 1: 500 anti-actin, anti-ß-tubulin (all from 
Sigma Chemical Co., Poole, UK), 1: 1000 anti-phospho- 
MAPK (Thr202/Tyr204), 1: 1000 STAT3 (Tyr705), 1: 250 
anti-phospho-STAT3,1: 1000 9B11 (anti-myc), 1: 1000 Src- 
pY416. (all from New England Biolabs, Hertfordshire, UK), 
anti-P-cadherin (Merckbiosciences, Nottingham, UK) or 
1: 5000 anti-Src kinase domain (Ardern et al., 2006). Bound 
antibody was detected by incubation with horseradish 
peroxidase conjugated secondary antibodies and visualized 
by enhanced chemiluminescence (Amersham Biosciences, 
Buckinghamshire, UK). When necessary, blots were stripped 
using the Re-Blot Plus Strong Antibody Stripping Solution 
(Chemicon International, Harrow, UK) and reprobed with 
additional antibodies. 
Antibody generation 
A polyclonal rabbit antibody against p120 phospho-tyrosine- 
296 was generated using the peptide 290-(C)GYDDLD- 
pYGMMSD-301. The N-terminal cysteine residue (bracketed) 
was added to facilitate coupling to the carrier protein keyhole 
limpet haemocyanin. Peptides were estimated to be > 90% 
pure by high-performance liquid chromatography, and com- 
position was confirmed by amino acid analysis (synthesis and 
analysis of peptides was carried out by Affiniti Research 
Products Ltd, Exeter, UK). About 200{ßg of conjugated 
peptide was emulsified in Freund's adjuvant (Sigma Chemical 
Co., Poole, UK), either complete for the primary immuniza- 
tion or incomplete for subsequent immunizations, as described 
previously (McLean et al., 1991). Serum was checked for 
positive reactivity and IgG was purified by affinity absorption 
to a protein G column (Amersham Biosciences, Buckingham- 
shire, UK). The elute was dialysed against PBS at 4°C for 16 h. 
Non-phospho-specific antibodies were removed by absorption 
against a Sepharose column containing the immunizing 
peptide in its unphosphorylated form and the remaining 
fraction was again absorbed against a protein G column, 
eluted and dialysed against PBS. The antibody was used at 
1: 125 dilution for immunoprecipitation and 1: 5000 for 
immunoblotting. 
Cell migration assays 
To monitor movement of individual cells in sparse cultures, 
cells were plated at 1x 10' per well of a six-well plate and 
allowed to adhere for 8 h. Images were then captured every 
15 min for 5h using an Axiovert 200 M Zeiss microscope with a 
x 20 objective and AQM Advance software (Kinetic Imaging, 
Nottingham, UK). About 100 individual cells per cell line were 
analysed using Tracking Analysis software (Kinetic Imaging). 
For wound-healing assays, cells were plated at a density of 
Ix 106 cells per well of a six-well plate. At 24 h later, a wound 
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was made using a sterile pipette tip and images of cells 
migrating into the wound recorded by timelapse video- 
microscopy at 15 min intervals until complete wound closure. 
Alternatively cells were plated on glass chamber slides and 
grown to confluence before wounding with a sterile pipette tip. 
After 6h, cells were fixed with 3.7% formaldehyde in PBS, 
permeabilized in PBS containing 0.5% Triton X-100 and 1% 
BSA, blocked with 10% FBS in PBS, and incubated with 
FITC-phalloidin for 45 min. Cells were visualized using a Leica 
DM IRBE confocal microscope with x 40 objective. 
Immunofluorescence 
Confocal imaging was carried out as described previously 
(Avizienyte et al., 2002) using anti-p120 antibody (BD 
Bioscience) and TRITC-phalloidin. For quantification of 
membrane ruffling, at least 100 cells were counted for each 
treatment and the results were presented from three indepen- 
dent experiments. Experiments in which cells were transfected 
with siRNA duplexes were processed 48-72h after transfec- 
tion. 
covered by invading and non-invading cells. A score of 0 
corresponds to no invasion, whereas the closer the score is to 1, 
the greater the invasion. Where indicated, E-cadherin-specific 
siRNA sequences (#1 GGAGAGCGGUGGUCAAAGAUU, 
#2 ACCAGAACCUCGAACUAUAUU) and P-cadherin- 
specific sequences (pool of equimolar amounts of #1 GACA 
ACGUCUUCUACUAUGUU, #2CAUAUGACGUGCAC 
CUUUCUU, #3 CAGCUCAAGUCUAAUAAAGUU) or 
control sequences (#1 UAGCGACUAAACACAUCAA, #2 
UAAGGCUAUGAAGAGAUAC) were introduced into the 
cells using Oligofectamine (Invitrogen, Paisley, UK) according 
to the manufacturers instructions. 
Cell proliferation assays 
Cells were plated at 1x 10' per well of a 96-well plate. At 24 h 
intervals, the number of viable cells was determined using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) proliferation assay (Plumb et al., 1989). Mean and 
s. e. m. values were calculated from quadruplicate wells. 
Matrigel invasion assays 
Inverse invasion assays were carried out as described 
previously (Scott et al., 2004) using complete Matrigel (BD 
Biosciences, Oxford, UK). Cells were seeded at 10` per 
Transwell (Corning Life Sciences, Sigma Chemical Co., Poole, 
Dorset, UK), and 10ng/ml EGF was added to the DMEM 
above the Matrigel. After 72 h, cells were stained with Calcein 
AM (Molecular Probes, Invitrogen, Paisley, UK). Horizontal 
z-sections through the Matrigel were taken at 15µm intervals 
using a Leica DM IRBE confocal microscope. The number of 
positive pixels in each image was determined using 'Image J' 
software (NIH), using a value of 150 for background 
subtraction. The sum of the values obtained for individual 
sections (excluding the first section which corresponds to the 
upper surface of the filter) was then expressed as a percentage 
of the control cell value. For each experiment, samples were 
run in duplicate and at least four z-series were taken per 
sample. Projected images used for display purposes were also 
created using 'Image J'. 
Organotypic invasion assays 
pECFP (Clontech, BD Biosciences, Oxford, UK) was intro- 
duced into A431-Scr or A431-p120- cells using the Amaxa 
Nucleofector System (Amaxa GmbH, Cologne, Germany) and 
pooled populations with uniform expression selected by 
FACS. These were plated on top of collagen/Matrigel (4 mg/ 
ml collagen/2.5 mg/ml Matrigel) gels containing 10% FBS. 
Where indicated, 5x 10' tumour-derived fibroblasts were 
added to the gel. After 24h, the gel was transferred onto a 
nylon filter and placed on a mesh support. This was partially 
submerged in media containing 10% FBS, whereas the rest of 
the gel including the A431 cells was in contact with air. After 5 
days, the gels were fixed with 4% paraformaldehyde per 0.25% 
gluteraldehyde per PBS, permeabilized with 0.2% Triton 
X-100/PBS and stained with TRITC-phalloidin. A multi- 
photon laser-scanning microscope was used to take five optical 
xz-sections of each gel and the area of non-invading cells and 
the total area over which cells had spread were measured. 
The invasion index =1 area of non-invading cells per total area 
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